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The use of natural products or their derivatives has become increasingly popular 
in cancer chemotherapy. Camptothecins and etoposides are two typical examples. 
Camptothecin is a topoisomerase I-targeting agent. It is a naturally occurring alkaloid 
derived from Camptotheca acuminata. In contrast to camptothecin, etoposide is a 
topoisomerase II inhibitor. It is a semi-synthetic derivative of podophyllotoxin, an 
antimitotic compound derived from mandrake plants. Camptothecins and etoposides 
are active against many types of malignancies, and recent studies have shown that 
these 2 classes of topoisomerase-targeting agents can also inhibit the proliferation of 
leukemia cells. Nevertheless, the cellular and molecular mechanisms by which 
topoisomerase-targeting agents can exert their anti-leukemic effect are far from being 
understood. 
In the present study, using the well-characterized murine myeloid leukemia 
WEHI-3B JCS cells as the model, the effects of topoisomerase-targeting agents on the 
proliferation, differentiation and survival of myeloid leukemia cells were studied. 
10-hydroxy-camptothecin (HCPT) and etoposide phosphate (EP), with higher water 
solubility and being less toxic than their parent compounds camptothecin (CPT) and 
etoposide (VP-16) respectively, were chosen for the mechanistic studies of their 
anti-leukemic activities. Using the tritiated thymidine ([^H]-TdR) proliferation assay, 
the results showed that the four topoisomerase-targeting agents inhibited the in vitro 
proliferation of six human and murine leukemia cell lines in a dose-dependent manner, 
with an estimated 50% inhibitory concentration (IC50) ranged from 3 - 400 nM. The 
results of the kinetic study also showed that both HCPT and EP inhibited the 
proliferation of JCS cells in a time-dependent manner. Besides using the [^H]-TdR 
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proliferation assay, the effects of HCPT and EP on the growth and clonogenicity of 
JCS cells were studied by the trypan blue exclusion assay and the soft agar clonogenic 
assay respectively. It was found that both HCPT and EP reduced the number and the 
% cloning efficiency of JCS cells at relatively non-cytotoxic concentrations. The 
anti-proliferative effect of HCPT on JCS cells seemed to be irreversible, whereas that 
of EP was reversible after 12 and 24 hours of incubation. In addition to the in vitro 
growth-inhibitory effect, both HCPT and EP inhibited the tumorigenicity and 
proliferation of JCS cells in vivo. Despite their potent anti-leukemic effect, the direct 
cytotoxicity of HCPT and EP on normal hematopoietic cells in vitro was minimal. In 
addition, their inhibitory effect on JCS cell proliferation appeared to be due to 
cytostatic rather than cytotoxic effect of the drugs, especially at lower concentrations. 
To investigate how HCPT and EP exerted their growth-inhibitory effect on the 
leukemia JCS cells, mechanistic studies were performed. These included the cell 
cycle study, the studies on the differentiation- as well as the apoptosis-inducing 
effects of HCPT and EP on JCS cells. The results of the cell cycle study showed that 
HCPT and EP arrested the JCS cell cycle at the Gq/Gi phase with a decrease in the 
percentage of JCS cells at the S phase. This disturbance of the cell cycle progression 
might be contributed by the alterations in the expression of the cell cycle-regulatory 
genes. The results of reverse transcription-polymerase chain reaction (RT-PCR) 
showed that HCPT slightly down-regulated the mRNA expression of cyclin A, cyclin 
B and cyclin E, however, EP had no appreciable effect on the expression of these three 
genes under the same experimental conditions. On the other hand, both HCPT and EP 
enhanced the mRNA expression of cyclin D3 and down-regulated the expression of 
Cdk-2 and Cdk-6. In addition, the combination effect of HCPT or EP with cytokines 
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on the proliferation of murine myeloid leukemia JCS cells was studied. Among the 
three cytokines tested, only TNF-a was found to act in synergy with HCPT and EP in 
inhibiting the proliferation of the JCS cells. IFN-y and IL-ip, however, gave only an 
additive inhibitory effect on JCS cell proliferation when combined with either HCPT 
or EP. 
The differentiation-inducing activity of HCPT and EP was examined by their 
effects on the morphological, functional and phenotypic characteristics of the 
leukemia JCS cells. It was found that both HCPT and EP induced morphological 
changes in JCS cells, including cell enlargement and an increase in cytoplasm to 
nucleus ratio. Flow cytometric analysis showed that both drugs increased the size and 
granularity of JCS cells. Besides morphological changes, HCPT and EP also exerted 
some functional changes in JCS cells. These included the increase in plastic adhering 
ability, the production of superoxide anions and non-specific esterase activity in JCS 
cells. In addition to functional changes, both HCPT and EP also enhanced the 
phenotypic expression of macrophage differentiation antigens Mac-1 and F4/80 in the 
JCS cells. Taking together, the results suggested that both HCPT and EP could induce 
the leukemia JCS cells to undergo differentiation via the macrophage/ monocyte 
pathway. 
In addition to the induction of differentiation, HCPT and EP also induced 
apoptosis-related morphological and biochemical changes in JCS cells. These 
included nuclear disintegration, intemucleosomal DNA fragmentation and the 
translocation of phosphatidylserine to the outer plasma membrane. The effect of 
HCPT and EP on the expression of apoptosis-related genes was also analyzed by 
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RT-PCR and Western blotting. It was found that both HCPT and EP enhanced the 
mRNA and protein expression of the pro-apoptotic FasL gene, whereas the expression 
of the anti-apoptotic Bcl-2 gene was down-regulated by both drugs. Interestingly, the 
mRNA expression of BCI-XL was only down-regulated by HCPT but not EP. To 
further investigate the underlying mechanisms of HCPT- and EP-induced apoptosis in 
the leukemia JCS cells, the activities of the downstream caspases 3, 8 and 9 were 
measured by fluorometric assay. It was found that both HCPT and EP significantly 
increased the activities of these three caspases. Using flow cytometry, mitochondrial 
membrane depolarization was also detected in JCS cells treated with HCPT and EP. 
I • 
Since Ca is known to play a pivotal role in apoptosis, therefore, the possible 
involvement of the calcium signaling system in the HCPT- and EP-induced apoptosis 
in JCS cells was also investigated. Our results, however, revealed that neither HCPT 
nor EP increased the intracellular Ca�— level in JCS cells under the prescribed 
experimental conditions. Collectively, our data suggested that both HCPT and EP 
could trigger the leukemia JCS cells to undergo apoptosis via both the death receptor 
and the mitochondrial pathways. 
In conclusion, the above findings showed that HCPT and EP might mediate their 
potent in vitro growth-inhibitory activity on the murine myeloid leukemia JCS cells 
via at least 3 ways: the induction of cell cycle arrest, differentiation and apoptosis. 
Moreover, the combination of HCPT or EP with TNF-a might have enhanced efficacy 
in the treatment of myeloid leukemia. Collectively, our study has provided a better 
insight into the action mechanisms behind the anti-leukemic activity of HCPT and EP. 
It is hoped that more effective therapeutic strategies can be developed for the 












目前，我們採用了一種已知其特點的氣科骨髓白血病純系細胞株W E H I - 3 B 





類及鼠科血癌細胞株的增生，而 I C s o值則介乎 3至 4 0 0納摩之間。動態性研究亦 
指出 1 0 -氫基-喜樹驗和雄依托泊芽能以時間依賴的方式抑制 J C S血癌細胞的增 
生。除此之外，我們發現低濃度的 1 0 -氫基-喜樹驗和填依托泊苦能減少 J C S細 
胞的數目及其克隆形成之能力。10-氫基-喜樹驗的抑制生長能力看來是不可逆轉 
的，這和填依托泊苦的實驗結果剛好相反。除了體外實驗，我們亦利用小白鼠進 



























除此之外， 1 0 -氫基-喜樹驗和填依托泊苦亦能令 J C S血癌細胞的細胞核分 
解、細胞核内的脫氧核糖核酸斷裂及令其鍵結絲胺酸的印填脂翻轉至細胞外一這 
些都是細胞〉周亡之特徵。利用反轉錄聚合錄鍵反應及西方免疫轉漬法，我們發現 











抑制 J C S血癌細胞之增生一這包括對細胞週期的改變、細胞分化與及调亡。我 
們希望上述的研究結果，有助我們發展出一些更有效的血癌療法。 
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Chapter 1 General Introduction 
1.1 What is hematopoiesis? 
Every day the human body produces billions of blood cells for normal tissue 
turnover as well as for body defense. This highly orchestrated process of blood cell 
development and homeostasis is known as "hematopoiesis" (Smith, 2003). In this 
section, several aspects of hematopoiesis in humans, including the complex network 
of hematopoietic development and the regulation of this life process by various 
environmental and genetic factors, will be reviewed. What happens if this "orchestra" 
goes astray? Therefore, besides normal hematopoiesis, the pathological features, 
molecular basis as well as current therapeutic strategies of leukemia — the malignant 
form of hematopoiesis, will be discussed. 
1.1.1 The development of hematopoietic progenitor cells 
Human blood contains a variety of mature blood cells, for example, B and T 
lymphocytes, erythrocytes and monocytes. These cell lineages play different roles in 
the human body, however, despite their functional diversity, they are originated from a 
common "ancestor" — the hematopoietic stem cells (HSCs) (Weissman et al.’ 2000). 
In humans, hematopoiesis begins early in the stage of embryogenesis. Two waves of 
V 
hematopoietic stem cell generation take place in the first month of human gestation. 
The first one occurs in the yolk sac, generating myeloid precursor cells devoid of 
lymphoid potential. On the other hand, recently it was identified that from the day 
of gestation, the development of hematopoietic cells takes place on the ventral 
endothelium of the dorsal aorta and vitelline artery. Cells emerging in that territory are 
the first multipotent, lympho-myeloid progenitors in human ontogeny (Peault et al” 
2002; Tavian et aL, 2001). Hematopoiesis then continues in the liver and spleen at 
— 
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mid-gestation. Finally, from the sixth to seventh month of fetal life and thereafter, the 
red bone marrow gradually becomes the major organ for hematopoiesis (Hoffbrand et 
a/., 2001). 
The process of hematopoiesis is depicted in Figure 1.1. As mentioned previously, 
this complex hematopoietic network begins with hematopoietic stem cells, which are 
pluripotent and self-renewable. HSCs are able to generate every lineage found in the 
hematopoietic system through intermediate progenitors (Jones et al., 1996). These 
include the common myeloid and lymphoid progenitors, which have their unique 
lineage specificity. Common myeloid progenitors can generate only basophils, 
eosinophils, erythrocytes, granulocytes, monocytes and platelets; on the contrary, 
common lymphoid progenitors generate only B and T lymphocytes. Hematopoiesis 
therefore involves irreversible differentiation commitment of the progeny to one or 
other lineage, and progressive maturation of cells within each lineage (Metcalf, 1998). 
V 
_ — 
Chapter 1 General Introduction 
^ Pluripotent stem cell 
變 趣 
Myeloid progenitor Lymphoid progenitor 
/ � � 
CFU-baso CFU-meg BFU-ery B or T cell progenitor 
CFU-eosin BFU-GM \ ” 
I Z � CFU-ery 
i B or T cell precursor CFU-M CFU-G 
i ^ I J 1 i 、 ii # 
I ^ t Eosinophil f i P ^ Monocyte ^ , Mature B or ^ 「， 一 Erythrocyte Basophil , ^ T lymphocyte Megakaryocyte Granulocyte 
V 
Figure 1.1. Development of hematopoietic lineages from pluripotent 
hematopoietic stem cells. Mature blood cells are developed from pluripotent 
hematopoietic stem cells. Generally speaking, throughout the whole developmental 
process, the proliferative capacity of the cells decreases with increasing degree of 
differentiation in their functions and number (flow chart modified from Alberts et al., 
1994; microscopic photos from Krause et al, 1997 and Wagner et al.，1998) 
BFU: burst-forming unit; CFU: colony-forming unit; GM： granulocyte-macrophage 
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1.1.2 The regulation of hematopoiesis by environmental factors 
For the sake of homeostatsis, hematopoiesis is under strict control by both 
environmental and genetic factors. In this section, the influence of environmental 
factors on the hematopoietic process will be discussed. 
Recently, there have been accumulating information on the role of cytokines in 
the regulation of hematopoiesis. Probably cytokines are the best-characterized 
environmental regulators of hematopoiesis (Zhu et al., 2002). Cytokines are a broad 
family of proteins mediating both the positive and negative signals on cellular 
quiescence, apoptosis, proliferation and differentiation. Generally speaking, cytokines 
function by binding to specific receptors. This ligand-receptor interaction then 
triggers a variety of signaling pathways, including protein kinase C (PKC) and 
mitogen activated protein kinase (MAPK) pathways (Rane et al.’ 2002). Under 
normal conditions, the survival and proliferation of HSCs are maintained at a basal 
level. This basal level is maintained by low levels of cytokines like F13 ligand, stem 
cell factor, thrombopoietin and additional cofactors produced by endothelial cells, 
fibroblasts and osteoblasts lining the bone marrow cavity. On the other hand, 
granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony 
stimulating factor (GM-CSF) from osteoblasts, thrombopoietin and the endocrine 
delivery of low levels of erythropoietin promote basal differentiation of HSC to 
granulocyte-monocyte lineage (Figure 1.2, top panel). 
Nevertheless, hematopoiesis is not always maintained at its basal level. In fact, it 
is constantly subjected to changes by other environmental factors like physiological 
stresses. Stresses enhance the production and delivery of lineage-specific cytokines, 
— 
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and this in turn leads to lineage-specific amplification of hematopoiesis. For example, 
increased erythropoietin is produced in kidney in response to hypoxia or anemia. 
During inflammation and infection, endothelial cells and fibroblasts secrete increased 
quantities of G-CSF and GM-CSF in response to interleukin-la (IL-la) and tumor 
necrosis factor-a (TNF-a) production by activated macrophages or monocytes. In 
addition, fibroblasts may also secrete increased amount of thrombopoietin in response 
to the production of transforming growth factor (TGF) by activated T cells or 
activated fibroblasts themselves (Figure 1.2, bottom panel). This lineage-specific 
amplification of hematopoiesis, together with better survival of progenitor and mature 
blood cells, fulfill what the body needs under physiological stress. When these 
stresses cease, the anti-apoptotic and proliferative processes would slow down, and 
hematopoiesis returns to its basal level (Koury et aL, 2002; Smith, 2003; Zhu et al., 
2002). 
— 
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Figure 1.2. Cytokine production in basal and amplified hematopoiesis. (Top panel) 
In normal conditions, hematopoiesis is maintained at a basal level. Nevertheless, 
physiological stresses can lead to lineage-specific amplification of hematopoiesis 
(Bottom panel). This amplification is promoted by the production and delivery of 
lineage-specific cytokines. 
V 
endo, endothelial cells; FB, fibroblasts; Flt-31, F13 ligand; HSC, hematopoietic stem 
cells; OB, osteoblasts; SCF, stem cell factor; TPO, thrombopoietin 
Adapted from Zhu et al, 2002 
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1.1.3 The regulation of hematopoiesis by transcription factors 
The role of environmental factors in hematopoiesis has been highlighted in 
section 1.1.2. In addition to this aspect, several transcription factors have been found 
to play critical roles in hematopoiesis, the typical examples include SCL, GATA-2, 
Lmo-2 and PU. 1. 
SCL stands for the stem cell leukemia hematopoietic transcription factor. SCL, 
also known as Tal, is essential for both primitive and definitive hematopoiesis. SCL 
protein shares homology with several basic-helix-loop-helix (bHLH) transcription 
factors within a restricted region of 56 amino acids. It can bind to E-box motif of 
DNA (CANNTG) in vitro (Zhu et al., 2002). In 1995, Robb and his colleagues studied 
the physiological role of SCL by using knockout mice. Mice heterozygous for the scl 
null mutation were intercrossed and their offspring were genotyped. Histological 
studies revealed the complete absence of recognizable hematopoiesis in the yolk sac 
of scl'^' embryos. In addition, transcripts of GATA-1 and PU.l transcription factors 
were absent in the RNA sample extracted from scl'^' yolk sacs and embryos. The 
results imply that SCL may be a crucial regulator of early hematopoiesis (Robb et al” 
�1995). 
Like SCL, GATA-2 is essential for both primitive hematopoiesis in yolk sac and 
definitive hematopoiesis in fetal liver, spleen and adult bone marrow. This is evident 
by both knockout experiments and the studies on clinical samples. In a knockout 
experiment, GATA-2''' embryonic stem cells were inoculated into wild type 
blastocysts, and the contribution of these mutant cells to hematopoiesis was 
undetectable in both fetal liver and adult hematopoietic compartment of chimeric 
— 
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mice (Tsai et ai, 1994). In the clinical samples from patients with aplastic anemia, the 
GATA-2 expression was found to be decreased in the CD34+ bone marrow cells 
(Fujmaki et al., 2001). Taken together, it is evident that GATA-2 plays a critical role 
in the regulation of hematopoiesis. 
The LIM-finger protein Lmo2 is required for yolk sac erythropoiesis., Again, in a 
knockout experiment, it was found that Lmo2''' mouse embryonic stem cells do not 
contribute to any hematopoietic lineage in adult chimeric mice, however, the 
reintroduction of an Lmo2-expression vector resumes the ability of Lmo2''' mouse 
embryonic stem cells to contribute to all lineages tested. Thus, Lmo2 plays a crucial 
role in the hematopoietic development (Yamada et ai, 1998). 
PU.l is a member of the Ets family of transcription factors. It controls early 
myeloid differentiation. This is evident by the deficiency of 7-knockout mice in 
developing mature macrophages, neutrophils, B cells and T cells, although 
erythrocytes and megakaryocytes were present (McKercher et cd； 1996). Another 
study showed that in PU. 1 -overexpressing hematopoietic precursors, lymphoid 
development is blocked whereas macrophage development is promoted (Anderson et 
ai, 2002). In addition, many myeloid specific promoters have PU.l binding sites 
upstream of the transcription start sites, for example, the genes encoding 
macrophage-colony stimulating factor (M-CSF) receptor (c-fms), granulocyte-colony 
stimulation factor (G-CSF) receptor, granulocyte-macrophage-colony stimulating 
factor (GM-CSF) receptor, scavenger receptor, CD 1 lb/CD 18 (Mac-1), 
myeloperoxidase (MPO), lysozyme, IL-1, etc. (Friedman, 2002). Taken together, it is 
evident that PU. 1 is a very critical regulator for determination of the developmental 
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pathway toward the myeloid lineage in hematopoiesis. 
1.2 Leukemia 
In 1847, the German pathologist Rudolf Virchow firstly described leukemia as 
"white blood" because microscopically, the relationship between red and colourless 
corpuscles was the reverse of the normal. Leukemia is the cancer of white blood cells. 
Leukemia starts in bone marrow but it can spread to the circulation, lymph nodes, 
spleen, liver, central nervous system and other organs (American Cancer Society, 
2003). It is due to the uncoupling of proliferation and differentiation of hematopoietic 
progenitor cells, resulting in neoplastic proliferation of these cells with the loss of 
differentiation capacity (Hoffbrand et al., 2001). 
According to Census and Statistics Department, cancer was the first "killer" 
disease in Hong Kong (Table 1.1). The death rate of malignant neoplasms per 100,000 
population was 169.6 and 167.8 in 2001 and 2002 respectively. The death rate is more 
than the double of the death rate of heart disease (Census and Statistics Department, 
2003). In Hong Kong, childhood cancer claims the lives of 60-70 children a year with 
V 
120-150 new cases each year. It is the second major cause of death among children 
above the age of one, and this is only next to accidents and poisoning. Leukemia is one 
of the most common types of childhood cancer (Children's Cancer Foundation, 2003). 
It is threatening the life of Hong Kong citizens, especially the young population and 
therefore it is worthy of considerable attention. In the following sections, a brief 
introduction will be made to the classification, pathology, etiology, molecular basis 
and current therapeutic strategies of leukemia. 
— 
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Table 1.1. Number of deaths and death rates by leading cause of death 
^ 2001 2002 
Cause Number Rate* Number Rate* 
Malignant neoplasms 11,406 169.6 11,389 167.8 
Diseases of heart 4,703 69.9 5,087 75.0 
Cerebrovascular disease 3,130 46.5 3,144 46.3 
Pneumonia 3,026 45.0 3,298 48.6 
Chronic lower respiratory 之，似 31.4 2,208 32.5 
diseases 
I 
*Death rate per 100,000 population 
(Modified from Census and Statistics Department, 2003) 
V 
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1.2.1 Classification of leukemia 
Leukemia is classified into acute or chronic according to the maturity of the 
leukemia cells. In acute leukemia, the leukemia cells fail to differentiate properly and 
they appear immature. Acute leukemia has a sudden onset with rapid progression. In 
chronic leukemia, on the contrary, the leukemia cells appear mature, but they are 
usually functionally abnormal. The lifespan of chronic leukemia cells is much longer 
than normal leukocytes, resulting in the over-infiltration of mature granulocytes or 
lymphocytes in bone marrow. Typically, chronic leukemia has a gradual onset with a 
prolonged clinical course. Anemia, neutropenia and thrombocytopenia are usually the 
consequences of bone marrow failure, which can lead to infection and hemorrhage 
(Dexter, 1977). 
Leukemia can also be classified into myeloid or lymphoid according to cell 
lineage. Lymphocytic leukemia develops from lymphocytes in bone marrow. Myeloid 
leukemia develops from either granulocytes or monocytes. Taking the two criteria 
together, there are four common types of leukemia: acute myeloid leukemia (AML), 
acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and chronic 
lymphoblastic leukemia (CLL). 
The French-American-British (FAB) system is commonly used in leukemia 
classification (Bain & Catovsky，1990). Based on light microscopy, electron 
microscopy, immunophenotyping, cytogenetic and molecular markers, the system 
subdivides ALL into three subtypes (L1-L3), AML into eight subtypes (M0-M7), 
CML with Philadephia chromosome (a reciprocal translocation between chromosome 
9 and 22) into six subtypes and CLL into seven subtypes (Hayhoe & Flemants, 1992). 
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A summary of the FAB system is shown in Table 1.2 and Figure 1.3. Originally, the 
FAB system was based entirely on the morphological appearance of bone marrow and 
peripheral blood films supplemented with certain cytochemical reactions (for example, 
Sudan black B for identifying granulocytic variants and non-specific esterase for 
identifying monocytic differentiation). In 1985 the system was revised to include the 
identification of surface markers and cytogenetics (Coasgeun & Bennett 1993), 
providing important therapeutic and prognostic information. 
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Table 1.2. The French-American-British (FAB) classification of leukemia 
Type Subtype ^ FAB type 
MO: minimal differentiation but positive 
antigenic markers 
Ml: myeloblastic (> 90% myeloblasts) 
M2: myeloblastic with granulocytic maturation 
(> 10% promyelocytes or later granulocytes) 
M3: promyelocytic (coarsely granular or Acute myeloid , � microgranular promyelocytes) leukemia (AML) , , M4: myelomonocytic (> 20% granulocytes and > 
20% monocytes) 
Acute M5A: monoblastic 
M5B: promonoblastic 
M6: erythroblastic (> 50% erythroblasts) 
M7: megakaryoblastic (>50% megakaryoblasts) 
LI: homogeneous small blasts with little 
cytoplasm Acute L2: heterogeneous larger blasts with variable lymphoblastic amounts of cytoplasm leukemia (ALL) , " . , , L3: homogeneous large blasts with vacuolated 
basophilic cytoplasm 
Philadelphia-positive chronic myeloid leukemia 
Philadelphia-negative chronic myeloid leukemia 
Chronic myeloid Juvenile chronic myeloid leukemia 
leukemia (CML) Chronic neutrophilic leukemia 
Eosinophilic leukemia 
Chronic myelomonocytic leukemia 
Chronic B-chronic lymphocytic leukemia 
B-prolymphocytic leukemia 
Chronic Hairy cell leukemia 
lymphoblastic Plasma cell leukemia 
leukemia (CLL) T-chronic lymphocytic leukemia 
T-prolymphocytic leukemia 
Adult T-cell leukemia/ lymphoma 
Modified from Hoffbrand et al.’ 2001 
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Figure 1.3. Diagrammatic representation of hematopoietic cascade with the FAB 
classification 
Adapted from Roslyne, 1999 
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1.2.2 Pathology and etiology of leukemia 
In section 1.2.1 it can be seen that acute leukemia has a sudden onset with rapid 
progression. In general, leukemia is a disease of abnormal cellular development 
(Seeker-Walker & Goldman, 1989). Leukemia cells are often unresponsive to growth 
factors and they cease to undergo the normal maturation process. The ceased or 
retarded cellular maturation leads to crowding of bone marrow with immature cells, 
inhibiting normal hematopoiesis including the production of normal mature white 
blood cells, which are the "soldiers" defending our body. Hence, leukemia patients are 
at risk of infection, and they may also suffer from other hematopoietic abnormalities 
like anemia and thrombocytopenia due to reduced production of red blood cells and 
platelets. In addition, the infiltration of lymph nodes, liver, spleen and brain with 
leukemia cells may occur, disturbing the normal function of body organs. 
Up till now, the causes of leukemia are unknown. The possible etiological factors 




The role of family history of cancer in leukemia etiology is controversial in both 
childhood and adult leukemia. In 1990，McKinney and his colleagues examined the 
records of 788 survivors of childhood leukemia bom between 1940 and 1969 and 
none of the 382 children bom to them have developed leukemia (McKinney et al.’ 
1990). Nevertheless, in 2001, Perrillat and colleagues suggested that a family history 
of cancer may be a risk factor for childhood acute leukemia in a study investigating 
the role of a family history of solid tumor or hematologic neoplasm in the etiology of 
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childhood acute leukemia (Perrillat et aL, 2001). For adult leukemia, an early study 
reported an unusual family history of cancer in adult ALL, with evidence of an 
increased risk in individuals with a family member diagnosed with leukemia 
(McKinney et al； 1990). Other studies suggested that the incidence of leukemia is 
higher in monozygous twins (Miller, 1968; Rosner & Lee, 1972). On the contrary, 
Rauscher and colleagues reported that the role of family history of cancer in leukemia 
etiology is unclear in their study (Rauscher et al.’ 2002). Clearly, the role of 
inheritance in leukemia needs further investigation. 
1.2.2.2 Environmental factors 
Three types of factors are under this category: chemicals, drugs and radiation. It 
has been well documented that exposure to high levels of certain chemicals is 
leukemogenic. Cigarette smoke is a typical example. In Britian, cigarette smoke was 
estimated to cause as many as 25% of all cases of AML (Austin & Cole, 1986; Kinlen 
& Roget, 1988). Exposure to other chemicals like benzene may cause bone marrow 
hypoplasia, dysplasia and chromosome abnormalities and is an unusual cause of 
myelodysplasia of AML. Certain drugs including alkylating agents (Brenner & Carter, 
1984), chloramphenicol (Shu et al., 1987) and phenylbutazone (Friedman, 1982) have 
been shown to be related to leukemia. In particular, the combination of alkylating 
agents in chemotherapy and irradiation results in higher incidence of "secondary" 
leukemia. Exposure to high doses of radiation is closely related to leukemogenesis. 
This is illustrated by the studies on the Japanese survivors of atomic bomb 
detonations showing increased events of CML (Greaves, 1987). 
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1.2.2.3 Virus infection 
It is well known that viruses can cause leukemia in vertebrates and in 
experimental animal models, however, conclusive evidence that viruses can directly 
cause leukemia in humans is still lacking. Nevertheless, the involvement of virus has 
been implicated in the induction of leukemia and lymphoma in humans. Human 
T-lymphotropic virus type 1 (HTLV-1) is one of the examples. It has been found that 
HTLV-1 has been associated with an adult T-cell leukemia/ lymphoma (ATLL) 
syndrome in patients of Caribbean or Japanese origin (Blattner, 1989; Gerard et ai, 
1995). ATLL is a T cell malignancy that occurs in �3-5o/o of HTLV-1 infected 
individuals after a very long period (40-60 years) of clinical latency (Mortreux et al, 
2003). Moreover, recent research suggested the possible co-existence of HIV infection 
and B chronic lymphoblastic leukemia (B-CLL) (Ravandi et al., 2003). Nevertheless, 
the role of retroviruses in human leukemogenesis remains unclear. 
1.2.3 Genetics of leukemia 
Recently, scientists have got a better picture about the genetic basis of leukemia. 
Generally speaking, there are four mechanisms of gene abnormality in leukemia. They 
are point mutations, translocations, gene and chromosomal deletions and 
chromosomal duplication or gene amplification. The genetic abnormalities commonly 
observed in different types of leukemia are summarized in Table 1.3. 
1.2.3.1 Point mutations 
The gain-of-function mutations in oncogenes can disturb the balance in cell 
proliferation. RAS oncogenes are one of the examples. A point mutation in one of the 
three codons (12, 13 or 61) accounts for virtually all of the activated RAS alleles in 
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human cancers. RAS oncogene activation commonly occurs in AML (20-30%), ALL 
(15-20%), myelodysplasia (20-40%) and myeloma (20%). N-RAS activation is the 
usual mutation found in hematopoietic malignancies. 
1.2.3.2 Translocations 
Translocation is the state in which part of a chromosome becomes attached to a 
different chromosome and is commonly observed in leukemia. Chimeric gene 
formation is one of the mechanisms in this aspect. Chimeric gene is formed by the 
fusion of parts of two genes. It encodes a novel "fusion protein" which may contribute 
to malignant change. Examples are BCR-ABL in t(9; 22) in CML and RARa-PML in 
t(15; 17) in AML Ms. 
1.2.3.3 Gene and chromosomal deletions 
The loss-of-flinction deletion of tumor-suppressor gene can promote leukemic 
formation. Deletion involves the removal of a sequence of DNA. This may involve a 
small part of a chromosome, the short or long arm or the entire chromosome. Deletion 
commonly occurs in chromosomes 5, 6，7, 11, 20 and Y (Hoffbrand et al., 2001). 
V . 
1.2.3.4 Chromosomal duplication or gene ampliHcation 
Chromosomal duplication involves a tandemly repeated DNA sequence because 
of replication accident or unequal crossing over. Gene amplification, on the other 
hand, involves the creation of extra, functional copies of genes in a cell or organism. 
It is not common in hematopoietic malignancies. In both processes, gains are 
commonly observed in chromosomes 8，12，19’ 21 and Y (Hoffbrand et al., 2001). 
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Table 1.3. Genetic abnormalities commonly observed in different types of 
leukemia 
Disease Genetic abnormality Oncogene(s) involved 
Myeloid 
t(8; 21) (q22; q22) ETO and CBFa (AMU) AML M2 
t(6; 9) DEK, CAN 
AMLM3 t(15;17) RARa, PML 
AMLM4 inv(16)(pl3q22), del(16q) CBFp, MYHll 
AML Ms del(llq); t(9; l l ) ; t( l l ; 19) ^ 
-5/del(5q); -7/del(7q) Unclear 
MDS* Point mutation N-RAS 
Secondary myeloid llq23 translocations MLL gene leukemia 
CML t(9; 22) ABL, BCR 
Myeloproliferative 20q-� P ^ DETtoFGFRl disease t(8; 13) 
Lymphoid 
t(12;21) TEL, AMU 
t(4; 11) AF4, MLL (ALU, HRX) 
t(9; 22) ABL, BCR 
Precursor B lineage 
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1.2.4 Current therapeutic strategies for leukemia 
With better understanding of the genetics and pathology of leukemia, scientists 
are making progress in tailoring new therapies for this disease. Generally, the current 
therapeutic strategies for leukemia include chemotherapy, stem cell transplantation, 
immunotherapy and gene therapy. 
1.2.4.1 Chemotherapy 
Chemotherapy involves the application of drugs to destroy cancer cells. It is 
often used together with surgery or radiation to treat cancer during metastasis and 
recurrence, or when there is a strong chance that it could recur. Generally speaking, 
chemotherapy has the advantage of simultaneous delivery of drugs to attack leukemia 
cells in circulation. Nevertheless, another side of the coin is a long list of side effects 
such as the loss of appetite, hair and weight; change in taste, nausea, vomiting, 
diarrhea, esophagitis and fatigue, which may be likely due to the cytotoxicity of drugs 
on normal cells (Hoffbrand et al., 2001). 
Currently, some chemotherapeutic agents have been studied in the treatment of 
CML. These include homoherringtonine with IFN-a, paclitaxel, QS21 (a plant extract 
that enhances immune responses) as part of a vaccine prepared from leukemia cells, 
monoclonal antibodies, combination of amifostin and GM-CSF/ interleukins. On the 
other hand, PSC 833 (a cyclosporine analogue used with chemotherapy to overcome 
drug resistance), dolastatin 10 and bryostatin have undergone phase II clinical trials. 
In addition, a new drug called STI571 (Glivec) has been found effective in treating 
CML that is in accelerated phase or in blast crisis, as well as in CML that no longer 
responds to interferon. The side effects of the drug were few and generally mild, 
Chapter 1 General Introduction 
although the liver was affected in a small number of patients. Despite the advances in 
new drug development, clearly continuous research is needed to develop 
chemotherapeutic regimens with potent anti-tumor activities and minimal side effects 
(American Cancer Society, 2003). 
1.2.4.2 Stem cell transplantation 
Stem cell transplantation (SCT) is a procedure involving the elimination of an 
individual's hematopoietic immune system by chemotherapy and/ or radiotherapy and 
replacing it with stem cells either from another individual or with a previously 
harvested portion of the individual's own hematopoietic stem cells. SCT includes both 
bone marrow transplantation (BMT), which is the collection of stem cells from bone 
marrow, and peripheral blood stem cell (PBSC) transplantation, which involves the 
collection of stem cells from peripheral blood. The exact role of SCT in the 
management of hematological diseases depends on factors like disease severity and 
subtype, remission status, age and, for allogeneic transplantation, the availability of 
donors (Hoffbrand et al., 2001). One of the examples for the application of SCT is the 
treatment of CLL. For CLL, institutions have begun trials of autologous marrow 
transplantation. There are also trials of a procedure called ”Transplant-Lite." In this 
approach, CLL patients are given doses of chemotherapy that are not high enough to 
destroy the bone marrow. They are then given stem cells from a compatible donor. 
These stem cells will grow in the marrow alongside the person's own cells and 
actually produce antibodies to the CLL cells and destroy them (American Cancer 
Society, 2003). 
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1.2.4.3 Immunotherapy 
Clinical studies have shown that the human immune system plays an important 
role in the control of various hematological malignancies. Nonetheless, leukemia can 
evade the immune responses because of the existence of various tumor escape 
mechanisms. Novel approaches to immunotherapy of leukemia aim at the reversal of 
immune escape mechanisms either by correction of the immune deficiency in the 
patients or by amplification of the immune mechanisms (Costello et al., 2003). 
The role of cytokines (hormone-like substances that regulate the immune system), 
such as interferons and interleukins, in cancer treatment is still evolving. Studies are 
in progress to determine the best way to combine these substances with other 
treatments such as chemotherapy, and to identify which types of leukemia are likely 
to respond. 
Another important type of immunotherapy is monoclonal antibodies. These are 
similar to the antibodies naturally produced by the immune cells to fight infections. 
The difference is that monoclonal antibodies can be created in the laboratory to 
specifically react with certain types of cancer cells. Some of these monoclonal 
antibodies can direct the patient's immune system to react and destroy the cancer cells. 
Another approach is to attach radioactive atoms to the monoclonal antibody. By 
specifically attaching to the cancer cells, the antibodies can target radiation therapy to 
destroy these cells. 
The use of dendritic cells (DC) in the immunotherapy of myeloid leukemia has 
also been studied (Choudhury et al., 1997; 1999). It has been shown that leukemic 
— 
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myeloid cells can be transformed to DC in the presence of GM-CSF. The transformed 
leukemic DC can then be used as vaccines for the generation of anti-leukemic 
immunity. 
1.2.4.4 Gene therapy 
As scientists are learning more about the DNA changes that cause normal bone 
marrow cells to become leukemia cells, they are developing ways to reverse or block 
the effect of these changes. For example, viruses that have been modified in the 
laboratory can be used to infect leukemia cells and add pieces of DNA specifically 
designed to repair damaged genes, or block the action of abnormal genes. This 
approach is still in the early stages of testing, but many researchers are optimistic 
about its potential for treating chronic leukemias. 
1.2.5 Novel approaches for the treatment of leukemia 
As mentioned previously, leukemia is caused by the uncoupling of proliferation 
and differentiation in hematopoietic progenitor cells, thus resulting in neoplastic 
proliferation of these cells with the loss of differentiation capacity. Recently, it has 
vbeen reported that natural products such as green tea catechin 
epigallocatechin-3-gallate (EGCG) and coumarins (Leung, 2002; Lung et al., 2002) 
could retard the proliferation of leukemia cells by the induction of differentiation and 
apoptosis. These implied the potential of differentiation therapy and induction of 
apoptosis in the treatment of leukemia. In the following sections details about these 
two novel therapeutic approaches will be discussed. 
— 
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1.2.5.1 Differentiation therapy of leukemia 
Differentiation therapy is a potentially less toxic approach of cancer treatment. It 
is based on the assumption that many cancer cell types exhibit reversible defects in 
differentiation, which upon appropriate treatment, results in tumor "reprogramming" 
and a concomitant loss in proliferative capacity and induction of terminal 
differentiation or apoptosis (Leszczyniecka et aL, 2001). In fact, differentiation 
therapy has had the greatest impact in hematopoietic malignancies. Chemicals such as 
phorbol esters represented one of the first examples of differentiation therapy against 
leukemia (Huberman & Callaham, 1979; Koeffler et al., 1980; Sachs, 1978). Previous 
researches also shown that physiological compounds or natural products such as 
cytokines, all-trans retinoic acid, bryostatin I and arsenic trioxide could induce 
leukemia cells to undergo differentiation (Cai et al” 2000; Drach et al., 1994; Kraft et 
al., 1989). The induction of differentiation in leukemia cells may be achieved by the 
direct interaction with DNA or indirect activation of other differentiation inducers 
(Sachs 1987). Table 1.4 shows some examples of inducers of myeloid cell 
differentiation. 
V 
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Table 1.4. Examples of inducers of myeloid cell differentiation. 
Differentiation inducers > Examples 
Chemotherapeutic agents Daunomycin，methotrexate, mitomycin C 
Actinomycin D, 5-bromodeoxyuridine, DNA-mteractmg agents . nitroso-guanidine 
Natural products Arsenic trioxide, bryostatin I 
Polycyclic hydrocarbons Benzopyrene, dimethylbenzanthracene 
Steroid hormones Dexamethsone, hydrocortisone, oestradiol 
Vitamins Vitamin A, retinoids, vitamin D3 
Modified from Sachs, 1993 
1.2.5.2 Induction of apoptosis in the treatment of leukemia 
Besides differentiation therapy, induction of apoptosis is another novel approach 
in the treatment of leukemia (Mak et al., 2002). Apoptosis is of physiological 
importance in maintaining homeostasis of an organism. It is a process by which an 
unwanted cell "commits suicide" after receiving the death signal from a sophisticated 
network of signaling cascades. The details about these cascades will be discussed in 
chapter 5. During apoptosis, a cell shows a variety of characteristic morphological and 
biochemical features. First of all, there is a marked decrease in cell volume with an 
increase in buoyant density. The nucleus of the cell condenses, and this is followed by 
invagination of the nuclear membrane and nuclear fragmentation. The cytoplasm 
condenses, and finally the membrane architecture is broken down with the formation 
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of membrane blebbings. Eventually, the cell is fragmented and separated into 
membrane-bound apoptotic bodies with closely packed nuclear materials and 
well-preserved cytoplasmic organelles (Golstein et al., 1991). The morphological and 
biochemical changes associated with apoptosis are summarized in Table 1.5. 
Table 1.5. Morphological and biochemical features of apoptosis 
Morphological features 
- Membrane blebbing, but no loss of integrity 
- Aggregration of chromatin at the nuclear membrane 
- B e g i n s with shrinking of cytoplasm and condensation of nucleus 
- E n d s with fragmentation of cell into smaller bodies 
- F o r m a t i o n of membrane bound vesicles (apoptotic bodies) 
-Mi tochondr ia become leaky due to pore formation involving proteins of the bcl-2 
family 
Biochemical features 
- T i g h t l y regulated process involving activation and enzymatic steps 
- E n e r g y (ATP)-dependent (active process, does not occur at 4 
- N o n - r a n d o m mono- and oligo-nucleosomal length fragmentation of DNA 
- Prelytic DNA fragmentation 
厂 Release of various factors (cytochrome C, apoptosis-inducing factor AIF) 
into cytoplasm by mitochondria 
- A c t i v a t i o n of caspase cascade 
-A l t e r a t i ons in membrane asymmetry 
Adapted from Eisel, et al., 2002 
— 
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1.3 Topoisomerase-targeting agents 
Recently, the use of natural products and their derivatives has been increasingly 
popular in cancer chemotherapy. Topoisomerase-targeting agents are one of the 
examples. In this section, the recent advances in the use of this class of natural 
products as chemotherapeutic agents in the treatment of cancer will be reviewed. 
1.3.1 What is topoisomerase? 
Topoisomerase is the major focus of research not only for cancer chemotherapy, 
but also for gene regulation, cell cycle, mitosis and chromosome structure (Wang, 
1987). It is the key molecular target of topoisomerase-targeting agents. In eukaryotic 
cells, the length of the DNA molecule and its anchorage to nuclear matrix attachment 
regions limit the free rotation of one strand around the other for DNA metabolism. 
Topoisomerases adjust DNA topology by making temporary cuts in DNA, allowing 
the DNA to rotate around or transverse through these breaks, thus enabling various 
cellular processes such as transcription and replication (Stewart et al,, 1998; Wang, 
1996). The first type I topoisomerase was characterized in Escherichia coli by James 
Wang in 1971 (Wang, 1971). Up till now, there are three types of topoisomerases 
known in eukaryotes - they are topoisomerase I，II and III (Berger, 1998; Wang, 
1991). A comparison of mammalian topoisomerase I，II and III is made in Table 1.6. 
— 
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Table 1.6. A brief comparison of the mammalian DNA topoisomerase I，II and 
III 
Top I Top Ila Top lip Top III 
Size of 100 kD, 170 kD, dimer 180 kD, dimer llOkD monomer monomer 
Size of mRNA 4.2 kb 6.2 kb 6.5 kb 3.8 kb (mam transcript) 
17pll.2-12.0 
Chromosomal (top3a) 20ql2.0-13.2 17q21-22 3p24 � ^ “ location 22qll-12 
(top3P) 
DNA double-DNA sinele- stranded breaks DNA DSB DNA DSB stranded breaks (DSB) Catalytic . ^ , Covalent Covalent intermediate Covalent , Covalent linkage to 5' linkage to 5' linkage to 3 
. linkage to 5' DNA terminus DNA terminus DNA terminus DNA terminus 
ATP No Yes Yes No 
dependence 
Cell-cycle 
Throughout G2-M Throughout -expression 
(Adapted from Pommier et al.’ 1998) 
V 
1.3.2 Structures and action mechanisms of Top I and Top 
Il-targeting agents 
Mammalian DNA is subjected to the inhibition by a variety of 
topoisomerase-targeting agents. For example, Top I is inhibited by camptothecins, 
indenoisoquinolines and indolocarbazoles (Pommier, et al., 1998; Pommier, 1999); a 
and P forms of Top II are inhibited by Top II poisons, catalytic inhibitors and 
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intercalators; for mammalian Top III，our knowledge about this enzyme is limited and 
therefore there is no information on Top III inhibitor. In this section, the structures 
and action mechanisms of Top I and Il-targeting agents will be briefly discussed. 
The camptothecin family is a class of Top I-targeting agents. They have Top I as 
their unique molecular target. The mother compound of this family, camptothecin, is a 
naturally occurring alkaloid found in the bark and wood of the Chinese tree 
Camptotheca acuminata (Figure 1.4). All camptothecins have a basic five-ring 
backbone with a chiral center located at carbon 20 (C-20) on the terminal lactone E 
ring (Figure 1.5). An intact lactone E ring is essential for Top I inhibitory activity. 
Neutral pH favours the rapid, reversible and non-enzymatic hydrolysis of the lactone 
ring, generating a carboxylate product which is at least ten-fold less active as a Top I 
inhibitor (Fassberg & Stella，1992; Kingsbury et al.，1991). The Top I-inhibitory 
activity of camptothecins is stereospecific, with the naturally occurring (S)-isomer 
being 10 to 100 times more biologically active than the (R)-isomer (Jaxel et al., 1989; 
Wani et al., 1987). Substitutions at C-9 or C-10 tend to increase Top I-inhibitory 
activity and the water solubility of the compound, however, substitutions at C-12 tend 
to decrease its activity (Jaxel et al., 1989). 
To understand the Top I-inhibitory activity of camptothecins, it is necessary to 
understand the mechanism of action of this enzyme. Several steps are involved in this 
process. First, human DNA topoisomerase I binds to the supercoiled, double-stranded 
DNA and cleaves the phosphodiester bond, resulting in a single-stranded DNA nick 
(Figure 1.6). During this process, the tyrosine residue (position 723) in Top I forms a 
transient covalent bond with the 3，end of the nick. This is known as "cleavable 
“ 
Chapter 50 General Introduction 
complex". This allows relaxation of DNA torsional strain either by passage of the 
intact single strand through the gap in the nicked DNA or by free rotation of the DNA 
about the non-cleaved strand. Consequently, the nick is religated and this is followed 
by the dissociation of Top I from the relaxed DNA. Camptothecins work by 
stabilizing the cleavable complex (Hsiang et al.’ 1985). Camptothecins interact 
non-covalently with Top I and this inhibits the religation of the DNA nick (Figure 
1.6). With the accumulation of stabilized cleavable complexes, single-stranded DNA 
breaks persist. Consequently, ongoing DNA synthesis converts this stabilized 
cleavable complex to more lethal DNA damage, according to the “fork collision 
model" (Hsiang et al., 1989). 
V 
— 
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• 
Figure 1.4. A photo of the Chinese tree, Camptotheca acuminata (喜樹)• 
Adapted from http://www.geocities.co.jp/NatureLand-Sky/6168/China/campto.html 
(A) O 
H3C �-�•• OH 
(B) 0 
H 〇 N 
H3C」、、、0H 
Figure 1.5. The chemical structures of (A) camptothecin and (B) 
lO-hydroxy-camptothecin 
Adapted from Calbiochem homepage. 
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Mechanism of action of topoisomerase I 
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Figure 1.6. Mechanisms of action of topoisomerase I and the camptothecins 
Adapted from Takimoto & Arbuck (2001) 
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The etoposide family is a class of Top Il-targeting agents. The mother compound 
of this family, etoposide (VP-16)，is a semisynthetic derivative of podophyllotoxin, 
the active principle in mandrake plants (Figure 1.7) (Cragg & Suffhess，1988). 
Recently, etoposide phosphate (EP) has been designed as a water-soluble prodrug of 
etoposide. EP is readily converted into VP-16 by endogenous phosphatase in plasma 
(Senter et al., 1988). The structures of VP-16 and EP are shown in Figure 1.8. Briefly, 
etoposides are Top II poisons having a characteristic planar aromatic portion. This 
planar aromatic portion mimics a base pair, and therefore it is hypothesized that Top 
II first cleaves the DNA at many sites, and etoposide binds specifically to the 
cleavage sites (3' terminus of cytosine) and prevent religation of these nicks 
(Robinson & Osheroff，1991). 
To have a better understanding of the action mechanisms of the topoisomerase 
Il-targeting agents like the etoposides, the characteristics and mode of action of 
topoisomerase II are briefly described as follows. In contrast to monomeric Top I， 
Top II is a homodimeric enzyme. Its catalytic cycle requires magnesium and ATP as 
an exogenous energy source, therefore Top II is a DNA-dependent ATPase. Top II 
catalyzes DNA strand passage according to the two-gate model (Roca, 1995; Roca & 
Wang, 1994) (Figure 1.9). In the initial stage of the catalytic cycle, the dimeric Top II 
binds to its DNA substrate preferably with the crossover regions. Top II has two 
conformations: open or closed clamp forms in the absence or presence of ATP, 
respectively (Wang, 1998). Top II binds to two segments of double-stranded DNA. It 
cleaves the G (gate) segment to pass the T (transported) segment through the 
enzyme-DNA complex. This step involves a conformational change in the enzyme 
from an open to a closed clamp form upon ATP binding. In the presence of Mg2+ 
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(under physiological conditions), the tyrosine active residue of each Top II monomer 
attacks a DNA phosphodiester bond four bases apart on the G duplex and becomes 
covalently linked to the 5' ends of the DNA nick whereas the 3’ ends are 3'-hydroxyls. 
This is followed by the passage of the T segment through the gap in the G segment. 
After the passage, T segment is released from the clamp, and the nicked G duplex is 
religated by Top II. Finally, the Top II-DNA complex is converted back to the open 
clamp form with the release of the G segment. 
V 
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Figure 1.7. The flower (left) and the fruit (right) of mandrake 
Adapted from © Daniel Reed - www.2bnthewild.com 
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Figure 1.8. The chemical structures of (A) etoposide and (B) etoposide phosphate 
Adapted from Calbiochem homepage 
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Figure 1.9. The catalytic cycle of topoisomerase n. 
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1.3.3 Anti-tumor activities of topoisomerase-targeting agents 
Camptothecins and etoposides are two novel classes of chemotherapeutic agents. 
Camptothecins emerged early in 1950s: a National Cancer Institute drug screening 
program discovered that the extracts derived from Camptotheca acuminata were 
cytotoxic to cancer cells. Until 1966，Wall and colleagues identified that camptothecin 
is the active component of these extracts (Wall, 1998). Because of its potent 
preclinical activity, camptothecin entered clinical trials in 1970s. Due to its 
insolubility in aqueous solutions, camptothecin was formulated as its sodium salt. 
Nevertheless, the results of the phase I studies showed that this sodium salt caused 
severe toxicities such as hemorrhagic cystitis, nausea and dose-limiting 
myelosuppression in cancer patients. After the failure in showing meaningful 
anti-tumor activity in phase II studies, further clinical development of this drug was 
halted (Creaven et al., 1972; Moertel et al, 1972). 
In 1980s, it was discovered that topoisomerase I was the unique molecular target 
of camptothecin (Hsiang & Liu, 1988). Since then, the clinical development of this 
drug was resumed with the development of more soluble, less toxic and even more 
potent camptothecin analogs. For example, in 1996, topotecan hydrochloride was 
approved in the United States for use as second-line chemotherapy for advanced 
ovarian cancer patients (Takimoto & Arbuck, 2001). Irinotecan hydrochloride, another 
camptothecin analog, was approved for use in patients with 5-fluorouracil-refractory 
advanced colorectal cancer (Creemers et a!., 1994; Slichenmyer et al., 1995). The 
application of camptothecins in cancer chemotherapy is of a long list and scientists 
are currently in search of new and potent camptothecin analogs (Yang et al., 2001). 
Like camptothecin, etoposide was introduced in clinical trials in 1971. In 1984， 
— 
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etoposide was approved by the U.S. Food and Drug Administration for marketing by 
Bristol Laboratories under the trade name VePesid. Since then, etoposide is 
commonly used in cancer chemotherapy. (Belani et al； 1994). Etoposide is active 
against a variety of malignant neoplasms, for example, etoposide and cisplatin are 
currently used as standard therapy for patients with small cell lung cancer (Ihde, 
1992). It is also a component of the standard treatment regimen for advanced 
testicular cancer (Richie, 1993). Besides small cell lung cancer and advanced 
testicular cancer, VP-16 is also active against ovarian cancer, non-Hodgkin's 
lymphomas, leukemias and neuroblastomas. As mentioned previously, etoposide 
phosphate has recently been designed as a water-soluble pro-drug of VP-16. This 
enables intravenous administration of this drug at high dosages. Despite its potent and 
diversified anti-cancer activities, there have been reports showing secondary 
leukemias could be induced by etoposide as well as other topoisomerase-targeting 
agents (Felix, 1998). Therefore, the application of these drugs in cancer chemotherapy 
should be taken with care and awaits further investigation. 
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1.4 Aims and scopes of this project 
The earliest description of cancer appeared in Egypt in approximately 1600 B.C. 
(American Cancer Society, 2003). At that time, Edwin Smith Papyrus mentioned in 
his writing about this disease, "there is no treatment". Cancer, including leukemia, has 
afflicted humans throughout the recorded history. With the advances in biomedical 
science, we now have a better picture about leukemia, however, this is only the tip of 
the iceberg - our understanding about the etiology of leukemia is still poor, and we 
are still far from developing the best regimen for the treatment of leukemia with the 
least side effects. To beat this giant, obviously, there is a pressing need for further 
exploration of this disease. 
Nature is a reservoir of chemotherapeutic drugs. Camptothecins, derived from 
the Chinese tree Camptotheca acuminata, and etoposides, with their origin from 
mandrake, are typical examples. Camptothecins and etoposides have been the subjects 
of enormous biochemical, pharmacological and clinical investigations. Their potent 
anti-tumor activity is especially interesting to researchers. Despite their anti-tumor 
potential in clinical situation, the mechanisms behind the anti-tumor activity of 
�camptothecins and etoposides remain obscure. In light of this, our project aims at 
studying the effect of 10-hydroxy-camptothecin, a member of the camptothecin 
family, and etoposide phosphate, a pro-drug of its parent compound etoposide, on the 
proliferation, differentiation and survival of myeloid leukemia cells. 
At the beginning, efforts would be made to study the effects of four 
topoisomerase-targeting agents (including two Top I inhibitors, camptothecin and 
10-hydroxy-camptothecin, as well as two Top II inhibitors, etoposide and etoposide 
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phosphate) on the proliferation of various types of leukemia cells, using the tritiated 
thymidine ([^H]-TdR) proliferation assay. After the initial screening process, further 
studies would focus on the anti-proliferative effect of 10-hydroxy-camptothecin 
(HCPT) and etoposide phosphate (EP), which are potent derivatives of their parent 
compound with higher water solubility, on the murine myeloid leukemia cell line 
WEHI-3B JCS, a well-characterized cellular model for leukemia research. Using 
[^H]-TdR proliferation assay, the kinetics and reversibility of their anti-proliferative 
activity would be evaluated. Besides the [^H]-TdR proliferation assay, soft agar 
clonogenic assay and trypan blue exclusion assay would also be used to study the 
effect of HCPT and EP on the clonogenicity and growth of the leukemia JCS cells in 
vitro. The cytotoxic effect of HCPT and EP on normal murine bone marrow cells, 
thioglycollate-elicited murine peritoneal macrophages, splenic lymphocytes and the 
murine myeloid leukemia JCS cells would be evaluated. In addition to various in vitro 
assays，the effects of HCPT and EP on the tumorigenicity and proliferation of JCS 
cells in vivo would also be investigated. 
After the initial study on the anti-proliferative effect of HCPT and EP on JCS 
cells, future experiments would focus on understanding the anti-leukemic mechanisms 
V 
of these two topoisomerase-targeting agents. Our hypothesis is that HCPT and EP 
may exert their anti-leukemic effect on JCS cells via three mechanisms: namely, 
disturbance in cell cycle progression, induction of differentiation and triggering of 
apoptosis. The effects of HCPT and EP on the cell cycle profile of JCS cells would be 
studied by flow cytometry. Then, the technique of reverse transcription polymerase 
chain reaction (RT-PCR) would be used to examine the effects of HCPT and EP on 
the expression of cell cycle-regulatory genes such as the cyclin and cyclin-dependent 
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kinase (CDK) genes. In addition to the mechanistic studies, attempts would be made 
to investigate the combination effect of HCPT, EP and cytokines including TNF-a, 
IFN-y and IL-lp on the proliferation of JCS cells. 
To test the differentiation-inducing effect of HCPT and EP, the morphology of 
both drug-treated and untreated JCS cells would be examined by light microscopy. 
The changes in cell size and granularity of the JCS cells would also be measured by 
flow cytometry. Further studies would be based on both functional and phenotypic 
criteria, for instance, the expression of lineage-specific differentiation antigens 
(Mac-1，F4/80 and Gr-1) and the plastic adherence, NBT-reducing activity and 
non-specific esterase activity of the JCS cells. 
Apoptosis is accompanied by both morphological and biochemical changes. To 
assess the apoptosis-inducing potential of HCPT and EP on the leukemia JCS cells, 
first of all, the morphology of the JCS cells stained by the DNA-binding Hoechst 
33342 fluorescent dye would be examined by fluorescence microscopy. DNA 
fragmentation assay and flow cytometry would also be carried out to assess the 
existence of apoptosis-related biochemical changes in the JCS cells. The expression of 
V 
some apoptosis-regulatory genes and proteins would be studied by RT-PCR and 
Western blotting, respectively. To further investigate the apoptotic pathways that 
might be involved, fluorescence probes such as fluo-3 and JC-1 would be used in flow 
cytometry. Finally, the activities of caspases 3, 8 and 9 in the drug-treated and 
untreated JCS cells would be measured by fluorometric assays. 
—— — -41 - ~ ‘ 
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2 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
2.1.1 Mice 
Inbred female BALB/c mice (H-2'^ ) aged 6 to 8 weeks old were bred at the 
University Laboratory Animal Services Centre of the Chinese University of Hong 
Kong under a specific pathogen-free condition. They were fed with animal diet 
(Chow 5001, Rodent Laboratory) and tap water ad libitum. 
2.1.2 Cell lines 
1) WEHI-3B JCS 
WEHI-3B (D") is a mineral oil-induced murine myelomonocytic leukemia cell line 
derived from the BALB/c mice. It was originally obtained from Dr. D. Metcalf 
(Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia) and 
subsequently subcloned at the John Curtin School of Medical Research, Australian 
National University, Canberra, Australia. One of the subclones designated as 
WEHI-3B JCS (Leung et aL, 1994) was used in this study. 
2) Ml 
Ml is a murine myeloblastic leukemia cell line originally established from a 
spontaneous myeloid leukemia of SL strain mice by Y. Ichikawa in the Kyoto 
University of Japan in 1969 (Ichikawa, 1969). It was purchased from the American 
Type Culture Collection (ATCC). 
3) HL-60 
HL-60 is a human promyelocytic leukemia cell line established from a 36-year-old 
“ ‘ -42- ‘ “ 
Chapter 2 Materials & Methods 
Caucasian female with acute promyelocytic leukemia (Collins et al., 1977). It was 
purchased from ATCC. 
4) K-562 
K-562 is a human chronic myelogenous leukemia cell line obtained from the 
pleural effusion of a 5 3-year-old female with chronic myelogenous leukemia in 
terminal blast crises (Lozzio & Lozzio，1975). It was also purchased from ATCC. 
5) PU5-1.8 
PU5-1.8 is a spontaneous macrophage-like tumor cell line originated from a 
BALB/c mouse (van Furth et al., 1985). It was obtained from the Department of 
Pathology, University of Cambridge, U.K. 
6) J774A.1 
J774A.1 is a macrophage-like tumor cell line which arose in a female BALB/c 
mouse in 1968 (van Furth et al., 1985). It was purchased from ATCC. 
2.1.3 Cell culture medium, buffers and other reagents 
1) Cell culture medium 
The powdered form of RPMI 1640 medium (GIBCO BRL Life Technologies Inc.), 
supplemented with 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid 
(HEPES) and 2 mM L-glutamine, was used for the preparation of culture medium. It 
was dissolved in double distilled water and was buffered with 2 g sodium bicarbonate 
(NaHCOs) (Sigma Chemicals Co.) per litre. The medium was adjusted to pH 7.12 by 
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1 M HCl and NaOH (Sigma Chemicals Co.). It was then sterilized by membrane 
filtration through a 0.22 |Lim Millipore filter and stored at 4°C until use. 
2) Serum supplements 
Fetal Calf Serum (FCS) (GIBCO BRL Life Technologies Inc.) was stored as 50 ml, 
20 ml and 10 ml aliquots. Heat inactivated-fetal calf serum (HI-FCS) was prepared by 
heating the FCS at 56�C for 30 minutes. The serum aliquots were stored at -20°C until 
use. 
3) Antibiotics 
Two types of antibiotics were used in alternate periods. The 
Antibiotic-Antimycotic (PSF) (10,000 units/ml penicillin G (sodium salt), 10,000 
|ig/ml streptomycin sulfate and 25 |Lig/ml amphotericin B as Fungizone in 0.85% 
saline) and Antibiotic (PSN) (5,000 |ig/ml penicillin G sodium, 5,000 ^g/ml 
streptomycin sulfate and 10,000 |ig/ml neomycin sulfate in 0.85% saline) lOOx stock 
solutions were purchased from GIBCO BRL Life Technologies Inc. They were stored 
at -20°C as 5 ml aliquots. 
V 
4) Complete RPMI medium 
“Plain RPMI medium" was prepared by supplementing RPMI medium with 1% 
antibiotics. Complete RPMI medium was prepared by supplementing plain RPMI 
medium with 10% or 20% HI-FCS. In the present study, most of the human and 
murine cell lines were cultured with 10% FCS. Complete RPMI medium 
supplemented with 20% FCS was used for the culture of HL-60 cells. 
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5 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
PBS (Sigma Chemical Co.) was prepared by dissolving the powder (8 g sodium 
chloride, 0.2 g potassium chloride, 0.2 g monobasic potassium phosphate and 1.15 g 
dibasic sodium phosphate) in one litre of double distilled water. The pH of the 
solution was adjusted to 7.12 followed by autoclaving at 121�C for 15 minutes. 
6) Dye solutions 
a) Hemacolor staining solutions 
Hemacolor staining solutions (Diagnostica Merck) were used to stain the cells on 
cytocentriflige slides. It consisted of three different solutions. Hemacolor solution 1 
(methanol) was used for cell fixation, solution 2 was a buffered color reagent red and 
solution 3 was a buffered color reagent blue. They were protected from light and 
stored at room temperature. 
b) Trypan blue solution 
Trypan blue solution (Sigma Chemical Co.) contained 0.4% (w/v) trypan blue 
dissolved in 0.817% sodium chloride and 0.06% dibasic potassium phosphate. 
V 
7) Ficoll-Paque solution 
Ficoll-Paque solution (Pharmacia Biotech) contained 5.7 g Ficoll, 9 g sodium 
diatrizoate and disodium ethylenediamine tetra-acetic acid (EDTA) in 100 ml water 
(density = 1.077 g/ml). It was used for in vitro isolation of lymphocytes and stored at 
4�C. 
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8 [i\ complete medium for 6 hours. The cells were harvested onto a glass m i c r o f i b e r 
0.1 M stock solution of 2-mercaptoethanol (Sigma Chemical Co.) was prepared in 
sterilized double distilled water and stored at -20°C until use. 
9) Methylthiazoletetrazolium (MTT) 
MTT was purchased from Sigma Chemical Co. in the form of powder. It was 
dissolved in double distilled water. The concentration of the stock solution was 5 
mg/ml and 30 |li1 of the stock was added to each test sample. 
10) Nitroblue tetrazolium (NBT) 
NBT was purchased from Sigma Chemical Co. in the form of powder. NBT 
solution (4 mg/ml) was freshly prepared each time by dissolving the powder in plain 
RPMI medium. 
11) Thioglycollate (TG) broth 
TG (3%) broth was prepared by adding 3 g of dehydrated thioglycollate powder 
(Difco Lab.) to 100 ml double distilled water. It was then heated to dissolve the 
powder completely and sterilized by autoclaving at 121°C for 15 minutes. It was 
stored at room temperature in dark for at least one month before use. 
12) Topoisomerase-targeting agents 
The estimated purity of the topoisomerase-targeting agents (Calbiochem®) used in 
this study is summarized in Table 2.1. The stock solutions were prepared by 
dissolving the powder in cell culture-tested, sterile dimethysulfoxide (DMSO) or plain 
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medium. All stock solutions were stored in dark at 4°C or -20°C and used within 30 
days. 
Table 2.1. Topoisomerase-targeting agents used in this study 
Topoisomerase-targeting agents Estimated purity (%) 
Camptothecin > 95% 
10-hydroxy-camptothecin > 95% 
Etoposide > 97% 
Etoposide phosphate > 90% 
13) Trypsin-EDTA solution 
Trypsin-EDTA solution (GIBCO BRL Life Technologies Inc.) contained 0.25% 
trypsin and 1 mM EDTA-tetrasodium in HBSS without Ca^^ and Mg2+. It was stored 
at -20°C as 5 ml aliquots until use. 
2.1.4 Radioisotope and scintillation fluid 
1) [Methyl-^H]-thymidine ([^H]-TdR) 
The stock solution (Amersham Life Science Ltd.) was stored at 4°C as 500 jil 
V aliquots with specific activity of 2 Ci/mmol. The working solution (25 |iCi/ml) was 
freshly prepared by diluting the stock solution with complete RPMI medium. In 
proliferation assays, 20 \i\ working solution was added to each well of the 96-well 
flat-bottomed microtiter plate. 
2) Liquid scintillation cocktail 
The OptiPhase "High" safe-2 liquid scintillation cocktail (Wallac Scintillation 
Products) was based on biodegradable solvents with dioctyl sulfosuccinate, sodium 
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salts and poly(ethyleneglycol)mono(4-nonylphenyl)-ether. It was ready-to-use and 
stored in dark at room temperature. 
2.1.5 Reagents and buffers for flow cytometry 
1) Propidium iodide (PI) DNA staining buffer 
PI DNA staining buffer was freshly prepared in PBS containing 50 |ig/ml 
propidium iodide (Boehringer Mannheim), 400 fig/ml ribonuclease A (RNase A) 
(Boehringer Mannheim), 10 mM EDTA (pH 7.4) (Sigma Chemical Co.), 0.1% 
trisodium citric acid (Sigma Chemical Co.) and 0.1% Triton X-100 (Sigma Chemical 
Co.). It was stored at 4°C until use. 
2) JC-1 staining solution 
5,5',6,6'-tetrachloro-1,1 ',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) 
is a lipophilic, cationic fluorescent dye which selectively accumulates in mitochondria. 
It can be used as a sensitive marker for the mitochondrial membrane potential of a cell. 
The stock solution of JC-1 (Molecular Probes Inc.) was prepared at the concentration 
of 5 mg/ml in DMSO and stored at -20°C. It was diluted in warm PBS before use. 
V 
3) Annexin V-fluos staining kit 
Annexin V-fluos staining kit (Roche Diagnostics Corporation) contained a vial of 
annexin V-fluorescein, PI and incubation buffer. Recombinant Annexin V is produced 
in Escherichia coli (strain NB42). The GST-tagged protein is purified with standard 
I 
purification protocols. Annexin V is a Ca -dependent phospholipid binding protein. It 
binds to negatively charged phospholipid surfaces with a high specificity for 
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phosphatidylserine (PS). Therefore, it stains apoptotic as well as necrotic cells. PI 
stains the DNA of leaky necrotic cells only. Staining of cells with these two dyes 
allows the differentiation of apoptotic cells from necrotic cells. The reagents were 
stored in dark at 4°C. 
4) Fluo-3/AM 
Fluo-3/AM was used for measuring intracellular Ca . It was purchased from 
Molecular Probes, Inc. in the form of powder. The stock solution (10 |iM) was 
prepared by dissolving the powder in DMSO and stored at -20°C. 
5) Fluorescein diacetate 
Fluorescein diacetate (Calbiochem®) was used for measuring non-specific esterase 
activity. The stock solution (20 mg/ml) was prepared by dissolving the powder in 
DMSO and stored at 
6) Hoechst 33342 
Hoechst 33342 (Molecular Probes, Inc) was used for nucleus staining. It was 
� supplied as 10 mg/ml solution in water and stored at 4°C. 
7) FACS medium 
FACS medium contained 2% HI-FCS and 0.05% sodium azide in PBS. It was 
used for washing and resuspending cells in FACS analysis and was stored at 4°C. 
Sodium azide inhibits internalization of cell-bound antibodies as well as patching and 
capping of the cells. 
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8 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
The shealth fluid (Becton Dickinson International) was a ready-to-use, balanced 
electrolyte solution containing sodium chloride, potassium chloride, disodium EDTA, 
sodium fluoride and an anti-microbial agent. It was stored at room temperature. 
2.1.6 Antibodies for flow cytometry 
1) Rat anti-mouse macrophage differentiation antigen CDllb 
(Mac-1) monoclonal antibody (clone Ml/70, rat IgGib isotype) 
It was obtained from the culture supernatant of the hybridoma cell line Ml/70 
(ATCC). Small volume aliquots of this antibody were stored at -70°C. 
2) Rat anti-mouse macrophage differentiation antigen F4/80 
monoclonal antibody (clone C1.A3-1, rat IgGzb isotype) 
It was obtained from the culture supernatant of the hybridoma cell line F4/80 
(ATCC). Small volume aliquots of this antibody were stored at -70°C. 
3) Rat anti-mouse myeloid differentiation antigen Gr-1 monoclonal 
V 
antibody (clone RB6-8C5, rat IgGib isotype) 
It was purchased from Pharmingen. The RB6-8C5 antibody reacts with Gr-1, the 
myeloid differentiation antigen. It was stored at 4°C. 
4) Fluorescein isothiocyanate (FITC)-conj ugated goat F(ab，)2 
anti-rat IgG (H+L chain specific) antibody 
The secondary antibody reacts with the heavy and light chains of rat IgG but with 
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minimal cross reactivity with mouse immunoglobulins. It was purchased from 
Southern Biotechnology Associates Inc. and stored at 4°C. 
5) Mouse IgG and rat IgG 
Mouse IgG and rat IgG (Sigma Chemical Co.) block the non-specific binding of 
immunoglobulins to the Fc receptors of the cells. They were stored in aliquots at 
-20�C. 
2.1.7 Recombinant cytokines 
1) Recombinant murine interleukin-ip (IL-ip) 
IL-ip (R&D systems) was originated from Escherichia coli. The biological 
activity was measured in a cell proliferation assay using a murine helper T cell line 
D.10.G4.1 and the specific activity was found to be 10^ units/mg. It was diluted in 
RPMI medium supplemented with 2% HI-FCS and stored at -20°C until use. 
2) Recombinant murine interferon-y (IFN-y) 
IFN-y (Pepro Tech EC Ltd.) was originated from Escherichia coli. The lyophilized 
’ protein was reconstituted in RPMI medium supplemented with 2% HI-FCS to a 
concentration of 10 |ig/ml and stored in aliquots at -20°C. Using a cytopathic effect 
inhibition assay with murine L929 cells challenged with the encephalomyocarditis 
(EMC) virus, the specific activity was found to be ICT units/mg. 
3) Recombinant murine tumour necrosis factor-a (TNF-a) 
Lyophilized TNF-a (Pepro Tech EC Ltd.) was originated from Escherichia coli. 
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After being reconstituted in autoclaved distilled water to a concentration of 100 |ig/ml, 
the solution was further diluted to a concentration of 10 iig/ml in RPMI medium 
supplemented with 2% HI-FCS. Small volume aliquots were stored at -20°C. the 
specific activity was 10^ units/mg as determined by the cytolysis of murine fibroblast 
L929 cells in the presence of actinomycin-D. 
2.1.8 Reagents for DNA extraction 
1) IGEPAL CA-630 lysis buffer 
IGEPAL CA-630 lysis buffer was purchased from Sigma Chemical Co. and 
IGEPAL is a registered trademark of Phone-Poulenc, Inc. It was prepared in 50 mM 
Tris [hydroxylmethyl] amino methane (Tris)-HCl, pH 7.5 with 3% non-ionic 
detergent IGEPAL CA-630 ((Octylphenoxy) polyethoxyethanol) and 20 mM EDTA. It 
was stored at room temperature. 
2) Proteinase K 
Proteinase K (Boehringer Mannheim) is a highly active subtilisin type of 
protease. It was purified from the mold Tritirachium album Limber. The stock 
� solution (20 mg/ml) was prepared by dissolving in autoclaved double distilled water. 
It was stored as 500 i^l aliquots at -20°C. 
3) Sodium acetate solution (NaOAc) 
NaOAc was purchased from Sigma Chemical Co. The stock solution (3M) was 
prepared by dissolving 24.61 g sodium acetate in 100 ml double distilled water. It was 
sterilized by autoclaving at 121°C for 15 minutes. The solution was stored at room 
temperature. 
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4 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
The pancreatic RNase (Boehringer Mannheim) was dissolved at a concentration 
of 10 mg/ml in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl. The stock solution was 
stored as 500 |li1 aliquots at -20°C. 
5) TioEo.i buffer 
The TioEo.i buffer contained 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in 
distilled water. It was stored at room temperature. 
2.1.9 Reagents for total RNA isolation 
1) DEPC-treated double distilled water 
Double distilled water was treated with 0.1% diethyl pyrocarbonate (DEPC) 
(Sigma Chemical Co.) and shaken thoroughly to disperse DEPC. It was allowed to 
stand overnight. The solution was then autoclaved at 121°C for 15 minutes to destroy 
the remaining DEPC, 
2) Tris-HCl buffer 
V 
Tris [hydroxymethyl] amino methane (Tris, Sigma Chemical Co.) was prepared 
as a 1 M stock solution in DEPC-treated double distilled water. The buffer was 
adjusted to pH 7.5 with hydrochloric acid (HCl) and sterilized by autoclaving at 
121�C for 15 minutes. 
3) Trizol reagent 
Trizol reagent (GIBCO BRL Life Technologies Inc.) was a ready-to-use reagent 
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for the isolation of total RNA from cells and tissues. It was a mono-phasic solution of 
phenol and guanidine isothiocyanate and stored in dark at 4°C. 
2.1.10 Reagents and buffers for RT-PCR 
1) Moloney murine leukemia virus reverse transcriptase (MMLV 
RT) 
MMLV RT (GIBCO BRL Life Technologies Inc.) was isolated from Escherichia 
coli. It was stored in the buffer containing 20 mM Tris-HCl (pH 7.5), 1 mM 
dithiothreitol (DTT), 0.01% (v/v) NP-40, 0.1 mM disodium EDTA, 0.1 M sodium 
chloride and 50% (v/v) glycerol at -20°C. One unit of its activity was defined as the 
amount of enzyme that would incorporate 1 mole of deoxythymidine triphosphate 
(dTTP) into acid-precipitable material in 10 minutes at 37°C using poly(A) and 
oligo-dTi2-i8 as template and primer respectively. 
2) First strand buffer 
First strand buffer (GIBCO BRL Life Technologies Inc.) was supplied as a 5X 
solution containing 250 mM Tris-HCl (pH 8.3)，375 mM potassium chloride and 15 
� mM magnesium chloride (MgCli). 
3) 01igo-dTi2-i8，sodium salt (pd(T)i2-i8, sodium salt) 
01igo-dTi2-i8 was purchased from Promega Corporation. It was prepared as a 
stock solution of 1 |ig/|al in TioEo.i buffer and stored at -20°C. 
Chapter 2 Materials & Methods 
76 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
The specific oligonucleotide primer pairs in reverse-transcription polymerase 
chain reaction (RT-PCR) were designed according to the published sequences of their 
cloned cDNA. They were designed to prime on the sense and antisense sequences of 
the corresponding cDNA respectively (Table 2.2). The PGR primers were synthesized 
by GIBCO BRL Life Technologies Inc. The lyophilized primer pairs were 
reconstituted in DEPC-treated double distilled water to a working concentration of 2.5 
\iM. The primers were stored at -20°C. 
5) rRNasin ribonuclease inhibitor 
The rRNasin ribonuclease inhibitor (Promega Corporation) was a recombinant 
protein derived from E, coli. It was supplied at a concentration of 40 units/|il and this 
inhibitor was active over a broad range, but required a minimium of 1 mM DTT to 
maintain its activity. It was stored at -20°C in a buffer of 20 mM HEPES-potassium 
hydroxide (HEPES-KOH, pH 7.6), 50 mM potassium chloride (KCl), 8 mM 
dithiothreitol (DTT) and 50% (v/v) glycerol. One unit was defined as the amount of 
rRNasin ribonuclease inhibitor required to inhibit 50% activity of 5 ng RNase A as 
� measured by the inhibition of hydrolysis of cytidine 2，. 3 ’-cyclic monophosphate. 
6) ThermoprimePius DNA polymerase 
ThermoprimePius DNA polymerase (Advanced Biotechnologies Ltd.) was a 
thermostable DNA polymerase isolated from Thermophilic bacteria. It was supplied 
with lOX reaction buffer (Buffer IV) and magnesium chloride (MgCy. These 
reagents were stored at -20°C. Thermoprime''^ "® DNA polymerase is a single 
polypeptide of approximately 94 kD having 5' to 3，polymerization-dependent 
TiJT — 
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exonuclease replacement activity, but lacking the 3' to 5' exonuclease activity. One 
unit of this enzyme was defined as the amount that would incorporate 10 nmoles of 
dNTPs into acid insoluble material in 30 minutes at 47°C. 
7) Ultrapure dNTP set, 2'-deoxynucleoside 5'-triphosphate, sodium 
salt 
The deoxynucleoside triphosphate (dNTP) set (Pharmacia Biotech.) had each 
nucleotide supplied as 100 mM solution in double distilled water (pH 7.5). The stock 
solution containing 10 mM of each dNTP was prepared in 1 mM Tris-HCl (pH 7.5) 
and stored at -20°C. 
V 
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Table 2.2. Primers used in RT-PCR and the predicted sizes of the PCR products. 
P^A Predicted size of the 
am lified Sequence (5’ to 3’） amplified PCR P - product (bp) 
Sense strand: 
r^APntr TGA AGGTCG GAG TCAACG GAT TTG GT ” < vjA.1 Uil . J ZZO Anti sense strand: CAT GTG GGC CAT GAG GTC CAC CAC 
Sense strand: 
Bel 2 AGC TGC ACC TGA CGC CCT T ^93 
Antisense strand: 
CAG CCA GGA GAA ATC AAA CAG AGG 
Sense strand: 
Bel X TGG CAA CCC ATC CTG GCA CCT 5 兆 e Xl Antisense strand: 
ACT GAA GAG TGA GCC CAG CAG AAC 
Sense strand: 
Bak GCC CAG GAC ACA GAG GAG GTT TTC ^^g 
Antisense strand: 
AAA CTG GCC CAA CAG AAC CAC ACC 
Sense strand: 
D , ATC CCA GAG TTT GAG TCG AGG GA 歲 Bad . ^ , 445 Antisense strand: 
TTC GAG CCC ACC AGG ACT GGA 
Sense strand: 
^ T ACA GCA ACC AGC AAT ACA FasL … . • J 178 Antisense strand: GTA TGG TTT CAC GAC TGG 
Sense strand: 
^ . TAC TTC CTG CAC CTG CAG CCT • Cyclin A “ . , , 399 “ Antisense strand: 
AGC ATG GAC TCC GAG CGA CT 
Sense strand: 
Cyclin B CCA TTA TTG ATC GGT TCA TGC AGA 584 
Antisense strand: 
ATG TGT ACA GTT CAG CTG TGC CAG 
, Sense strand: � ^ ^ CCC AGC AGT AAG AAG GCA GAG � ^ Cyclin E “ . ^ , 287 Antisense strand: 
CAG CTT CTG GAG CAC TCA GTG 
Sense strand: 
Cdk-2 CAC AGC CGT GGA TAT CTG GAG ^53 
Antisense strand: 
TTG CGA TAA CAA GCT CCG TC 
Sense strand: 
Cdk-4 ACG CCT GTG GTG GTT ACG CT 刑 
Antisense strand: 
CCA TCT CTG GCA CCA CTG AC 
Sense stand: 
Cdk-6 ATG GAG AAG GAC AGC CTG AGT CGC 们 
Antisense strand: 
I AGT CTT GAT CAA CAT GCT CAA ACA 
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2.1.11 Reagents and buffers for gel electrophoresis 
1) Ethidium bromide (EtBr) 
EtBr was purchased from Sigma Chemical Co in the form of powder. The stock 
solution (10 mg/ml) was prepared by dissolving EtBr in double distilled water. The 
working solution was prepared by 1,000-fold dilution of the stock solution. Both the 
stock and working solution were kept in dark at room temperature. 
2) Gel loading solution (5X) 
The gel loading solution (Sigma Chemical Co.) was a 5X solution of 0.05% (w/v) 
bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8) and 0.5% sodium dodecyl 
sulfate (SDS). It was used for non-denaturing agarose gel electrophoresis of nucleic 
acids. 
3) Tris-HCl buffer (pH 7.5) 
Tris[hydroxylmethyl] amino methane (Tris, Sigma Chemicals Co.) was prepared 
as 1 M stock solution in DEPC-treated double distilled water. The buffer was adjusted 
to pH 7.5 with hydrochloric acid (HCl) and then autoclaved at 121°C for 15 minutes. 
� It was stored at 4°C. 
4) Tris-borate-EDTA (TBE) electrophoresis buffer (5X) 
The 5X TBE electrophoresis buffer stock was prepared by dissolving 54 g Tris, 
27.5 g boric acid and 20 ml 0.5 M EDTA in 1 litre double distilled water. The pH of 
the buffer was adjusted to 8. The working TBE buffer (0.5X) was prepared by diluting 
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one part of the 5X stock TBE buffer with nine parts of double distilled water. Both the 
stock and working solutions were stored at 4°C. 
5) Agarose gel 
1% and 2% agarose gels were prepared by dissolving 10 g and 20 g agarose 
(Sigma Chemicals Co.) respectively in 1 litre 0.5X TBE buffer by heating at 70�C. 1% 
agarose gel was used for RNA gel electrophoresis while 2% agarose gel was used for 
gel electrophoresis of DNA and PCR products. 
2.1.12 Reagents and buffers for Western blot analysis 
1) 30% (w/v) acrylamide solution 
The acrylamide (30%) stock solution was prepared by dissolving 30 g 
acrylamide and 0.8 g N,N'-methylene-bis-acrylamide (Sigma Chemicals Co.) in 100 
ml double distilled water. It was protected from light and stored at 4°C. 
2) 10% (w/v) ammonium persulfate (APS) 
10% working solution of ammonium persulfate (Bio-Rad Lab.) was prepared by 
dissolving 0.5 g APS in 5 ml double distilled water. 500 [i\ aliquots of 10% APS were 
stored at -20°C. 
3) Cell lysis buffer 
The cell lysis buffer contained 20 mM Tris-HCl (pH 8)，120 mM sodium 
chloride, 1% (v/v) Triton X-100 (Sigma Chemicals Co.), 1 mM EGTA, 50 |iM 
2-mercaptoethanol and one tablet of complete protease inhibitor cocktail (Boehringer 
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Mannheim) in 50 ml double distilled water. Each complete protease inhibitor cocktail 
when dissolved in 50 ml lysis buffer yielded 1 mM EDTA and a mixture of several 
protease inhibitors with a broad spectrum of activity on serine, cysteine and 
metalloproteases and calpains inhibitors. The cell lysis buffer was kept as 5 ml 
aliquots and stored at -70®C. 
4) Coomassie blue staining and destaining solution 
The Coomassie blue staining and destaining solutions were used to stain and 
destain the SDS-polyacrylamide gel. The staining solution was prepared by mixing 
one part of 0.05% Coomassie blue (Bio-Rad Lab.) in acetic acid, three parts of 
methanol and ten parts of double distilled water. The destaining solution was prepared 
by mixing one part of acetic acid, three parts of methanol and ten parts of double 
distilled water. 
5) ECL films (Hyperfilm 顶 ECL ™) 
The HyperfilmTM ECI/m (Amersham Life Science) was a high performance 
chemiluminescence film used for Western blot analysis. It was designed for 
� processing in automatic processors at temperatures up to 38°C. The film was stored in 
a dry place at 4°C and protected from light and noxious fumes. 
6) RPN 2108 ECL Western blot analysis system 
The Western blot detection kit (Amersham Pharmacia Biotech.) contained 
detection reagent 1 (62.5 ml), detection reagent 2 (62.5 ml), anti-mouse Ig secondary 
antibody (horseradish peroxidase-linked whole antibody from sheep, 100 
anti-rabbit Ig secondary antibody (horseradish peroxidase-linked whole antibody from 
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donkey, 100 |li1), and 5 g blocking reagent. The kit was used for the detection of either 
mouse or rabbit membrane bound primary antibodies and was stored at 4°C. 
7) Lower buffer for the separating gel 
It was a 1.5 M Tris-HCl buffer adjusted to pH 8.8 (Sigma Chemicals Co.). This 
buffer was stored at 4°C. 
8) 2X SDS sample buffer 
2X SDS sample buffer contained 2-mercaptoethanol and bromophenol blue (100 
ml). It was prepared by dissolving 1.51 g Tris base, 20 g glycerol, 10 ml 
2-mercaptoethanol and 4.6 g SDS in 80 ml double distilled water. The pH of the 
buffer was adjusted to 6.8 with HCl, and the volume was then added up to 100 ml. 
Bromophenol blue was added to a final concentration of 0.006%. The sample buffer 
was stored at 4°C. All reagents mentioned were purchased from Sigma Chemicals Co. 
9) N,N,N',N'-tetra-methylethylenediamine (TEMED) 
TEMED (Bio-Rad Lab) was stored at 4°C. It was used to initialize the 
� polymerization of SDS-polyacrylamide gel. 
10) Prestained SDS-PAGE standards 
The calibrated molecular weights of Kaleidoscope Standards (Bio-Rad Lab.) 
contained different color dyes attached to standard proteins including myosin 
(202,000)，p-galactosidase (133,000), bovine serum albumin (71,000)，carbonic 
anhydrase (41,800), soybean trypsin inhibitor (30,600), lysozyme (17,800) and 
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aprotinin (6,900). The standard proteins (total 625 }j,g) were prepared in 33% (v/v) 
glycerol, 3% SDS, 10 mM Tris (pH 7.0), 10 mM DTT, 2 mM EDTA and 0.01% NaN� . 
It was stored at -20°C. 
11) PVDF Western blot membranes 
The microporous polyvinylidene difluoride (PVDF) membrane (Boehringer 
Mannheim) had a pore size of 0.45 |im and was stored at room temperature. 
12) Primary antibodies 
a) Mouse anti-Bcl-2 monoclonal antibody 
It is a mouse monoclonal antibody (Transduction Laboratories) raised against a 
sequence of amino acids 49-179 of human Bcl-2. Each vial contained 250 |ig/ml 
mouse IgGl in 50% glycerol, 20 mM sodium phosphate pH 7.5，150 mM NaCl, 1.5 
mM NaNs and 1 mg/ml BSA. The antibody reacts with Bcl-2 of human, dog, rat, 
chicken and mouse origin and was stored as small aliquots at -20°C. 
b) Rabbit anti-FasL polyclonal antibody 
It is a rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.) raised against 
a recombinant protein corresponding to amino acids 100-278 mapping at the carboxyl 
terminus of FasL of rat origin. Each vial contained 200 |ig IgG in 1 ml PBS 
containing 0.1% sodium azide and 0.2% gelatin. It reacts with FasL of mouse, rat and 
human origin and was stored at 4°C. 
Chapter 2 Materials & Methods 
84 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
Goat anti-mouse alkaline phosphatase conjugated antibodies and goat anti-rabbit 
alkaline phosphatase conjugated antibodies were purchased from Pharmingen. The 
alkaline phosphatase conjugated to the antibody reacted with the chromogenic 
substrate and enabled the visualization of the proteins being recognized by these 
antibodies. They had a concentration of 1 mg/ml and were stored at 4°C. 
14) 5% skimmed milk solution (blocking agent) 
Nestle skimmed milk powder (1 gm) was freshly prepared in 20 ml washing 
buffer. The solution was kept at 4°C and warmed to 37°C before use. 
15) 10% sodium dodecyl sulfate (SDS) solution 
10% SDS solution was prepared by dissolving 10 g SDS (Sigma Chemical Co.) 
in 100 ml double distilled water and was stored at room temperature. 
16) Tris-glycine-SDS electrophoresis buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concentrate (Sigma Chemicals Co.) 
V 
contained 0.25 M Tris-HCl, pH 7.5，1.92 M glycine and 1% SDS in double distilled 
water. It was sterilized by filtration through a 0.2 |im Millipore filter and was stored at 
4°C. The lOX concentrate was freshly diluted to IX working solution for SDS-PAGE. 
17) Tris-glycine buffer (lOX) 
Tris-glycine buffer lOX concentrate (Sigma Chemicals Co.) contained 0.25 M 
Tris-HCl, pH 7.5 and 1.92 M glycine in double distilled water. It was sterilized by 
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filtration through a 0.2 \xm Millipore filter and was stored at 4°C. 
18) Tris-glycine-methanol transfer buffer (lOX) 
The transfer buffer was prepared by mixing 20% methanol in IX Tris-glycine 
buffer. It was stored at 4°C. 
19) Upper buffer for the stacking gel 
It was a 0.5 M Tris-HCl buffer adjusted to pH 6.8 (Sigma Chemicals Co.) and 
was stored at 4°C. 
20) Washing buffer 
The washing buffer contained 10 mM Tris-HCl (pH 7.5), 100 mM sodium 
chloride and 0.1% (w/v) Tween 20 (Sigma Chemicals Co.). It was stored at 4°C. 
2.1.13 Reagents for measuring caspase activity 
1) Cell lysis buffer 
The cell lysis buffer contained 1% IGEPAL-CA 630 (Sigma), 150 mM NaCl, 50 
V 
mM Tris-HCl (pH 7.5)，protease inhibitor (Roche) in 50 ml distilled water. It was 
stored at 4°C. 
2) Reaction buffer 
The reaction buffer contained 10 mM HEPES-KOH (pH 7.0), 40 mM 
p-glycerophosphate, 50 mM NaCl, 2 mM MgCh, 5 mM EGTA, 0.1% CHAPS, 100 
|ig/ml BSA, 10 mM DTT. It was stored at 4°C. 
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86 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
The stock solution (IM) was prepared by dissolving DTT in distilled water. It 
was stored at -20°C. It was added to the reaction buffer to a final concentration of 10 
mM just before use for full enzyme activity. 
4) Caspase 3 substrate, Ac-DEVD-AMC 
Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) (Sigma 
Chemicals Co.) is a specific fluorogenic caspase 3 substrate. The stock solution (2 
mM) was prepared by dissolving in DMSO. It was stored at -20°C. 
5) Caspase 3 inhibitor, Ac-DEVD-CHO 
Ac-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) (Bachem Co.) is a specific 
reversible inhibitor of caspase 3. The stock solution (0.05 M) was prepared by 
dissolving in sterile double distilled water. It was further diluted with RPMI medium 
to 1 mM. Both the stock and the diluted solutions were stored at -20°C. 
6) Caspase 8 substrate, Ac-IETD-AMC 
N-Acetyl-Ile-Glu-Thr-Asp-7-Amido-4-methylcoumarin (Ac-IETD-AMC) (Sig-
ma Chemicals Co.) is a fluorogenic substrate for caspase 8 and granzyme B. The 
stock solution (1 mM) was prepared by dissolving in DMSO. It was stored at -20°C. 
7) Caspase 8 inhibitor II，Z-IETD-FMK 
Z-IETD-FMK is a potent, cell permeable and irreversible inhibitor of caspase 8 
and granzyme B (Calbiochem Chemicals Co.). The stock solution (10 mM) was 
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prepared by dissolving in DMSO. It was stored at -20°C. 
8) Caspase 9 substrate, Ac-LEHD-AFC 
N-Acetyl-Leu-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin (Ac-LEHD-
AFC) (Sigma Chemicals Co.) is a fluorescent substrate for caspase 9. The stock 
solution (5 mM) was prepared by dissolving in DMSO. It was stored at -20°C. 
9) Caspase 9 inhibitor, Z-LEHD-CHO 
Z-LEHD-CHO is a potent, cell permeable and irreversible inhibitor of caspase 9 
(Calbiochem Chemicals Co.). The stock solution (10 mM) was prepared by dissolving 
in DMSO. It was stored at -20°C. 
10) 7-amino-4-methyl coumarin (AMC) 
AMC is standard marker for the quantification of caspase-3 and caspase-8 
activity. The stock solution (0.05 M) was prepared by dissolving in DMSO. It was 
further diluted with lysis buffer to 100 |liM. 
11) 7-amino-4-trifluoromethyl coumarin (AFC) 
AFC is standard marker for the quantification of caspase-9 activity. It is a yellow 
powder and the stock solution (0.02 M) was prepared by dissolving in methanol. It 
was further diluted with lysis buffer to 80 foM. 
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2.2 Methods 
2.2.1 Culture of the leukemia cell lines 
In general, the murine and human leukemia cell lines were maintained in 
complete RPMI medium supplemented with 10% FCS as continuous suspension 
cultures. The only exception is the human leukemia HL-60 cells which were 
maintained in complete RPMI medium supplemented with 20% FCS. All the cell lines 
were cultured in 25 or 75 cm^ tissue culture flasks and incubated at 37°C in a 
humidified incubator supplied with 5% carbon dioxide (CO2). The cell lines were 
subcultured at 2-3 day intervals depending on their doubling times. Cells in 
exponential growth phase were used for experiments and long-term storage of cell 
lines was done by cryo-preservation in liquid nitrogen. 
2.2.2 Isolation and preparation of normal hematopoietic cells 
2.2.2.1 Preparation of murine bone marrow cells 
BALB/c mice were sacrificed by cervical dislocation. The femurs were removed 
with aseptic techniques with the removal of the attached muscle. The contamination 
with the peripheral blood cells should be avoided. The femurs were then put into a 
universal container with cold complete RPMI medium. The marrow plugs were flushed 
with a 2 ml syringe fitted with a 25 G needle into complete RPMI medium. The flushed 
cells were transferred dropwise to a 4 ml Ficoll-paque gradient and spun at 2,000 rpm 
for 15 minutes to remove the red cells. The bone marrow cells were collected at the 
interface and washed twice with plain RPMI medium by spinning at 2,000 rpm for 5 
minutes. The pellet was then suspended to the required cell density in complete RPMI 
medium. 
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2.2.2.2 Preparation of murine splenic lymphocytes 
BALB/c mice were sacrificed by cervical dislocation. The spleens were removed 
with aseptic techniques with the removal of attached fatty tissue. The spleens were then 
put into a culture dish with cold complete RPMI medium and pestled on the sieve to 
obtain individual splenocytes. The splenocytes were transferred dropwise to a 4 ml 
Ficoll-paque gradient and spun at 2,000 rpm for 15 minutes to remove the red cells. The 
splenic lymphocytes were collected at the interface and washed twice with plain RPMI 
medium by spinning at 2,000 rpm for 5 minutes. The pellet was then suspended to the 
required cell density in complete RPMI medium. 
2.2.2.3 Preparation of murine peritoneal macrophages 
BALB/c mice were injected intraperitoneally (i.p.) with 1 ml 3% thioglycollate 
broth and sacrificed 3 days later by cervical dislocation. The mice were placed ventral 
side up on a clean surface. The skin of the abdomen was disinfected with 70% ethanol, 
cut and pulled apart to expose the peritoneal membrane. Air was injected to inflate the 
peritoneal cavity. Each time 2.5 ml PBS was injected into the abdominal cavity using 
a 2.5 ml syringe fitted with a 18-gauge needle and washed for 3 times. The peritoneal 
exudate cells were then washed with cold plain RPMI medium. They were finally 
resuspended in complete RPMI medium for further use. 
2.2.3 [^H]-TdR proliferation assay 
Different leukemia cells, with the indicated cell number, were incubated with the 
control solvent or different concentrations of topoisomerase-targeting agents in the 
wells of 96-well flat-bottomed microliter plates at 37°C for 48 hours inside a 
humidified 5% CO2 incubator. The cells were then pulsed with 0.5 ^iCi [^H]-TdR in 
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20 [i\ complete medium for 6 hours. The cells were harvested onto a glass microfiber 
filter after one freezing-and-thawing cycle. The radioactivity, in counts per minute 
(cpm), was measured by the Beckman LS6000 liquid scintillation counter. The results 
were expressed as the percentage inhibition of [^H]-TdR incorporation, using the 
untreated cells as a control (Leung et al., 1994). The percentage inhibition of 
[^H]-TdR incorporation was calculated by the following equation: 
% inhibition = [ (cpm of control - cpm of test sample)/ cpm of control ] x 100% 
2.2.4 Determination of cell viability 
2.2.4.1 Trypan blue exclusion assay 
Trypan blue exclusion assay was based on the integrity of plasma membrane. It 
was used to determine the number of viable cells in cultures. Cells were cultured with 
different concentrations of topoisomerase-targeting agents at 37°C. The viability of 
the cells was then determined after 48 hours by mixing 10 [i\ cell suspension with 10 
\i\ of 0.4% trypan blue solution. Viable cells with intact membrane were visualized as 
clear cell bodies while the leaky dead cells were stained blue. By scoring the number 
of viable and dead cells, the percentage viability of the samples can be estimated. The 
’ results were expressed as the mean percentage of cell viability 士 S.E. of triplicate 
cultures. The percentage viability was calculated by the equation below: 
% cell viability = (no. of viable cells/ no. of total cells counted) x 100% 
2.2.4.2 MTT colorimetric assay 
Thioglycollate-elicited murine peritoneal macrophages (5 x 10^ cells/ml) were 
incubated with control solvent or different concentrations of topoisomerase-targeting 
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agents in the wells of 96-well flat-bottomed microtiter plates at 37°C for 48 hours 
inside a humidified 5% CO2 incubator. The cells were then incubated with 30 [i\ MTT 
(5 mg/ml) for 4 hours. Then the medium was withdrawn and 100 \x\ DMSO was 
added to dissolve the MTT deposited in each well. The absorbance of the samples 
were measured at 450 nm. The percentage viability of the cells was calculated by the 
equation below: 
% viability =[ (OD450 of control — OD450 of test sample)/ OD450 of control ] x 100% 
2.2.5 Assays for anti-leukemic activity in vivo 
2.2.5.1 In vivo tumorigenicity assay 
JCS cells (10^ cells/ml) were incubated with topoisomerase-targeting agents for 8 
hours at 37°C. The cells were harvested and washed three times with plain RPMI 
medium. Viable JCS cells (10^) in 0.5 ml RPMI medium were injected i.p. into each 
BALB/c mouse in groups of five. Viable leukemia cells were recovered from the 
mouse peritoneal cavity and counted at day 14 post-tumor inoculation. 
2.2.5.2 In vivo anti-tumor study 
V 
JCS cells (10^ cells) in 0.5 ml RPMI medium were inoculated intraperitoneally 
into BALB/c mice in groups of five on day 0. Starting from day 8，different dosages 
of topoisomerase-targeting agents were injected intraperitoneally on alternate days. 
Viable leukemia cells recoverable from the peritoneal cavity of mice were counted at 
day 17 post-tumor inoculation. 
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2.2.6 Assessment of differentiation-associated characteristics 
2.2.6.1 Morphological studies 
To assess the ability of topoisomerase-targeting agents to induce differentiation 
in leukemia cells, WEHI-3B JCS cells (2 x cells/ml) were incubated with different 
concentrations of topoisomerase-targeting agents in 25 cm^ culture flasks at 37°C for 
3 days. Cytospin slides of the cells were then prepared by fixing 2 x 10^  cells onto a 
microscopic slide by cytocentrifugation at 500 rpm for 5 minutes using the Shandon 
Cytospin 3 centrifuge (Shadon Scientific Ltd., U.K.). The cells were allowed to be 
air-dried. They were then stained with each Hemacolor staining solution for 15 
seconds and destained under running tap water. Finally, the air-dried cells on the 
slides were mounted with neutral mounting medium, Canada Balsam (Sigma 
Chemicals Co.) and the cell morphology was examined under the light microscope. 
2.2.6.2 NBT reduction assay 
Leukemia cells were firstly treated with indicated concentrations of 
topoisomerase-targeting agents for 3 days at 37°C. They were harvested and washed 
with PBS by spinning at 1500 rpm for 5 minutes. A 1:1 (v/v) mixture of cell 
suspension (2 x 10^  cells/100 |il) and a freshly prepared NBT-PMA (plain RPMI 
containing 4 mg/ml NBT and 4 |ag/ml PMA) was incubated for 4 hours at 37°C in 
dark. The cells were then fixed on a slide glass using cytospin and counter-stained 
with 1% safranin in methanol. The differentiated cells, which gave intracellular 
black-blue formazan deposits, were examined by scoring a minimum of 200 cells in 
triplicate for each sample. 
Chapter 2 Materials & Methods 
2.2.6.3 Assay of plastic adhering ability 
JCS cells (104 cells/ml) were incubated with control solvent, HCPT (20 and 40 
nM) and EP (200 and 400 nM) at 37�C for 72 hours. Both the adherent and 
non-adherent cells were harvested and counted. The results were expressed as % 
adherent cells to the total number of cells. 
2.2.6.4 Surface antigen immunophenotyping by flow cytometry 
JCS cells (104 cells/ml) were incubated with control solvent, 40 nM HCPT or 
400 nM EP at 37°C for 72 hours. The untreated cells were harvested and suspended in 
2 ml medium. On the other hand, the treated cells were allowed to stand at room 
temperature for a while after taking out from the incubator to detach the differentiated 
cells with a short period of cold shock. The cells were then harvested by a scalper or by 
washing them twice with cold plain RPMI with vigorous shaking. The harvested cells 
were suspended in 2 ml medium. Cell count was then performed in the hemocytometer. 
JCS cells (2.5 X 10^) were then added to a transparent conical centrifuge tube 
containing 10 ml FACS medium and spun at 1,500 rpm for 5 minutes. The supernatant 
was removed by aspiration and the pellet was suspended in a final volume of 0.2 ml 
V FACS medium. Rat IgG (10 |Lig/ml) and mouse IgG (10 |j.g/ml) were then added to the 
cell suspension to block Fc receptor non-specific binding. After incubation at 4°C for 
30 minutes (with occasional shaking), the cells were washed once with the FACS 
medium. The pellet was suspended in a final volume of 50 |j,l FACS medium and 
dispended into each well of a 96-well U-bottomed plate ( � 2 x 10^  cells / 50 |il / well). 
Fifty microliter primary antibody or PBS was added to each well. After incubated at 
4°C for 30 minutes (with occasional shaking), the cells were washed twice with FACS 
medium twice by spinning at 1,300 rpm for 3 minutes at 4°C. FITC-conjugated sheep 
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anti-rat Ig (1 |Lig) was then added to each well. After incubation at 4°C for 30 minutes 
(with occasional shaking), the cells were washed three times with FACS medium by 
spinning at 1,300 rpm for 3 minutes at The pellet was suspended in 0.6 ml FACS 
fixative in FACS tube. FACS analysis was performed. 
2.2.6.5 Assay of non-specific esterase activity 
JCS cells (104 cells/ml) were incubated with control solvent, 40 nM HCPT or 400 
nM EP at 37°C for 72 hours. The untreated cells were harvested and suspended in 2 ml 
medium. On the other hand, the treated cells were allowed to stand at room temperature 
for a while after taking out from the incubator to detach the differentiated cells with a 
short period of cold shock. The cells were then harvested by a scalper or by washing 
them twice with cold plain RPMI with vigorous shaking. The harvested cells were 
suspended in 2 ml medium. The harvested cells were then suspended in HI-FCS-RPMI 
with the cell density of 2 x 10^  cells/well in 200 |j.L The cell suspension was then 
dispensed into 96-well U-bottomed plate. Fluorescein diacetate (200 fig/ml，20 jil) was 
added to each well. The samples were incubated at room temperature in dark for 30 
minutes with occasional shaking. The cells were washed twice with FACS medium by 
� spinning at 1,300 rpm for 3 minutes at 4°C. The pellet was suspended in 0.8 ml FACS 
fixative in FACS tube and kept in dark. FACS analysis was performed. 
2.2.7 Assays for apoptosis 
2.2.7.1 Assessment of apoptosis by Hoechst 33342 staining 
Cytospin slides of the treated and untreated JCS cells were prepared by fixing 2 x 
10^  cells onto a microscopic slide by cytocentrifugation at 500 rpm for 5 minutes 
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using the Shandon Cytospin 3 centrifuge (Shadon Scientific Ltd., U.K.). The cells 
were allowed to be air-dried. The cells were then fixed with 2% paraformaldehyde in 
PBS for 20 minutes at room temperature. After washing with PBS, the cells were 
incubated with Hoechst 33342 (20 jig/ml) in PBS for 15 minutes at room temperature. 
After washing with PBS, the nuclear morphology of the stained cells was observed 
under a fluorescence microscope (Zeiss Axioskop) using (G 365, FT 395，LP 420) 
filter set and 20 x Plan-NEOFLUAR objective. 
2.2.7.2 DNA fragmentation assay 
DNA fragmentation is the hallmark of apoptosis. Apoptotic DNA fragments were 
isolated from the apoptotic cells by the method of Herrmann et al. (1994). WEHI-3B 
JCS cells (104 cells/ml) were incubated with indicated concentrations of 
topoisomerase-targeting agents in 75 cm^ culture flask at 37°C for different periods of 
time and the untreated cells acted as the control. At least 10^ cells were harvested and 
washed once with cold PBS by centrifugation at 250g for 5 minutes. The cell pellets 
were then treated with 200 |il IGEPAL CA-630 lysis buffer for 10 minutes at 37°C. 
The samples were centrifuged at l,000g for 5 minutes to collect the supematants 
， containing the apoptotic DNA fragments. 50 5% SDS was added and the 
supematants were incubated with 10 |li1 RNase A (0.4 |Lig/|il) at 56°C for 1.5 hours to 
remove the cellular RNA. 20 |li1 proteinase K (1.5 |ig/|Lil) was then added at 56�C for 
further 1.5 hours to remove the proteins. The DNA was then precipitated with 0.1 
volume of 3 M sodium acetate and 2.5 volumes of absolute ethanol. After 
centrifugation at 12,000g for 30 minutes, the DNA pellets were washed with 70% 
ethanol and absolute ethanol followed by vacuum aspiration with a speed vacuum 
concentrator (Savant 110 Speed-Vac®). The dried pellets were resuspended in 20 [i\ 
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TioEo.i buffer and incubated at 65°C for 5 minutes. Finally the resuspended DNA was 
subjected to 2% agarose gel electrophoresis. 
2.2.7.3 Annexin V-FITC staining of apoptotic cells 
JCS cells (104 cells/ml) were incubated with control solvent, HCPT (20 and 40 
nM) or EP (200 and 400 nM) at 37°C for different time points. 10^-10^ cells were 
harvested by centrifugation at 1,800 rpm for 5 min. at room temperature. The cells 
were washed in 0.5 ml cold PBS, followed by centriftigation at 1,800 rpm for 5 
minutes. The pellet was gently suspended in 100 \i\ Annexin V incubation reagent and 
incubated in dark for 15 minutes at room temperature. The binding buffer (400 |j,l, IX) 
was then added to each sample. The cellular fluorescence was measured by flow 
cytometer (FACSort) within 1 hour for maximal signal detection. 
2.2.7.4 Determination of the mitochondrial membrane potential 
The mitochondrial membrane potential (AWm) of both treated and untreated 
JCS cells was measured by JC-1 staining method (Dorrie et al” 2001). 1.3 |LI1 of JC-1 
solution (5 mg/ml in DMSO) was diluted with 1 ml warm PBS. The working solution 
was then incubated with the leukemia cells (10 cells) under investigation for 15 
minutes at 37°C. Then the cells were chilled on ice and subjected to flow cytometric 
analysis. Excitation was made at 488 nm and the emissions of red and green 
fluorescence were measured simultaneously. 
2.2.8 Cell cycle analysis (DNA content evaluation) 
JCS cells (10^) were first treated with different concentrations of 
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topoisomerase-targeting agents at for 48 hours at 37°C. They were harvested and 
washed with PBS by spinning at 1,500 rpm for 5 minutes. Cells were then fixed with 
1 ml 70% ethanol at 4°C for 30 minutes. After that cells were washed with PBS again 
by spinning at 2,000 rpm for 10 minutes to remove the ethanol. Cells were then 
resuspended in 1 ml propidium iodide DNA staining solution (50 |ig/ml PI) in dark at 
room temperature. After 1.5 hours, flow cytometric analysis was then performed. Cell 
cycle distribution calculations were performed using the MODFIT program. 
2.2.9 Gene expression study 
1) Isolation of total cellular RNA 
JCS cells (10^) were treated with indicated concentrations of 
topoisomerae-targeting agents for different periods of time at 37°C. The cells were 
harvested by centrifugation at 250xg for 5 minutes at 4°C. The cells were lysed by 1 
ml TRIZOL reagent (1 ml TRIZOL for 5-10 x 10^ cells) with vigorous shaking. The 
cell lysate solutions were incubated at room temperature for 5 minutes to allow the 
complete dissociation of nucleoprotein complexes. 200 fa.1 chloroform per 1 ml 
TRIZOL reagent was added to the samples and then shaked vigorously for 15 seconds. 
V The samples were allowed to stand at room temperature for about 3 minutes and were 
centrifuged at 12,000xg for 15 minutes at 4°C. Following centrifugation, the upper 
aqueous layer containing RNA (-400 ^il) was being transferred to another new 
micro-centrifuge tube. 500 |LI1 isopropanol was then added to precipitate the RNA. The 
samples were incubated at -20°C overnight. After overnight incubation, the samples 
were centrifuged at 12，000xg at 4°C for 10 minutes. The supematants were discarded 
and the RNA pellets were washed with 1 ml 75% ethanol per 1 ml of TRIZOL. The 
samples were centrifuged at 7，500g at 4®C for 5 minutes. The supematants were 
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removed by vacuum aspiration and the RNA pellets were air-dried for about 5 
minutes. The RNA collected was then dissolved in 30 |il DEPC-treated water and 
stored at -70°C until use. 100-fold dilution of RNA was prepared and the 
concentration of the diluted RNA was determined by measuring the absorbance at 260 
nm. Small aliquots of RNA with a working concentration of 0.5 |ig/|il were prepared 
with DEPC-treated water and stored at - 70�C. The purity of the RNA samples was 
assessed by measuring the ratio of A260/A280 (it should have a value ranged from 1.0 to 
2.0) and the integrity of RNA was checked by running 1 \i\ total RNA (0.5 (xg) on a 
1% agarose gel. 
2) Reverse transcription (RT) 
The total cellular RNA was heated at 65�C for 5 minutes before being used in the 
cDNA synthesis. Reverse transcription was performed by the thermocycler, Gene Amp 
PGR System 9700 (Perkin-Elmer Co.). Total RNA (1 |ig) was mixed with a reaction 
mixture containing IX first strand buffer, 0.5 mM of each dNTP, 40 units of rRNasin 
ribonuclease inhibitor, 10 mM DTT, 0.1 |ag oligo-dTi2-i8 and 200 units of M-MLV 
reverse transcriptase. The mixture was incubated at 37�C for 1 hour and 99�C for 5 
minutes. The reaction was terminated by chilling the samples at 4°C, and the resulting 
cDNA was stored at -20°C until use. 
3) Polymerase chain reaction (PCR) 
The cDNA samples prepared by reverse transcription were first boiled for 5 
minutes followed by chilling on ice immediately. For each sample, cDNA (equivalent 
to 0.1 |ig of total RNA) in 2 \i\ was mixed with a 23 jil reaction mixture containing 1 
unit o f T h e r m o p r i m e P i u s DNA polymerase, IX PCR buffer, 0.2 mM dNTPs, 1.5 mM 
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MgCb and 0.2 _ of each sense and anti-sense oligonucleotide primer in a PCR tube. 
A negative control with no cDNA sample was prepared to check for any 
contaminations. The reaction mixtures in PCR tubes were then put to the 
thermocycler, GeneAmp PCR System 9700 (Perkin-Elmer Co.), which was 
programmed with certain rounds of temperature cycling. The samples were subjected 
to an initial denaturation at 94°C for 5 minutes in the first cycle. This was followed by 
25-30 thermal cycles with denaturation at 94°C for 30 seconds, annealing at 55°C for 
1 minute and elongation at 72°C for 1 minute. In the last cycle, one more step in 
elongation for 5 minutes was performed to complete the reaction. The amplified PCR 
products were then stored at -20°C until use. The annealing temperature and the 
number of cycles were optimized empirically for each primer set. The amount of 
cDNA used in each sample was normalized with reference to that of the housekeeping 
gene GAPDH. 
4) Agarose gel electrophoresis 
The PCR products were analyzed by 2% agarose gel electrophoresis. Briefly, 5 
li\ PCR sample was mixed with 1 \x\ 5X gel loading buffer. The mixture was subjected 
to electrophoresis in 0.5X TBE electrophoresis buffer in a 2% agarose gel at a 
constant voltage of 100 volts for 2-3 hours. 0.5 ^g of 100 bp DNA ladder (GIBCO 
BRL Life Technologies Inc.) was loaded as the size marker. After electrophoresis, the 
gel was stained with 1 |ig/ml ethidium bromide solution for 5 minutes and was 
destained with distilled water for 15 minutes. The stained gel was then analyzed by 
the Bio-Rad Gel Doc 2000 under UV illumination. 
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2.2.10 Protein expression study 
2.2.10.1 Protein extraction 
JCS cells (104 cells/ml) were treated with topoisomerase-targeting agents for 
different periods of time at 3TC. The cells were harvested and washed twice with 
cold PBS by centrifuging at 250xg for 5 minutes at 4°C. Cell viability was determined 
by trypan blue exclusion assay and viable cells were mixed and vortexed vigorously 
with lysis buffer. The cell lysates were kept on ice for 30 minutes and then centrifiiged 
at 14,000 rpm for 5 minutes at 4�C. The supernatant (protein) of each sample was 
collected for further studies. 
2.2.10.2 Protein quantification 
The protein concentration of each sample was measured by Bradford protein 
assay. Standard bovine serum albumin (BSA) solutions at 2 ^ig/ml, 4 i^g/ml, 6 |ag/ml, 
8 )j,g/ml, and 10 fa,g/ml were prepared with double distilled water in triplicate with 2 
mg/ml BSA stock solution. Protein samples (1 each) were diluted with double 
distilled water. BSA standards (800 |al) or protein samples were mixed with 200 \x\ 
Bradford reagent (Bio-Rad Lab.). They were then allowed to stand at room 
temperature for 5 minutes and the absorbance at 595 nm was recorded using the 
Bradford reagent as the blank. A standard curve was constructed by plotting the 
absorbance versus the concentration of BSA standards. The concentration of each 
protein sample was estimated from the standard curve. 
2.2.10.3 Western blot analysis 
SDS-PAGE was carried out to separate the proteins according to the molecular 
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weights. The protein samples were normalized with reference to the amount of P-actin 
present. An appropriate amount (10 - 50 jig) of protein was mixed with 2X protein 
loading buffer. The protein samples were then boiled for 5 minutes and loaded onto 
the SDS-polyacrylamide gel with 5% stacking gel. Pre-stained protein markers (8 ^il) 
were also loaded and the gel was run under constant voltage of 100 - 150 volts for 2-3 
hours. The percentage of acrylamide added in the running gel varied according to the 
molecular weight of the target protein. The higher the molecular weight of the target 
protein, the lower the percentage of acrylamide gel. The composition of different 
percentages of SDS-polyacrylamide gel is shown in Table 2.3. 
After electrophoresis, the stacking gel was removed and the running gel was 
washed by distilled water and soaked in transfer buffer for 5 minutes. Three pieces of 
3 mm Whatman chromatography papers soaked with transfer buffer were placed on 
the semi-dry electroblotter (Bio-Rad Lab.). One PVDF membrane activated by 100% 
methanol was then covered on the filter papers. The gel was carefully placed on the 
membrane and three more pieces of pre-wet filter papers were covered on the gel. 
Finally, air bubbles were excluded by rolling a glass tube on the surface of the filter 
paper. The proteins were allowed to transfer to the PVDF membrane for 30-40 
V 
minutes at 16 V. After the protein transfer, the membrane was removed and incubated 
with 5% skimmed milk at room temperature for at least 1 hour to block the 
non-specific sites for probing. Primary antibody probing the target protein was 
incubated at a ratio of 1:1,000-2,000 with the membrane in the presence of 5% 
skimmed milk at 4°C overnight. 
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2.2.10.4 ECL Assay 
After blotting with primary antibody, the PVDF membrane with transferred 
proteins was washed for 30 minutes. The membrane was then incubated with 
horseradish peroxidase-linked secondary antibody (1:1,000 dilution) in 5% skimmed 
milk for one hour at room temperature. After washing for 30 minutes, the membrane 
was subjected to ECL assay. A mixture containing 0.5 ml each of detection reagent 1 
and reagent 2 was used per membrane. The membrane was then immersed in the 
reagent mixture and allowed to react for 1 minute. Excess reagent was removed. The 
membrane was covered with Glad Wrap and was placed on an ECL film in dark room 
for different periods of exposure time (30 s, 1 min, 2 min, 5 min, 10 min and 30 min). 
Finally the film was developed and the specific protein bands could be visualized. 
Table 2.3. Composition of the SDS-polyacrylamide gel 
5% stacking Separatinggel(5 ml) 
gel (3 ml) 10% 12% 
Distilled water 1.677 ml 2.4 ml 2 ml 1.65 ml 
Lower buffer - 1.25 ml 1.25 ml 1.25 ml 
Upper buffer 0.75 ml - -
� 30% 
acrylamide 0.5 ml 1.25 ml 1.65 ml 2 ml 
stock 
10% SDS 0.03 ml 0.025 ml 0.025 ml 0.025 ml 
10% APS 0.04 ml 0.075 ml 0.075 ml 0.075 ml 
TEMED 1.25 i^l 1.25 1.25 \x\ 
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2.2.11 Measurement of caspase activity 
2.2.11.1 Protein extraction 
The method for the measurement of caspase activity was adopted from Mack et 
al (2000). JCS cells (lO"^  cells/ml) were treated with topoisomerase-targeting agents 
for different periods of time (12 and 24 hours) at T^TC. The cells were harvested and 
washed twice with cold PBS by centrifuging at 1,500 rpm for 5 minutes at 4°C. Cell 
viability was determined by trypan blue exclusion assay and viable cells were mixed 
with lysis buffer and vortexed vigourously. The cell lysates were kept on ice for 10 
minutes and then centrifuged at 14,000 rpm for 5 minutes at 4°C. The supematants 
were collected for further assay. 
2.2.11.2 Quantification of proteins 
The protein concentration of the cell lysates was determined by Bradford protein 
assay as described in section 2.2.10.2. The concentrations of the protein samples were 
determined from the standard curve and 50-100 [ig of the protein was subjected to the 
caspase activity assay. 
2.2.11.3 Fluorometric measurement of caspase activity 
To confirm the correlation between caspase activities with the signal detection, a 
control reaction was set up by incubating 10 |j.1 induced cell lysate with the indicated 
volume of corresponding caspase inhibitors and 90 jil reaction buffer at 37°C for 30 
minutes. After that the cell lysate and reaction buffer were incubated with the 
indicated amount of the corresponding caspase substrates at 37°C for 1 hour. The 
fluorescence units released were measured by the fluorescent plate reader, Cytofluo. 
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The amount of fluorescence units released represented the caspase activity which can 
be quantified by comparing with the standard curve of free fluorescence units. 
2.2.12 Statistical analysis 
In most cases, each experiment was performed at least twice and the results of 
only one representative experiment were presented. The data were expressed as 
arithmetic mean 士 standard error. The student's t-test was used for statistical analysis. 
Normally, p < 0.05 was regarded as significantly different. 
V 
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3.1 Introduction 
Cell proliferation involves the increase in cell number by division. It plays a 
pivotal role in the growth and tissue turnover of an organism. To maintain 
homeostasis in an organism, undoubtedly, the rate of cell proliferation should be 
under strict and proper control. Nevertheless, for instance, if the gain-of-fiinction 
oncogene mutation and the loss-of-function tumor suppressor gene mutation occur in 
a cell, the uncoupling in proliferation with growth control would tilt the cell to 
carcinogenesis. Therefore, the basic principle of cancer therapy is the use of agents 
that can suppress the out-of-control proliferation in cancer cells but with minimal 
toxicity on normal cells. 
DNA topoisomerases I and II (Top I and Top II) are ubiquitous nuclear enzymes 
that are involved in many essential nuclear functions such as DNA replication, 
transcription, recombination and chromatid segregation and solve the topological 
problems associated with these cellular processes by introducing temporary single- or 
double-stranded breaks in the DNA (Champoux, 2001). These two enzymes are the 
molecular targets of a wide variety of pharmaceutical drugs and inhibitors of these 
� enzymes have been shown to have potent anti-tumor activity (Pommier et al., 2001; 
Takimoto & Arbuck, 2001). 
As mentioned in Section 1.3, topoisomerase-targeting agents are active against a 
variety of malignant neoplasms, including cancers of the lung, ovary, gastrointestinal 
tract, central nervous system and the hematopoietic system. In the present study, 
efforts had been made to study the effects of four topoisomerase-targeting agents, 
including camptothecin (CPT), 10-hydroxy-camptothecin (HCPT), etoposide (VP-16) 
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and etoposide phosphate (EP), on the in vitro proliferation of leukemia cells. In 
addition, the direct in vitro cytotoxicity of HCPT and EP on normal hematopoietic 
cells was also assessed. Besides the in vitro assays, the in vivo anti-tumor effect of 
HCPT and EP on the murine myeloid leukemia WEHI-3B JCS cells, a 
well-characterized model for cancer research, was also investigated. Moreover, 
attempts were made to examine the underlying mechanisms for the in vitro 
anti-proliferative effect of HCPT and EP on the leukemia JCS cells. These include the 
study of the effects of HCPT and EP on cell cycle kinetics, and the expression of the 
cell cycle-regulatory genes such as that of cyclins and cyclin-dependent kinases (cdk), 
using flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR). 
In addition, the anti-leukemic effect of HCPT or EP in combination with different 
cytokines was also investigated. 
V 
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3.2 Results 
3.2.1 The anti-proliferative effect of topoisomerase-targeting agents 
on human and murine leukemia cell lines in vitro 
Initially, four topoisomerase-targeting agents [these included two topoisomerase 
I- (Top I) targeting agents 10-hydroxy-camptothecin and its parent compound 
camptothecin; and two topoisomerase II- (Top II) targeting agents etoposide 
phosphate and its prodrug etoposide] were selected in this study. The tritiated 
thymidine ([^H]-TdR) proliferation assay, a sensitive method for measuring the 
incorporation of [^H]-TdR into the DNA of proliferating cells, was used to examine 
the effects of these agents on the proliferation of leukemia cells. As shown in Figure 
3.1 - 3.12, the four topoisomerase-targeting agents inhibited the proliferation of both 
human and murine leukemia cells in a dose-dependent manner, with an estimated 
50% inhibitory concentration (IC50) ranged from 3 - 400 nM (Table 3.1). It can be 
seen that different leukemia cell lines showed differential sensitivity to the four 
topoisomerase-targeting agents. Generally speaking, among the leukemia cell lines 
tested, the human myelogenous leukemia K-562 cells were found to be the most 
sensitive to Top I-targeting agents camptothecin and 10-hydroxycamptothecin 
气. 
whereas the murine myelomonocytic leukemia WEHI-3B JCS cells were most the 
sensitive to the Top Il-targeting agents etoposide and etoposide phosphate (Table 3.1). 
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Figure 3.1. Anti-proliferative effect of topoisomerase I-targeting agents on the 
murine myelomonocytic leukemia WEHI-3B JCS cells. JCS cells (lO* cells/ml) 
were incubated with different concentrations of (A) CPT and (B) HCPT at 37�C for 
48 hours. Cultures were then pulsed with 0.5 |iCi of [^H]-TdR for 6 hours before 
harvest. Radioactivity was measured by the liquid scintillation counter and expressed 
as counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.2. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
� murine myelomonocytic leukemia WEHI-3B JCS cells. JCS cells (lO^ cells/ml) 
were incubated with different concentrations of (A) VP-16 and (B) EP at 37�C for 48 
hours. Cultures were then pulsed with 0.5 )j.Ci of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
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Figure 3.3. Anti-proliferative effect of topoisomerase I-targeting agents on the 
� murine myeloblastic leukemia Ml cells. Ml cells (5x10"^  cells/ml) were incubated 
with different concentrations of (A) CPT or (B) HCPT at 37�C for 48 hours. Cultures 
were then pulsed with 0.5 i^Ci of [^H]-TdR for 6 hours before harvest. Radioactivity 
was measured by the liquid scintillation counter and expressed as counts per minute 
(cpm). The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the solvent control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.4. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
� murine myeloblastic leukemia Ml cells. Ml cells (5x 10'^  cells/ml) were incubated 
with different concentrations of (A) VP-16 or (B) EP at 37°C for 48 hours. Cultures 
were then pulsed with 0.5 |aCi of [^H]-TdR for 6 hours before harvest. Radioactivity 
was measured by the liquid scintillation counter and expressed as counts per minute 
(cpm). The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the solvent control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.5. Anti-proliferative effect of topoisomerase I-targeting agents on the 
“ human promyelocytic leukemia HL-60 cells. HL-60 cells (10^ cells/ml) were 
incubated with different concentrations of (A) CPT or (B) HCPT at 37�C for 48 hours. 
Cultures were then pulsed with 0.5 |j,Ci of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.6. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
� human pro myelocytic leukemia HL-60 cells. HL-60 cells (10^ cells/ml) were 
incubated with different concentrations of (A) VP-16 or (B) EP at 37�C for 48 hours. 
Cultures were then pulsed with 0.5 of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.7. Anti-proliferative effect of topoisomerase I-targeting agents on the 
� human myelogenous leukemia K-562 cells. K-562 cells (5x10"^ cells/ml) were 
incubated with different concentrations of (A) CPT or (B) HCPT at 37�C for 48 hours. 
Cultures were then pulsed with 0.5 |LiCi of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.8. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
� human myelogenous leukemia K-562 cells. K-562 cells (5x10'^  cells/ml) were 
incubated with different concentrations of (A) VP-16 or (B) EP at 37°C for 48 hours. 
Cultures were then pulsed with 0.5 fiCi of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
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Figure 3.9. Anti-proliferative effect of topoisomerase I-targeting agents on the 
murine macrophage-like leukemia PU5-1.8 cells. PU5-1.8 cells (5 x 1O* cells/ml) 
were incubated with different concentrations of (A) CPT or (B) HCPT at 37°C for 48 
hours. Cultures were then pulsed with 0.5 i^ Ci of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.10. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
� murine macrophage-like leukemia PU5-1.8 cells. PU5-1.8 cells (5x10"^ cells/ml) 
were incubated with different concentrations of (A) VP-16 or (B) EP at 37�C for 48 
hours. Cultures were then pulsed with 0.5 |j,Ci of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.11. Anti-proliferative effect of topoisomerase I-targeting agents on the 
� murine macrophage-like leukemia J774A.1 cells. J774A.1 cells (5x10'^ cells/ml) 
were incubated with different concentrations of (A) CPT or (B) HCPT at 37°C for 48 
hours. Cultures were then pulsed with 0.5 |aCi of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
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Figure 3.12. Anti-proliferative effect of topoisomerase Il-targeting agents on the 
murine macrophage-like leukemia J774A.1 cells. J774A.1 cells (5 xlO* cells/ml) 
were incubated with different concentrations of (A) VP-16 or (B) EP at 37�C for 48 
hours. Cultures were then pulsed with 0.5 )iCi of [^H]-TdR for 6 hours before harvest. 
Radioactivity was measured by the liquid scintillation counter and expressed as 
counts per minute (cpm). The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
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Table 3.1. The estimated IC50* values of topoisomerase-targeting agents on 
various human and murine leukemia cell lines 
Estimated IC50 values (nM) 
Types of leukemia 
CPT HCPT VP-16 EP 
WEHI-3B 
A/r • 1 .J T^� 4.6 12 40 100 Murine myeloid JCS 
leukemia Ml 33 65 60 100 
„ , HL-60 4.7 8 180 150 Human myeloid 
leukemia K562 3 2.5 175 175 
Murine PU5-1.8 17 7 160 150 
macrophage-like 
leukemia J774A.1 23 13 150 400 
* IC50 value is the estimated concentration of topoisomerase-targeting agent causing 
50% inhibition of [^H]-TdR incorporation under specified experimental conditions. 
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After the initial screening on the four topoisomerase-targeting agents, the 
kinetics of the anti-proliferative effect of 10-hydroxy-camptothecin and etoposide 
phosphate on WEHI-3B JCS cells was further studied. HCPT and EP were chosen for 
further studies since they are relatively more water-soluble than their respective 
parent compounds, moreover, they inhibited the proliferation of JCS cells with 
relatively low IC50 values. In addition to the 48-hour treatment, JCS cells were treated 
with HCPT or EP for 24 or 72 hours. The results show that both HCPT and EP 
inhibited the proliferation of JCS cells dose- and time-dependently (Figure 3.13). 
Besides using the [^H]-TdR proliferation assay, the effects of HCPT and EP on 
the growth of JCS cells were also examined by the trypan blue exclusion assay. As 
shown in Figure 3.14, both HCPT and EP reduced the number of viable JCS cells in a 
dose-dependent manner, when compared with the solvent control. 
V 
-100- “ 
Chapter 3 The anti-pro I iferative effect 
(A) I 100 n | _ ^ 7 2 h r | 
I • 48 hr 
| 8 0 _ |-->--24hr| - ^ ^ 食 
！ 遍 / i 
I 2 � 
1 0 i K ^ - t 1 1 1 1 1 
系 0 5 10 15 20 25 
Concentration of HCPT (nM) 
(B) 
§ 1 0 0 . 
I —— 
讓 60- f / 
§ 4 0 - A i I 一 N 
e ' / - A - 48 hr 
§ i! 
3 20 - ^ - - » - • 24 hr 
I ：一 ,， 
家 0 , , , , , , 
0 100 200 300 400 500 600 Concentration of EP (nM) 
Figure 3.13. Kinetic study on the anti-proliferative effect of 
10-hydroxy-camptothecin and etoposide phosphate on the murine myeloid 
leukemia WEHI-3B JCS cells. JCS cells (lO* cells/ml) were incubated with different 
concentrations of (A) HCPT or (B) EP at 37°C for 24, 48 or 72 hours. Cultures were 
then subjected to [^H]-TdR proliferation assay as described under Materials and 
Methods. The results were expressed as % inhibition of [^H]-TdR incorporation 
compared to the solvent control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.14. The growth-inhibitory effect of 10-hydroxy-camptothecin and 
etoposide phosphate on the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated with different concentrations of (A) HCPT or (B) 
EP at 37°C for 48 hours. The details were described under Materials and Methods. 
The number of viable cells in each sample was estimated by the trypan blue exclusion 
assay. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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The above experiments clearly demonstrated the growth-inhibitory effect of 
10-hydroxy-camptothecin and etoposide phosphate on the leukemia JCS cells. So, the 
next question is whether the inhibitory effect reversible. To address this question, the 
reversibility test had been performed. The drugs were replaced by complete culture 
medium after 12 and 24 hours of incubation. The [^H]-TdR uptake by the JCS cells 
was then measured after 48 hours of incubation. As shown in Figure 3.15, the 
reversibility of the anti-proliferative effect on JCS cells was dependent on the duration 
of drug exposure and the concentration of drug used. It appeared that the 
anti-proliferative effect of HCPT was almost irreversible whereas that of EP was 
reversible after 12 and 24 hours of incubation, when a lower concentration (200 nM) 
of drug was used. 
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Figure 3.15. Reversibility study of the anti-proliferative effect of 
10-hydroxy-camptothecin and etoposide phosphate on the murine myeloid 
leukemia WEHI-3B JCS cells. JCS cells (10^ cells/ml) were incubated with different 
concentrations of (A) HCPT or (B) EP at 37�C for 12，24 and 48 hours. The drug was 
then replaced by complete culture medium and the cultures were incubated up to 48 
hours. Cultures were then subjected to the [^H]-TdR proliferation assay as described 
under Materials and Methods. The results were expressed as % inhibition of[^H]-T(iR 
incorporation compared to the vehicle control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
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3.2.2 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the clonogenicity of the murine myeloid leukemia WEHI-3B JCS 
cells 
To study the effects of HCPT and EP on the clonogenicity of JCS cells, the soft ' 
agar clonogenic assay was performed. Briefly, 400 JCS cells were incubated with 
control solvent or different concentrations of HCPT or EP in soft agar for 7 days at 
37�C. The number of colonies (containing more than 50 cells) in the soft agar was 
counted after hematoxylin staining. It was observed that both HCPT and EP could 
significantly lower the % cloning efficiency of JCS cells in soft agar. 
Table 3.2. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
clonogenicity of murine myeloid leukemia WEHI-3B JCS cells in soft agar 
No. of colonies formed in soft agar % cloning efficiency 
Solvent control 241 ± 9 60.25 土 2.25 
20nM HCPT 52.5 土 3.5* — 13.13 ±0.88* 
40nM HCPT 20.3 土 8.6* — 5.08 ±2.14* 
200nM EP 63.3 土 11* • 15.8 ±2.76* 
400nM EP 38.5 土 0.5* — 9.63 土 0.13* 
The soft agar clonogenic assay was performed as described under Materials and 
Methods. The results were expressed as % cloning efficiency, which represents the 
number of colonies per 100 cells seeded in the soft agar plate. 
* Significantly different from control, p < 0.03 
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3.2.3 Effects of 10-hydroxy-camptothecin and etoposide phosphate on 
the tumorigenicity and proliferation of the murine myeloid leukemia 
WEHI-3B JCS cells in vivo 
In addition to the in vitro studies, animal experiments were performed to '• 
investigate the anti-proliferative effect of HCPT and EP on JCS cells in vivo. The in 
vivo study was divided into two parts. Firstly, the effect of HCPT and EP on the 
tumorigenicity of JCS cells in vivo was studied. JCS cells were pretreated with control 
solvent, HCPT or EP in vitro for 8 hours at 37°C. The drugs were then washed away 
and 10^ viable JCS cells were injected i.p. into each BALB/c mouse. Viable JCS cells 
recoverable from the mouse peritoneal cavity were counted at day 14 post-tumor 
inoculation. Secondly, the effect of HCPT and EP on the in vivo growth of JCS cells 
was examined. Briefly, 10^ JCS cells were inoculated i.p. into each BALB/c mouse on 
day 0. From day 8 onwards, different doses of HCPT and EP were injected i.p. into 
the tumor-bearing mice on alternate days. Viable JCS cells recoverable from the 
mouse peritoneal cavity were counted at day 17. The results are shown in Figures 3.16 
and 3.17. In addition to their in vitro anti-proliferative effect, it was found that both 
HCPT and EP inhibited the tumorigenicity and growth of JCS cells in vivo in a 
� dose-dependent manner. 
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Figure 3.16. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
tumorigenicity of the murine myeloid leukemia WEHI-3B JCS cells in syngeneic 
BALB/c mice. JCS cells (lO^ cells/ml) were incubated with control solvent, different 
concentrations of HCPT (20 or 40 nM) or EP (200 or 400 nM) for 8 hours at 37°C. 
The treated cells were washed three times with RPMI 1640 medium. 10^ viable cells 
were then injected i.p. into each BALB/c mouse in groups of five. Viable JCS cells 
recoverable from the peritoneal cavity were counted at day 14 post-tumor inoculation. 
* Significantly different from control, p < 0.03 
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Figure 3.17. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
in vivo growth of the murine myeloid leukemia WEHI-3B JCS cells in syngeneic 
BALB/c mice. JCS cells (10^) were inoculated i.p. into each BALB/c mouse in 
groups of five on day 0. From day 8 onwards, control solvent, different doses of (A) 
HCPT (0.1 or 0.5 mg/kg) or (B) EP (1 or 5 mg/kg) were injected i.p. into the 
tumor-bearing mice on alternate days. Viable JCS cells recoverable from the 
peritoneal cavity were counted at day 17. 
* Significantly different from the control: P < 0.05 
** Significantly different from the control: P < 0.01 
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3.2.4 Cytotoxic effect of 10-hydroxy-camptothecin and etoposide 
phosphate on normal hematopoietic cells and WEHI-3B JCS cells in 
vitro 
As shown in previous sections (3.2.1 - 3.2.3), the topoisomerase-targeting agents 
HCPT and EP exhibited significant anti-proliferative effect on JCS cells both in vitro 
and in vivo. Is the observed growth-inhibitory effect due to direct cytotoxicity of the 
drugs on the leukemia JCS cells? To evaluate the cytotoxic property of these two 
drugs, normal hematopoietic cells including murine bone marrow cells, splenic 
lymphocytes, peritoneal macrophages, and the myeloid leukemia WEHI-3B JCS cells 
were treated with different concentrations of HCPT and EP for 48 hours. The 
percentage of viable cells was estimated by trypan blue exclusion assay or MTT assay. 
As shown in Figure 3.18-3.21，both HCPT (0 一 40 nM) and EP (0 - 400 nM) did not 
show any significant cytotoxic activity (< 10% decrease in viability) on the normal 
hematopoietic cells. For the leukemia JCS cells, HCPT was more cytotoxic than EP. It 
can be seen that 0 - 2 0 nM HCPT did not show any significant cytotoxic activitiy on 
JCS cells, however, the viability of JCS cells decreased to about 40% as the 
concentration of HCPT was increased to 50 nM. 
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Figure 3.18. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
viability of murine bone marrow cells. BALB/c mouse-derived bone marrow cells 
(5x10^ cells) were incubated with control solvent, (A) HCPT (5 - 40 nM) or (B) EP 
(50 - 400 nM) at 37°C for 48 hours. After staining with trypan blue solution (0.4% 
w/v), the numbers of viable and dead cells were counted under light microscope. The 
results were expressed as % viability of murine bone marrow cells. 
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Figure 3.19. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
viability of murine splenic lymphocytes. BALB/c mouse-derived splenic 
lymphocytes (5x10^ cells) were incubated with control solvent, HCPT (5 - 40 nM) or 
EP (50 - 400 nM) at 37°C for 48 hours. After staining with trypan blue solution (0.4% 
w/v), the numbers of viable and dead cells were counted under light microscope. The 
results were expressed as % viability of murine splenic lymphocytes. 
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Figure 3.20. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
viability of murine peritoneal macrophages. BALB/c mouse-derived peritoneal 
macrophages (5x10^ cells) were incubated with control solvent, HCPT (5 一 40 nM) or 
EP (50 - 400 nM) at 37°C for 48 hours. The viability of the macrophages was 
determined by MTT assay. The results were expressed as % viability of murine 
peritoneal macrophages. 
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Figure 3.21. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
viability of WEHI-3B JCS cells. JCS cells (lO* cells/ml) were incubated with control 
solvent, HCPT (5 - 40 nM) or EP (50 - 400 nM) at 37°C for 48 hours. After staining 
with trypan blue solution (0.4% w/v), the numbers of viable and dead cells were 
counted under light microscope. The results were expressed as % viability of JCS 
cells. 
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3.2.5 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the cell cycle kinetics of WEHI-3B JCS cells 
It is well known that inhibitor! of cell proliferation is often due to the regulation 
of cell cycle progression. Since HCPT and EP exhibited potent anti-proliferative 
effect on the leukemia JCS cells, it is of interest to further investigate whether these 
drugs could alter the cell cycle kinetics of the JCS cells. In the present study, the 
effect of HCPT and EP on the cell cycle profile of the leukemia JCS cells was 
examined by flow cytometric analysis. JCS cells were treated with HCPT (40 nM) or 
EP (400 nM) for 48 hours. The DNA of the fixed cells was then stained with 
propidium iodide (PI). As shown in Figure 3.22, both HCPT and EP increased the 
proportion of J C S cells in the G Q / G I phase by about 1 . 3 - 1 . 9 fold. Nevertheless, the 
percentage of cells in the S phase dropped drastically (to < 8%). About 50% of JCS 
cells in the control group were in the S phase whereas the majority of cells in the two 
treatment groups were arrested in the G Q / G I phase. Therefore, it is likely that Go/Gi 
phase arrest is one of the check points where HCPT and EP exert their 
anti-proliferative effect on JCS cells. The presence of a hypodiploid peak in both 
treatment groups was due to the fragmented DNA, which is commonly observed in 
cells undergoing apoptosis. 
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% of viable JCS cells in 
JCS cells trcEtcd with Sub-Gi phase Go/Gi phase S phase G2/M phase 
(A) Vehicle 0 34.6 50.92 14.48 
(B) 40 nM HCPT 27.72 45.27 7.96 19.04 
(C) 400 nM EP 13.41 66.81 0.35 19.43 
Figure 3.22. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
cell cycle kinetics of murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO* 
cells/ml) were either treated with vehicle, 40 nM HCPT or 400 nM EP at 37°C for 48 
hours. Harvested cells (10^) were fixed with ethanol and the DNA was stained with 
propidium iodide (PI) under hypotonic conditions. The fluorescence intensity of the 
cells was analyzed by FACSort flow cytometer. Cell cycle distribution was calculated 
by the MODFIT program. 
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3.2.6 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the expression of cell cycle-regulatory genes in the murine myeloid 
leukemia WEHI-3B JCS cells 
A typical representation of cell cycle is shown in Figure 3.23. A resting cell is in 
its quiescent state known as Go phase. Upon stimulation by growth signals, a 
quiescent cell enters the Gi phase of cell cycle, preparing itself for DNA synthesis. If 
a cell passes through the restriction point at late Gi phase, it enters S phase and is 
committed to complete the cell cycle. In S phase, a cell replicates its genome by DNA 
synthesis. When the cell progresses through G2 phase, it prepares to undergo cell 
division, which takes place in M phase. After cell division, the cell re-enters Go or Gi 
phase and the cell cycle is complete. 
In a normal cell, the cell cycle is tightly regulated by a network of cyclins and 
cyclin dependent kinases (CDKs). The interaction between these molecules in 
different phases of cell cycle is shown in Figure 3.23. In Section 3.2.5, the results 
show that both HCPT and EP could induce G Q / G I phase arrest in JCS cells. So, it is 
interesting to find out how HCPT and EP could affect the expression of these genes 
� that might contribute to G Q / G I arrest. To elucidate the molecular mechanism behind 
this phenomenon, reverse transcription-polymerase chain reaction (RT-PCR) was used 
to study the cell cycle-regulatory gene expression pattern. Briefly, JCS cells (lO� 
cells/ml) were incubated with control solvent, 40 nM HCPT or 400 nM EP for 
different periods of time (3，6, 12 or 24 hours). Total cellular RNA was extracted by 
using TRIZOL reagent. After reverse transcription, the gene expression pattern was 
examined by PCR. The results are shown in Figure 3.24 - 3.27. It was observed that 
HCPT slightly down-regulated the mRNA expression of cyclin A (43% reduction after 
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24 hours of treatment), cyclin B (41% reduction after 24 hours of treatment) and 
cyclin E (38% reduction after 6 hours of treatment), however, EP had no appreciable 
effect on the expression of these three genes under the same experimental conditions 
(Figure 3.24 and 3.25). On the other hand, both HCPT and EP enhanced the 
expression of cyclin D3 after 24 hours of treatment. As for the CDK genes, it was 
found that HCPT slightly down-regulated the mRNA expression of Cdk-2 and Cdk-6 
after 24 hours of treatment whereas EP down-regulated the expression of these two 
genes after 3 hours of treatment (Figure 3.26 and 3.27). Nevertheless, they had no 
significant effect on the expression of Cdk-4 gene. 
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Figure 3.23. Involvement of cyclins and cyclin dependent kinases (CDKs) in the 
regulation of cell cycle 
Modified from Eisel etal., 2002 
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Figure 3.24. Effect of 10-hydroxy-camptothecin on the expression of cyclin genes 
in the murine myeloid leukemia WEHI-3B JCS cells. JCS cells (2 x 10^) were 
treated with control solvent or 40 nM HCPT for different periods of time (3 - 24 
hours). Total RNA was extracted from the cells using TRIZOL reagent. The RNA 
samples were reverse-transcribed and amplified by PGR using specific primer pairs. 
The RT-PCR products were analyzed in 2% agarose gel. The band intensity was 
measured using ImageQuant (Molecular Dynamics) software. The value at the bottom 
of each band represents the relative intensity after normalization with GAPDH and 
comparison was made with the corresponding control. 
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Figure 3.25. Effect of etoposide phosphate on the expression of cyclin genes in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (2 x 10^) were treated 
with control solvent or 400 nM EP for different periods of time (3 - 24 hours). Total 
RNA was extracted from the cells using TRIZOL reagent. The RNA samples were 
reverse-transcribed and amplified by PGR using specific primer pairs. The RT-PCR 
products were analyzed in 2% agarose gel. The band intensity was measured using 
ImageQuant (Molecular Dynamics) software. The value at the bottom of each band 
V represents the relative intensity after normalization with GAPDH and comparison was 
made with the corresponding control. 
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Figure 3.26. Effect of lO-hydroxy-camptothecin on the expression of 
cyclin-dependent kinase (CDK) genes in the murine myeloid leukemia WEHI-3B 
JCS cells. JCS cells (2 x 10^) were treated with control solvent or 40 nM HCPT for 
different periods of time (3-24 hours). Total RNA was extracted from the cells using 
TRIZOL reagent. The RNA samples were reverse-transcribed and amplified by PCR 
using specific primer pairs. The RT-PCR products were analyzed in 2% agarose gel. 
The band intensity was measured using ImageQuant (Molecular Dynamics) software. 
The value at the bottom of each band represents the relative intensity after 
normalization with GAPDH and comparison was made with the corresponding 
control. 
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Figure 3.27. Effect of etoposide phosphate on the expression of cyclin-dependent 
kinase (CDK) genes in the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (2 X 10^) were treated with control solvent or 400 nM EP for different periods of 
time (3-24 hours). Total RNA was extracted from the cells using TRIZOL reagent. 
The RNA samples were reverse-transcribed and amplified by PCR using specific 
primer pairs. The RT-PCR products were analyzed in 2% agarose gel. The band 
intensity was measured using ImageQuant (Molecular Dynamics) software. The value 
at the bottom of each band represents the relative intensity after normalization with 
GAPDH and comparison was made with the corresponding control. 
V 
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3.2.7 Combination effect of 10-hydroxy-camptothecin or etoposide 
phosphate with cytokines on the proliferation of the murine myeloid 
leukemia WEHI-3B JCS cells 
It has been well documented that cytokines such as tumor necrosis factor-alpha 
(TNF-a) and interleukins (IL) are involved in the modulation of the growth, maturity 
and survival of myeloid leukemia cells (De Benedetti et al., 1990; Leung et al., 1994; 
Mak et al., 2002). Cytokines have become increasingly popular in cancer 
immunotherapy, for instance, the combination of 5-fluorouracil, cisplatin and IFN-a 
for the treatment of advanced hepatocellular carcinoma is under clinical trial 
(Komorizono et al., 2003). In this study, attempts were made to investigate the 
combination effect of HCPT or EP with cytokines including TNF-a, IFN-y and IL-1|3 
on the proliferation of murine myeloid leukemia JCS cells. The results are shown in 
Figure 3.28 - 3.30. Among the three cytokines tested, only TNF-a (at concentration > 
300 U/ml) was found to act in synergy with HCPT and EP in inhibiting the 
proliferation of the JCS cells. On the other hand, IFN-y and IL-lp gave only a slight 
additive effect on inhibiting the proliferation of JCS cells when combined with either 
HCPT or EP. 
V 
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Figure 3.28. Effect of 10-hydroxy-camptothecin, etoposide phosphate and TNF-
a on the proliferation of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (10^ cells/ml) were incubated either alone with TNF-a (100 - 500 U/ml) or iin 
the presence of (A) HCPT (7.5 or 10 nM) and (B) EP (25 or 50 nM) at 37�C for 48 
hours. Cultures were then subjected to [^H]-TdR proliferation assay described under 
Materials and Methods. The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 士 S.E. 
of quadruplicate cultures. 
* Synergistic effect was observed 
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Figure 3.29. Effect of 10-hydroxy-camptothecin, etoposide phosphate and IFN-y 
on the proliferation of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated either alone with IFN-y (100 - 1000 U/ml) or in 
the presence of (A) HCPT (7.5 or 10 nM) and (B) EP (25 or 50 nM) at 37�C for 48 
hours. Cultures were then subjected to [^H]-TdR proliferation assay described under 
Materials and Methods. The results were expressed as % inhibition of [^H]-TdR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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Figure 3.30. Effect of 10-hydroxy-camptothecin, etoposide phosphate and IL-ip 
on the proliferation of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated either alone with IL-1 p (2 - 10 ng/ml) or in the 
presence of (A) HCPT (7.5 or 10 nM) and (B) EP (25 or 50 nM) at 37�C for 48 hours. 
Cultures were then subjected to [^H]-TdR proliferation assay described under 
Materials and Methods. The results were expressed as % inhibition of [^H]-TclR 
incorporation compared to the solvent control. Each point represents the mean 土 S.E. 
of quadruplicate cultures. 
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3.3 Discussion 
In the present study, the effect of four topoisomerase-targeting agents on the 
proliferation of leukemia cells was investigated, using six murine and human 
leukemia cell lines. The four topoisomerase-targeting agents included two 
topoisomerase I (Top I) inhibitors 10-hydroxycamptothecin (HCPT) and its parent 
compound camptothecin (CPT), and two topoisomerase II- (Top II) targeting agents 
etoposide (VP-16) and its pro-drug etoposide phosphate (EP). HCPT and EP are two 
novel topoisomerase-targeting agents, having their own advantage over their 
respective parent compound. For instance, HCPT has been shown to be more potent 
and less toxic than CPT and has recently undergone clinical trials (Zhang et al” 1998). 
EP, with higher solubility in aqueous solution, is easier to administer than etoposide 
(Greco & Hainsworth，1996). Moreover, intravenous administration of etoposide has 
been reported to cause a hypersensitivity reaction in 1-3% of patients, but etoposide 
phosphate can be safely administered without any adverse hypersensitivity response 
(Siderov et al., 2002). This was the reason why they were chosen in the present study. 
By comparing the 50% inhibitory concentrations, it can be seen that the six leukemia 
cell lines displayed differential sensitivity to the four topoisomerase-targeting agents, 
’ with the human myelogenous leukemia K-562 cells being more sensitive to Top I 
inhibitors CPT and HCPT, whereas the murine myelomonocytic leukemia WEHI-3B 
JCS cells were more sensitive to Top II inhibitors VP-16 and EP. The mechanisms for 
the differential sensitivity of various leukemia cell lines to these four 
topoisomerase-targeting agents remain unclear and await further investigations. 
Interestingly, recent studies suggested that the differential sensitivity of cancer cells to 
topoisomerase-targeting agents might be correlated to cell-to-cell difference in the 
rate of DNA repair, mutations in the ATM gene and the level of multidrug resistance 
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protein, etc (Fedier et al., 2003; Hansen et al., 2003; Vassal et aL, 2003). After the 
initial screening, the kinetics of the anti-proliferative effect of HCPT and EP on the 
murine myeloid leukemia WEHI-3B JCS cells was further studied. The murine 
myeloid leukemia cell line WEHI-3B JCS was chosen for further investigation not 
only because they had been subcloned and well-characterized in our laboratory both 
in vitro and in vivo (Chan et al., 1997; Fung et al., 1997; Leung et al., 1994; Mak et 
al., 1993; 1994; 2002)，but also they were found to be the most sensitive to the 
anti-proliferative effect of Top Il-targeting agents than other cell lines (Table 3.1). The 
results of the kinetic study showed that both HCPT and EP inhibited the proliferation 
of JCS cells in a dose- and time-dependent manner, with the maximum inhibitory 
activity achieved after 48 hours of drug treatment. The potent anti-proliferative effect 
of HCPT and EP was further confirmed by their significant inhibitory effect on the 
growth and clonogenicity of the JCS cells. Besides the in vitro anti-proliferative effect, 
both HCPT and EP inhibited the tumorigenicity and growth of JCS cells in vivo. Our 
results are in line with an earlier report showing that 9-nitro-camptothecin (a 
derivative of CPT) could delay the growth of the human U-937 leukemia in nude mice 
(Pantazis et al., 1993). 
V 
The results of the reversibility test suggested that the anti-proliferative effect of 
HCPT on JCS cells was almost irreversible whereas that of EP was reversible after 12 
and 24 hours of drug treatment. Since HCPT is more hydrophobic than EP, this will 
enable it to be taken up more efficiently by the leukemia JCS cells than that of EP, 
and this may account for the observed irreversibility of the anti-proliferative effect of 
HCPT. To evaluate the cytotoxic property of these two drugs, normal hematopoietic 
cells including murine bone marrow cells, splenic lymphocytes, peritoneal 
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macrophages, and the myeloid leukemia WEHI-3B JCS cells were treated with 
different concentrations of HCPT and EP for 48 hours and the percentage of viable 
cells was estimated by trypan blue exclusion assay or MTT assay. Generally speaking, 
both HCPT (0 - 40 nM) and EP (0 - 400 nM) did not show any significant cytotoxic 
activity on the normal hematopoietic cells. Moreover, EP did not show any significant 
toxicity on JCS cells, and HCPT was toxic (-60% viability) only at a higher 
concentration (50 nM). Our results showed that the anti-proliferative activity of HCPT 
and EP could not be attributed directly or solely to their direct cytotoxic effect on the 
cells. Interestingly, Jones and colleagues demonstrated that cell cycle regulation might 
play an important role in determining the effect of CPT on malignant and normal cells 
(Jones et al., 1997)，and this should be worthy of further investigation. 
It is well documented that retardation of cell proliferation is closely related to the 
regulation of cell cycle progression (Fukumi et aL, 2000; Higginbottom et al., 2002). 
Therefore, effort had been made to further investigate the effect of HCPT and EP on 
the cell cycle kinetics of JCS cells. Similar to the previous findings in our laboratory 
(Leung, 1999; Leung, 2002), both HCPT (40 nM) and EP (400 nM) arrested the JCS 
cell cycle in the G Q / G I phase. Moreover, the presence of a hypodiploid peak in both 
v 
treatment groups implied the possible induction of apoptosis in the drug-treated JCS 
cells. To elucidate the molecular mechanism of HCPT- and EP-induced cell cycle 
arrest in JCS cells, the mRNA expression of various cyclin and cyclin-dependent 
kinase (cdk) genes was examined by RT-PCR. It was observed that HCPT slightly 
down-regulated the mRNA expression of cyclin A and cyclin B after 24 hours of 
treatment whereas a slight reduction of cyclin E expression was seen after 6 hours of 
treatment. Surprisingly, EP had no appreciable effect on the expression of these three 
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genes under the same experimental conditions. The reason(s) for the differential 
regulation of cyclin gene expression by HCPT and EP remains obscure. However, it is 
known that cyclin A regulates the cell cycle progression and its synthesis is required 
for the progression to S phase (Howe et al., 1995). Cyclin B is active in M phase and 
it regulates the expression of proteins required for mitotic spindle construction and 
cytoskeleton reorganization (Yoshitome et al., 2003). Like cyclin A, cyclin E is 
responsible for the progression of cell cycle from Gi to S phase (Schraml et al., 2003). 
On the other hand, both HCPT and EP modulated the expression of cyclin D3, Cdk-2 
and Cdk-6, which are involved in the regulation of Gi phase, with no significant effect 
on the expression of Cdk-4 gene. In conclusion, alterations in the mRNA expression 
of cyclin and cdk genes might be one of the ways by which HCPT and EP arrested the 
JCS cell cycle at G Q / G I phase. 
In our study, attempts had also been made to investigate the combination effect 
of HCPT or EP with cytokines including TNF-a, IFN-y and IL-lp on the proliferation 
of murine myeloid leukemia JCS cells. These three cytokines had been shown to be 
capable of inhibiting the proliferation and inducing the differentiation of the JCS cells 
at higher concentrations (Chan et al., 1997; Leung et al, 1994; Mak et al., 1993). The 
V 
proinflammatory cytokine tumor necrosis factor- (TNF) a is secreted systemically by 
activated macrophages and in liver by biliary epithelial and venous endothelial cells 
(Loffreda et al., 1997). It has been recently reported that TNF-a was involved in 
arsenic trioxide-induced apoptotic cell death of murine myeloid leukemia cells (Mak 
et a!., 2002). On the other hand, IFNs are a family of cytokines with pleiotropic 
biological effects mediated by scores of responsive genes. IFNs, including IFN-y, 
were the first human proteins to be effective in cancer therapy and can induce 
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apoptosis in a variety of human malignancies (Chawla-Sarkar et al., 2003). Our 
results showed that among the three cytokines tested, only TNF-a acted in synergy 
with HCPT or EP in inhibiting the proliferation of the leukemia JCS cells, indicating 
combination of TNF-a and topoisomerase-targeting agents may provide a novel and 
more effective approach in the treatment of some forms of leukemia. 
V 
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4.1 Introduction 
Differentiation is the developmental process by which cells become structurally 
and functionally specialized. It is usually accompanied by the retardation in 
proliferation and increased expression of certain differentiation markers. Like many 
types of cancer, leukemia is characterized by the neoplastic proliferation of 
hematopoietic progenitor cells with the loss of differentiation capacity (Hoffbrand et 
al., 2001). Therefore, differentiation therapy is a possible approach for the treatment 
of leukemia, and this is supported by previous reports showing that myeloid leukemia 
cells could be induced to undergo terminal differentiation by cytokines and 
phytochemicals isolated from Chinese medicinal plants (Leung et al, 1994; Mak et 
al, 1996). 
There has been increasing evidence showing that both type I and type II DNA 
topoisomerase inhibitors play an important role in cellular differentiation. For 
example, Nakaya et al. (1991) demonstrated that topoisomerase inhibitors had strong 
differentiation-inducing activity for a variety of human and murine myeloid leukemia 
cells. On the other hand, Kondo et al. (1991) showed that topoisomerase inhibitors 
’ were capable of triggering the in vitro differentiation of the mouse embryonal 
carcinoma F9 cells into parietal endoderm-like cells. More recently, the human 
malignant melanoma SB IB cells could undergo differentiation towards the 
non-malignant, melanocyte-like cells in response to 9-nitrocamptothecin, a 
topoisomerase I inhibitor (Pantazis et al.’ 1999). In chapter 3, it was observed that 
both 10-hydroxy-camptothecin and etoposide phosphate exhibited potent 
anti-leukemic activity on the murine myeloid leukemia WEHI-3B JCS cells, both in 
vitro and in vivo. To study the possible differentiation-inducing activity of HCPT and 
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EP on the murine myeloid leukemia WEHI-3B JCS cells, morphological, phenotypic 
and functional analyses were carried out. First of all, cytocentrifuge slides of the JCS 
cells were prepared and the morphology was examined by light microscopy. The 
changes in cell size and granularity were also measured by flow cytometry. The 
differentiation-related functional activities such as plastic-adherence and 
NBT-reducing activity of the JCS cells were also analyzed. In addition, to elucidate 
the phenotypic characteristics of the differentiated cells, the levels of Mac-1，F4/80 
and Gr-1 surface antigen expression were measured by flow cytometry. 
V 
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4.2 Results 
4.2.1 Morphological changes in the murine myeloid leukemia 
WEHI-3B JCS cells treated with 10-hydroxy-camptothecin and 
etoposide phosphate 
Myeloid leukemia cells undergoing differentiation are usually accompanied by 
morphological changes including cell enlargement, increase in cytoplasm to nucleus 
ratio and increase in vacuolation. To examine the differentiation-inducing potential of 
10-hydroxy-camptothecin and etoposide phosphate on the murine myeloid leukemia 
WEHI-3B JCS cells, JCS cells were incubated with control solvent, HCPT (20 and 40 
nM) or EP (200 and 400 nM) at 37�C for 72 hours. Cytocentrifuge preparations of 
both treated and untreated JCS cells were made on microscopic slides and the 
morphology was studied. The morphological changes of HCPT- and EP-treated JCS 
cells are shown in Figure 4.1 and 4.2. It was observed that both drugs could induce 
morphological differentiation in JCS cells in a dose-dependent manner, and the 
drug-treated cells had increased in cell size as well as an increase in the cytoplasm to 
nucleus ratio, especially at higher drug concentrations. Moreover, there was a 
significant increase in the proportion of intermediate stages cells and mature 
macrophage-like cells after HCPT or EP treatment of the leukemia JCS cells (Table 
4.1). 
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Figure 4.1. Morphological changes in the murine myeloid leukemia WEHI-3B 
JCS cells treated with lO-hydroxy-camptothecin. JCS cells (lO* cells/ml) were 
incubated with (A) control solvent, (B) 20 nM HCPT or (C) 40 nM HCPT at 37�C for 
72 hours. The cells were cytocentrifuged onto microscopic slides and stained with 
Hemacolor solutions (magnification: 400x). 
• 135-
Chapter 4 The differentiation-inducins effect 
� • M S x b I 
• 
•ft-眷 % A 
( c ) I V f 
j L W ^ J r 擎 % s 
Figure 4.2. Morphological changes in the murine myeloid leukemia WEHI-3B 
JCS cells treated with etoposide phosphate. JCS cells (lO* cells/ml) were incubated 
with (A) control solvent, (B) 200 nM EP or (C) 400 nM EP at 37�C for 72 hours. The 
cells were cytocentrifuged onto microscopic slides and stained with Hemacolor 
solutions (magnification: 400x). 
一 
Chapter 4 The diiferentiation-inducins effect 
Table 4.1. Morphological changes in murine myeloid leukemia WEHI-3B JCS 
cells treated with 10-hydroxy-camptothecin and etoposide phosphate. 
Treatment of JCS % of cells 
cells with Blast cells Intermediate stages Mature cells 
Control solvent 65.5% 33% 1.5% 
20 nM HCPT 3.8% 62.1% 34.1% 
40 nM HCPT 9% 46% 45% 
200 nM EP 6% 59.5% 34.5% 
400 nM EP 2.5% 58.5% 39% 
JCS cells (104 cells/ml) were incubated with control solvent, HCPT (20 and 40 nM) or 
EP (200 and 400 nM) at 37°C for 72 hours. The cells were cytocentrifiiged onto 
microscopic slides and stained with Hemacolor solutions for morphological 
identification of the cells. The cells were scored as blast cells (myeloblasts), 
intermediate stages (promyelocytes and myelocytes) and mature cells 
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4.2.2 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the size and granularity of the murine myeloid leukemia WEHI-3B 
JCS cells 
In addition to morphological studies, the differentiation-inducing effect of 
10-hydroxy-camptothecin and etoposide phosphate on the murine myeloid leukemia 
WEHI-3B JCS cells was also investigated by flow cytometry. JCS cells were 
incubated with control solvent, HCPT (40 nM) or EP (400 nM) at 37°C for 72 hours. 
Two parameters were analyzed by flow cytometry - forward scatter (FSC) and side 
scatter (SSC). FSC reveals cell size whereas SSC is positively correlated to the 
granularity of JCS cells. The results are shown in Figure 4.3. It was observed that both 
HCPT and EP significantly increased the size and granularity of JCS cells, as revealed 
by the marked increase in the FSC and SSC of the drug-treated JCS cells. 
V 
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Figure 4.3. Effects of lO-hydroxy-camptothecin and etoposide phosphate on the 
size and granularity of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated with (A) control solvent, (B) 40 nM HCPT or (C) 
400 nM EP at 37°C for 72 hours. The paraformaldehyde-fixed cells were then 
analyzed by the FACSort flow cytometer. 
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4.2.3 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the plastic adhering property of the murine myeloid leukemia 
WEHI-3B JCS cells 
In Section 4.2.1 it had been shown that HCPT- and EP-treated JCS cells 
exhibited some morphological features that are characteristics of monocytic cell 
differentiation. Besides morphological changes, some functional changes like the 
increase in plastic adhering ability are usually observed in myeloid leukemia cells 
undergoing differentiation along the monocytic pathway. In this study, the plastic 
adhering ability of HCPT- and EP-treated WEHI-3B JCS cells was evaluated. Briefly, 
JCS cells were incubated with control solvent, HCPT (40 nM) or EP (400 nM) at 
37°C for 72 hours. Both the adherent and non-adherent JCS cells were harvested and 
counted. As shown in Figure 4.4, HCPT and EP significantly increased the plastic 
adhering ability of JCS cells, which increased from � l O � / � i n the control cells to 
-45-60% in the drug-treated cells. 
气. 
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Figure 4.4. The plastic adhering ability of the murine myeloid leukemia 
WEHI-3B JCS cells treated with 10-hydroxy-camptothecin and etoposide 
phosphate. JCS cells (lO. cells/ml) were incubated with control solvent, HCPT (20 
and 40 nM) or EP (200 and 400 nM) at 37°C for 72 hours. Both the adherent and 
non-adherent cells were harvested and counted. The results were expressed as % 
adherent cells to the total number of cells. 
* Significantly different from the control: P < 0.02 
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4.2.4 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the NBT-reducing activity of the murine myeloid leukemia WEHI-3B 
JCS cells 
Besides an enhancement in plastic adherence, an increased production of 
superoxide anions is also a common functional characteristic of myeloid leukemia 
cells undergoing differentiation. To assess the production of superoxide anions, 
nitroblue tetrazolium (NBT) was used. NBT is an electron acceptor. Superoxide 
anions can reduce the NBT molecules, thereby converting them from the 
water-soluble form to insoluble, dark blue nitroblue diformazan deposits. Cells 
capable of superoxide anion production are therefore stained with these deposits. In 
the present study, JCS cells were incubated with control solvent, HCPT (20 and 40 
nM) or EP (200 and 400 nM) at 37�C for 72 hours. The harvested cells were 
incubated NBT-PMA solution. The JCS cells were then cytocentrifuged onto 
microscopic slides and counter-stained with 1% safranin in methanol. As shown in 
Figure 4.5 and 4.6，both HCPT and EP enhanced the NBT-reducing activity of JCS 
cells in a dose-dependent manner, and the % NBT+ cells was increased from -20% in 
the control JCS cells up to �70o/o-90o/o in the drug-treated cells. 
V 
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Figure 4.5. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
NBT-reducing activity of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated with (A) control solvent, (B) 40 nM HCPT or (C) 
400 nM EP at 37�C for 72 hours. The 1:1 (v/v) mixture of cell suspension (2x10^ 
cells/1 OOfxl) was incubated with freshly prepared NBT-PMA solution for 4 hours at 
37°C in the dark. The cells were then cytocentrifuged onto microscopic slides and 
counter-stained with 1% safranin in methanol. The cells were examined by light 
microscopy (400x magnification) and the differentiated cells with intracellular dark 
blue diformazan deposit were counted. 
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Figure 4.6. Effect of 10-hydroxy-camptothecin and etoposide phosphate on the 
NBT-reducing activity of the murine myeloid leukemia WEHI-3B JCS cells. JCS 
cells (104 cells/ml) were incubated with (A) control solvent, (B) 40 nM HCPT or (C) 
400 nM EP at 37�C for 72 hours. The 1:1 (v/v) mixture of cell suspension (2x10^ 
cells/lOOjal) was incubated with freshly prepared NBT-PMA solution for 4 hours at 
37°C in the dark. The cells were then cytocentrifuged onto microscopic slides and 
counter-stained with 1% safranin in methanol. The differentiated cells with 
intracellular dark blue diformazan deposit were scored by counting a minimum of 200 
cells in triplicate for each experiment. 
* Significantly different from the control: P < 0.002 
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4.2.5 Surface antigen immunophenotyping of the murine myeloid 
leukemia WEHI-3B JCS cells treated with 10-hydroxy-camptothecin 
and etoposide phosphate 
Cellular differentiation is usually accompanied by phenotypic changes on the cell 
surface. Certain lineage-specific differentiation antigens may be expressed on the cell 
surface, and they can be used as markers for differentiation studies. Previous work 
had shown that the expression of Mac-1 and F4/80 surface antigens was enhanced in 
WEHI-3B JCS cells undergoing monocytic differentiation (Leung et al” 1994; Mak et 
al., 1993). To determine the differentiation pathway of the HCPT- and EP-treated JCS 
cells, FACS analysis was carried out. Figure 4.7 - 4.12 show that at concentrations 
that triggered morphological differentiation, both HCPT and EP enhanced the 
expression of the macrophage differentiation antigens, Mac-1 and F4/80, whereas the 
granulocyte differentiation antigen, Gr-1, remained relatively unchanged. The results 
suggest that both HCPT and EP induced phenotypic changes associated with the 
acquisition of mature macrophage/ monocyte characteristics in JCS cells. The 
differentiation-inducing effect is selective for the macrophage/ monocyte lineage. 
V 
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Figure 4.7. Effect of 10-hydroxy-camptothecin on Mac-1 antigen expression in 
the murine myeloid leukemia WEHI-3B JCS cells. JCS cells (10^ cells/ml) were 
incubated with (A) control solvent or (B) 40 nM HCPT at 37�C for 72 hours. The 
cells were then incubated with anti-Mac-1 monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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Figure 4.8. Effect of etoposide phosphate on Mac-1 antigen expression in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO* cells/ml) were 
incubated with (A) control solvent or (B) 400 nM EP at 37°C for 72 hours. The cells 
were then incubated with anti-Mac-1 monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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Figure 4.9. Effect of lO-hydroxy-camptothecin on F4/80 antigen expression in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO* cells/ml) were 
incubated with (A) control solvent or (B) 40 nM HCPT at 37�C for 72 hours. The 
cells were then incubated with anti-F4/80 monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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Figure 4.10. Effect of etoposide phosphate on F4/80 antigen expression in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO^ cells/ml) were 
incubated with (A) control solvent or (B) 400 nM EP at 37�C for 72 hours. The cells 
were then incubated with anti-F4/80 monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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Figure 4.11. Effect of lO-hydroxy-camptothecin on Gi^l antigen expression in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO^ cells/ml) were 
incubated with (A) control solvent or (B) 40 nM HCPT at 37°C for 72 hours. The 
cells were then incubated with anti-Gr-1 monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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Figure 4.12. Effect of etoposide phosphate on Gr-1 antigen expression in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (10^ cells/ml) were 
incubated with (A) control solvent or (B) 400 nM EP at 37°C for 72 hours. The cells 
were then incubated with anti-Gr-l monoclonal antibody followed by the 
FITC-conjugated secondary antibody. The cells were fixed with paraformaldehyde 
and the fluorescence intensity (FL-1 height) was measured by the FACSort flow 
cytometer. 
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4.2.6 Induction of non-specific esterase activity in the murine myeloid 
leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin and 
etoposide phosphate 
The results in Section 4.2.5 suggest that the majority of HCPT- and EP-treated 
JCS cells were undergoing differentiation towards the macrophage/ monocyte lineage. 
To further assess their functional characteristics, the non-specific esterase activity of 
JCS cells was studied by flow cytometry. 
Cellular esterases act on selected substrates. Therefore, under defined reaction 
conditions, it is possible to determine the hematopoietic cell types by measuring their 
esterase activity. For example, a -naphthyl acetate esterase (non-specific esterase) is 
detected primarily in monocytes, macrophages and histocytes, but not in granulocytes. 
Non-specific esterase can convert its substrate, fluorescein diacetate, into a 
fluorescent product that can be detected by FACSort flow cytometer at the FL-1 
channel. The results shown in Figure 4.13 indicate that both HCPT and EP 
significantly increased the non-specific esterase activity of JCS cells. 
V 
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Figure 4.13. Induction of non-specific esterase activity in the murine myeloid 
leukemia WEHI-3B JCS cells by lO-hydroxy-camptothecin and etoposide 
phosphate. JCS cells (lO^ cells/ml) were incubated with control solvent, (A) 40 nM 
HCPT or (B) 400 nM EP at 37�C for 72 hours. The JCS cells were then incubated 
with fluorescein diacetate. The cells were fixed with paraformaldehyde and the 
fluorescence intensity (FL-1 height) was measured by the FACSort flow cytometer. 
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4.3 Discussion 
Differentiation therapy i s � a novel, potentially less toxic approach for the 
treatment of cancer. This therapeutic approach is based on the observation that many 
cancer subtypes display alterations in the normal differentiation process and growth 
control that can be corrected by appropriate treatment (Sachs, 1978). Previous studies 
had shown that natural products and cytokines could induce differentiation in various 
types of cancer, especially in hematological malignancies (Leung et al, 1994; Mak et 
al., 2001; 2002). In fact, it was also found that camptothecins and etoposides could 
induce differentiation in various types of cancer. For example, 
10-hydroxy-camptothecin was reported to be capable of inducing the differentiation 
of the human promyelocytic leukemia HL-60 cells and hepatoma Hep G2 cells (Ling 
et al., 1991; Zhang et al., 2000). On the other hand, Pantazis et al. (1999) 
demonstrated that 9-nitrocamptothecin could induce differentiation in human 
malignant melanoma cells. Moreover, etoposide was shown to trigger the 
differentiation of human myeloid leukemia cells in vitro (Constantinou et aL, 1992; 
Rius et al； 1991). In addition, etoposide together with vitamin D3 were found to act 
synergistically in inducing the differentiation of the human promyelocytic leukemia 
� HL-60 cells (Torres et al, 2000). Therefore, it is of interest to study the potential 
differentiation-inducing activity of 10-hydroxy-camptothecin and etoposide phosphate 
on the leukemia JCS cells. In the present study, the differentiation-inducing activity of 
HCPT and EP was assessed by a number of criteria. Initially, the morphology of both 
drug-treated and untreated JCS cells were examined by light microscopy. The results 
showed that both HCPT (20 and 40 nM) and EP (200 and 400 nM) induced 
morphological changes in JCS cells. These included cell enlargement and the increase 
in cytoplasm to nucleus ratio. The JCS cells were also examined by flow cytometry, 
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and the results showed that both HCPT (40 nM) and EP (400 nM) markedly increased 
the size and granularity of JCS cells. These features were characteristic of 
hematopoietic cells undergoing differentiation. Therefore, the functional and 
phenotypic characteristics of the differentiated JCS cells were further studied. 
Some functional changes like the increase in plastic adhering ability is usually 
observed in myeloid leukemia cells undergoing monocytic differentiation. In our 
study, it was found that both HCPT (20 and 40 nM) and EP (200 and 400 nM) 
significantly increased the proportion of adherent JCS cells by at least four fold. 
HCPT (20 and 40 nM) and EP (200 and 400 nM) also significantly increased the 
production of superoxide anions as measured by the NBT-reducing activity of the JCS 
cells. The non-specific esterase activity was also enhanced in both HCPT- and 
EP-treated JCS cells as determined by flow cytometry. In addition to functional 
studies, the phenotypic characteristics of the JCS cells were also investigated by flow 
cytometry. An increased expression of the macrophage differentiation antigens, 
Mac-1 and F4/80, was observed in HCPT- and EP-treated JCS cells. Nevertheless, the 
expression of the granulocyte differentiation antigen, Gr-1, remained relatively 
unchanged. Taken together, our results suggest that both HCPT and EP induced the 
V 
majority of the leukemia JCS cells to undergo differentiation via macrophage/ 
monocyte pathway. In contrast, an earlier report had shown that treatment of the 
murine WEHI-3B D+ cells with various topoisomerase II inhibitors (including 
etoposide) induced the differentiation of this cell line along the granulocytic pathway, 
whereas exposure of the WEHI-3B D+ cells to camptothecin or cisplatin did not cause 
the maturation of the cells (Rappa et al., 1990). The discrepancy in these findings 
remains unclear, perhaps this is due to the heterogeneity in responsiveness of different 
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WEHI-3B subclones to differentiation inducers, since WEHI-3B D+ cells can 
differentiate to macrophage-granulocyte colonies in response to G-CSF but not to 
TNF-a whereas WEHI-3B JCS^cells are unresponsive to G-CSF but differentiated to 
macrophage-like cells in the presence of TNF-a (Mak et al., 1993). 
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5.1 Introduction 
Cell death can occur via either of two mechanisms, necrosis or apoptosis. 
Necrosis is the pathological process resulted from the exposure to serious physical or 
chemical insult. Apoptosis, also known as "normal" or "programmed" cell death, is 
the physiological process by which unwanted or useless cells are eliminated during 
development and other normal biological process (Eisel et al., 2002). Cells 
undergoing necrosis or apoptosis can be distinguished by the differences in their 
morphological and biochemical features (Schwartzman & Cidlowski，1993; Vermes & 
Haanan, 1994). For example, necrotic cells lose their membrane integrity whereas the 
membrane of an apoptotic cell remains intact. 
Recently, interest in apoptosis has grown greatly because of its importance in 
development and its role in the action mechanisms of many anti-cancer agents. With 
the dedication of scientists, there has been a rapid advance in the understanding of the 
molecular basis of apoptosis in the past few years. As an important physiological 
process, apoptosis is undoubtedly regulated by a sophisticated network of signaling 
cascades. Generally speaking, apoptosis can be mediated via at least two pathways: 
’ the death receptor pathway and the mitochondrial pathway (Figure 5.1). The death 
receptor pathway can be triggered by the stimulation of several different cell surface 
receptors in association with caspase activition. The CD95/APO-1 (Fas) receptor 
ligand system is one of the examples. The binding of Fas ligand to Fas receptor 
induces receptor trimerization. The trimerized death domain recruits pro-caspase 8 
through a Fas associated death domain (FADD)/M0RT1 adaptor, leading to 
death-inducing signaling complex (DISC) formation. The pro-caspase 8 is 
autoactivated at DISC. In the downstream, caspase 8 directly processes pro-caspase 3, 
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and caspase 3 cleaves various cellular proteins including inhibitor of 
caspase-activated DNase (ICAD). The cleavage of ICAD results in caspase-activated 
DNase (CAD) formation, and CAD degrades chromosomal DNA. 
In the mitochondrial pathway, caspase 8 cleaves Bid, a pro-apoptotic member of 
Bcl-2 family. The translocation of truncated Bid (tBid) to mitochondria releases 
cytochrome c into cytosol with the generation of reactive oxygen species (Eskes et al., 
1998; Narita et al., 1998). Bcl-2 or BC1-XL, the anti-apoptotic members of Bcl-2 family, 
can inhibit the release of cytochrome c. The released cytochrome c then activates 
caspase 9 together with apoptotic protease-activating factor-1 (Apaf-1), and caspase 9 
in turn activates caspase 3 and finally leading to the degradation of chromosomal 
DNA through CAD (Nagata，1997; Nagata & Golstein, 1995; Raff, 1998; Vaux & 
Korsmever, 1999). 
In this chapter, the apoptosis-inducing effect of 10-hydroxy-camptothecin and 
etoposide phosphate on the leukemia JCS cells was studied. The induction of 
apoptosis was measured by various techniques, including morphological study by 
fluorescence microscopy, DNA fragmentation assay and flow cytometric analysis on 
V 
phosphatidylserine translocation by Annexin V-PI staining. In addition, attempts had 
been made to elucidate the molecular mechanisms by which HCPT and EP could 
trigger apoptosis of JCS cells. Firstly, the techniques RT-PCR and Western blotting 
were used to examine the expression of some apoptosis-regulatory genes at both 
transcriptional and translational levels respectively. Secondly, the mitochondrial 
membrane potential and the intracellular Ca^^ level of both drug-treated and untreated 
JCS cells were determined by flow cytometry. Finally, the activities of caspases 3，8 
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and 9 in drug-treated JCS cells were determined by fluorometric measurement. 
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Figure 5.1. An overview of the apoptotic pathways. Apoptosis can be mediated via 
at least two pathways: the death receptor pathway and the mitochondrial pathway. The 
stimulation of several different cell surface receptors in association with caspase 
V activition, for instance, the CD95/APO-1 (Fas) receptor ligand system, triggers the 
death receptor pathway. The mitochondrial pathway, on the other hand, can be 
triggered by stimuli like truncated Bid, Bad or p53. Both pathways result in the 
degradation of chromosomal DNA via a series of signaling cascades. 
Adapted from http://claim.springer.de/EncRef/CancerResearch/samples/0003.htm 
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5.2 Results 
5.2.1 Induction of nuclear disintegration in the murine myeloid 
leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin and 
etoposide phosphate 
As mentioned in the introduction, apoptosis is featured by a number of 
morphological changes. Nuclear disintegration is one of the examples. To examine 
whether HCPT and EP can induce the leukemia JCS cells to undergo apoptosis, the 
morphology of the JCS cells was examined by fluorescence microscopy. Briefly, JCS 
cells were treated with control solvent, HCPT (40 nM) or EP (400 nM) for 48 hours. 
Cytocentrifuge slides of the JCS cells were prepared and the cells were stained with 
Hoechst 33342. The stained JCS cells were then examined by fluorescence 
microscopy. Hoechst 33342，also known as pentahydrate or bis-benzimide, is a cell 
membrane-permeant, minor groove-binding DNA stain that fluoresces bright blue 
upon binding to DNA (Molecular Probes, 2003). As shown in Figure 5.2, the nuclei of 
HCPT- and EP-treated JCS cells were disintegrated whereas that of the untreated cells 
remained round and intact, indicating that both HCPT and EP could induce apoptosis 
in the leukemia JCS cells. 
V 
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Figure 5.2. Induction of nuclear disintegration in the murine myeloid leukemia 
WEHI-3B JCS cells by lO-hydroxy-camptothecin and etoposide phosphate. JCS 
cells (104 cells/ml) were incubated with (A) control solvent, (B) 40 nM HCPT or (C) 
400 nM EP at 37°C for 48 hours. Cytocentrifuge slides of the JCS cells were prepared 
, and the cells were fixed with 2% paraformaldehyde and stained with Hoechst 33342. 
The stained JCS cells were then examined by fluorescence microscopy for the 
disintegration of nucleus. The fluorescence images were shown in parallel with the 
phase contrast images. 
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5.2.2 Induction of DNA fragmentation in the murine myeloid 
leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin and 
etoposide phosphate 
Apart from morphological changes, the induction of apoptosis is accompanied by 
a number of biochemical changes. One of the biochemical changes is non-random 
mono- and oligo-nucleosomal fragmentation of DNA, an irreversible event that 
commits the cell to death before changes occur in the permeability of cell membrane. 
This process is executed by nuclear endonucleases, which cleave the linker DNA 
leading to the formation of mono- and oligonucleosomal DNA fragments. By 
analyzing the genomic DNA in 2% agarose gel, the occurrence of "DNA ladder", that 
is, a characteristic series of DNA fragments in multiples of 180-200 base pairs, can be 
observed. 
In this experiment, JCS cells were treated with control solvent, HCPT (5 - 40 nM) 
or EP (50 - 400 nM) for 4 - 48 hours. As shown in Fig. 5.3 - Fig. 5.6, both HCPT and 
EP induced JCS cells to undergo apoptosis in a dose- and time-dependent manner. It 
was found that 20 nM HCPT and 50 nM EP were the lowest concentrations capable of 
,,, inducing JCS cells to undergo apoptosis. Moreover, 40 nM HCPT induced apoptosis 
in JCS cells after 8 hours of treatment whereas apoptosis was only observed at 12 
hours or more after treatment of JCS cells with 400 nM EP. 
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Figure 5.3. Dose-dependency for the induction of DNA fragmentation in the 
murine myeloid leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin. JCS 
cells (104 cells/ml) were incubated with control solvent or HCPT (5 - 40 nM) at 37°C 
for 48 hours. Total cellular DNA was extracted according to the procedure described 
under Materials and Methods. The DNA samples were subjected to electrophoresis in 
a 2% agarose gel. The gel stained with ethidium bromide was observed for the 
presence of apoptotic DNA ladder. 
M: 100 bp DNA marker 
1: control solvent, 48 hours 
2: 5 nM HCPT, 48 hours 
3: 10 nM HCPT, 48 hours 
4: 20 nM HCPT, 48 hours 
5: 40 nM HCPT, 48 hours 
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Figure 5.4. Kinetic study on the induction of DNA fragmentation in the murine 
myeloid leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin. JCS cells 
(104 cells/ml) were incubated with control solvent or HCPT (40 nM) at 37�C for 
’ different periods of time (4 - 24 hours). Total cellular DNA was extracted according to 
the procedure described under Materials and Methods. The DNA samples were 
subjected to electrophoresis in a 2% agarose gel. The gel stained with ethidium 
bromide was observed for the presence of apoptotic DNA ladder. 
M: 100 bp DNA marker 
1: control solvent, 24 hours 
2: 40 nM HCPT, 4 hours 
3: 40 nM HCPT, 8 hours 
4: 40 nM HCPT, 12 hours 
5: 40 nM HCPT, 24 hours 
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Figure 5.5. Dose-dependency for the induction of DNA fragmentation in the 
murine myeloid leukemia WEHI-3B JCS cells by etoposide phosphate. JCS cells 
(104 cells/ml) were incubated with control solvent or EP (50 - 400 nM) at 37°C for 48 
� hours. Total cellular DNA was extracted according to the procedure described under 
Materials and Methods. The DNA samples were subjected to electrophoresis in a 2% 
agarose gel. The gel stained with ethidium bromide was observed for the presence of 
apoptotic DNA ladder. 
M: 100 bp DNA marker 
1: control solvent, 48 hours 
2: 50 nM EP, 48 hours 
3: 100 nM EP, 48 hours 
4: 200 nM EP, 48 hours 
5: 400 nM EP, 48 hours 
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Figure 5.6. Kinetic study on the induction of DNA fragmentation in the murine 
myeloid leukemia WEHI-3B JCS cells by etoposide phosphate. JCS cells (lO* 
cells/ml) were incubated with control solvent or EP (400 nM) at 37°C for different 
periods of time (4 - 24 hours). Total cellular DNA was extracted according to the 
, procedure described under Materials and Methods. The DNA samples were subjected 
to electrophoresis in a 2% agarose gel. The gel stained with ethidium bromide was 
observed for the presence of apoptotic DNA ladder. 
M: 100 bp DNA marker 
1: control solvent, 24 hours 
2: 400 nM EP, 4 hours 
3: 400 nM EP, 8 hours 
4: 400 nM EP, 12 hours 
5: 400 nM EP, 24 hours 
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5.2.3 Induction of phosphatidylserine translocation in murine 
myeloid leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin 
and etoposide phosphate 
Besides nuclear disintegration and DNA fragmentation, apoptosis is also 
characterized by alterations in the plasma membrane. In normal cells, the distribution 
of phospholipid is asymmetric. The inner plasma membrane contains anionic 
phospholipids such as phosphatidylserine (PS) whereas the outer layer is mainly 
composed of neutral phospholipids. Nevertheless, in early apoptotic cells, PS 
redistributes to the outer plasma membrane. Annexin V is a calcium-dependent 
phospholipid-binding protein with high affinity for PS (Vermes et al., 1995). In this 
experiment, both HCPT- or EP-treated and untreated JCS cells were stained with 
FITC-conjugated Annexin V and propidium iodide (PI), a DNA stain excluded by 
cells with intact plasma membrane. By flow cytometric analysis, the early apoptotic 
cells can be distinguished from the late apoptotic and/ or necrotic cells (Figure 5.7). 
As shown in Figure 5.8 and Figure 5.9，both HCPT (40 nM) and EP (400 nM) were 
capable of inducing detectable PS translocation in JCS cells after 24 hours of 
treatment. 
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Figure 5.7. Flow cytometric analysis by Annexin V-FITC and PI staining. The 
green fluorescence emitted by Annexin V-FITC and the red fluorescence emitted by 
PI are detected by channel FLl and FL2 respectively. (A) The lower left quadrant (LL) 
represents healthy cells without PS translocation; (B) the lower right quadrant (LR) 
represents early apoptotic cells with PS translocation; (C) the upper left quadrant (UL) 
corresponds to necrotic cells and (D) the upper right quadrant (UR) represents 
necrotic or late apoptotic cells. 
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Figure 5.8. Induction of PS translocation in JCS cells by 
lO-hydroxy-camptothecin. JCS cells (lO* cells/ml) were treated with control solvent 
(left) or 40 nM HCPT (right) for (A) 24 hours or (B) 48 hours. The JCS cells were 
harvested and stained with Annexin V-FITC and PI as described under Materials and 
Methods. Stained cells were analyzed for green (FL-1) and red (FL-2) fluorescence 
intensities using FACSort flow cytometer. 
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Figure 5.9. Induction of PS translocation in JCS cells by etoposide phosphate. 
JCS cells (104 cells/ml) were treated with control solvent (left) or 400 nM EP (right) 
for (A) 24 hours or (B) 48 hours. The cells were harvested and stained with Annexin 
V-FITC and PI as described under Materials and Methods. Stained cells were 
analyzed for green (FL-1) and red (FL-2) fluorescence intensities using FACSort flow 
cytometer. 
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5.2.4 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the expression of apoptosis-regulatory genes in the murine myeloid 
leukemia WEHI-3B JCS cells 
The apoptosis-inducing effect of HCPT and EP on JCS cells had been 
demonstrated by fluorescence microscopy, DNA fragmentation assay and flow 
cytometry with Annexin V-PI staining. To elucidate the underlying molecular 
mechanisms, the technique of reverse transcription-polymerase chain reaction 
(RT-PCR) was used. In our study, the expression of several apoptosis-regulatory genes, 
including Bad, Bak, Bcl-2, BCI-XL and FasL, was examined. The Bcl-2 family of 
proteins plays important roles in regulating the mitochondrial pathway of apoptosis. 
This includes Bad and Bak, the pro-apoptotic members and Bcl-2 and BC1-XL, the 
anti-apoptotic counterparts of this family. Fas ligand (FasL), on the other hand, is 
involved in the death receptor pathway upon binding with Fas receptor (Tafani et al” 
2002). 
The results are shown in Figure 5.10 and 5.11. The amount of PCR product was 
normalized by comparing to a house-keeping gene, GAPDH. It was observed that 
both HCPT (40 nM) and EP (400 nM) enhanced the mRNA expression of FasL in 
JCS cells with different kinetics of up-regulation. For HCPT-treated cells, significant 
up-regulation of FasL gene expression was observed at 3 hours of treatment and 
reached a maximum at -12 hours (Figure 5.10). On the other hand, only a slight 
increase (-35%) in FasL gene expression was seen at 12 hours after treatment of JCS 
cells with EP, with a more prominent up-regulation (-53%) seen at 24 hours after EP 
treatment (Figure 5.11). In general, the expression of the pro-apoptotic genes such as 
Bak and Bad remained virtually unchanged after treatment with HCPT and EP, 
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although a slight transient decrease in Bak expression was seen at 3 - 6 hours after 
treatment with HCPT (Figure 5.12). Interestingly, the expression of anti-apoptotic 
genes such as BCI-XL and 5c/-2 was clearly down-regulated in HCPT-treated JCS cells 
at 6 hours of treatment (Figure 5.12)，whereas only a slight decrease in the expression 
of Bcl-2 gene was seen in EP-treated cells at all the time points tested (Figure 5.13). 
V 
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Figure 5.10. Regulation of pro-apoptotic gene expression in the murine myeloid 
leukemia WEHI-3B JCS cells by 10-hydroxy-camptothecin. JCS cells (lO^ 
cells/ml) were treated with control solvent (C) or 40 nM HCPT for different periods 
of time (3 - 24 hours). Total RNA was extracted from the JCS cells by TRIZOL 
reagent as described under Materials and Methods. The RNA was reverse-transcribed 
and amplified by PCR using specific primer pairs. RT-PCR products were analyzed in 
2% agarose gel. The band intensity was analyzed using the ImageQuant (Molecular 
Dynamics) software. The value at the bottom of each band represents the relative 
intensity after normalization with respect to GAPDH. 
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Figure 5.11. Regulation of pro-apoptotic gene expression in the murine myeloid 
leukemia WEHI-3B JCS cells by etoposide phosphate. JCS cells cells/ml) 
were treated with control solvent (C) or 400 nM EP for different periods of time (3 -
24 hours). Total RNA was extracted from the JCS cells by TRIZOL reagent as 
described under Materials and Methods. The RNA was reverse-transcribed and 
amplified by PGR using specific primer pairs. RT-PCR products were analyzed in 2% 
agarose gel. The band intensity was analyzed using the ImageQuant (Molecular 
Dynamics) software. The value at the bottom of each band represents the relative 
intensity after normalization with respect to GAPDH. 
V 
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Figure 5.12. Regulation of anti-apoptotic gene expression in the murine myeloid 
leukemia WEHI-3B JCS cells by lO-hydroxy-camptothecin. JCS cells (lO* 
cells/ml) were treated with control solvent (C) or 40 nM HCPT for different periods 
of time (3 - 24 hours). Total RNA was extracted from the JCS cells by TRIZOL 
reagent as described under Materials and Methods. The RNA was reverse-transcribed 
and amplified by PCR using specific primer pairs. RT-PCR products were analyzed in 
2% agarose gel. The band intensity was analyzed using the ImageQuant (Molecular 
Dynamics) software. The value at the bottom of each band represents the relative 
intensity after normalization with respect to GAPDH. 
V 
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Figure 5.13. Regulation of anti-apoptotic gene expression in the murine myeloid 
leukemia WEHI-3B JCS cells by etoposide phosphate. JCS cells (lO* cells/ml) 
were treated with control solvent (C) or 400 nM EP for different periods of time (3 -
24 hours). Total RNA was extracted from the JCS cells by TRIZOL reagent as 
described under Materials and Methods. The RNA was reverse-transcribed and 
amplified by PCR using specific primer pairs. RT-PCR products were analyzed in 2% 
agarose gel. The band intensity was analyzed using the ImageQuant (Molecular 
Dynamics) software. The value at the bottom of each band represents the relative 
intensity after normalization with respect to GAPDH. 
V 
-176 _ 
Chapter 5 Apoptosis-inducing effect 
5.2.5 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the expression of apoptosis-regulatory proteins in the murine myeloid 
leukemia WEHI-3B JCS cells 
In view of the differential up-regulation and down-regulation in the expression of 
FasL and Bcl-2 genes respectively in the HCPT- and EP-treated JCS cells, therefore, 
the expression of these two apoptosis-regulatory proteins was also examined by 
Western blotting. Figure 5.14 shows that both 40 nM HCPT and 400 nM EP 
significantly enhanced the expression of FasL protein after 24 hours of treatment. The 
expression level of Bcl-2 protein, on the other hand, was down-regulated by -50% in 
HCPT- and EP-treated JCS cells after 48 hours and 24 hours of treatment respectively. 
V. 
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H48 H24 C E24 E48 
Fas/L 48 kDa 
4.54 2.69 1 2.23 5.77 
Bcl-2 25 kDa 
0.53 0.76 1 0.53 0.57 
p-actin 鄉 ? 一 " ‘ 40 kDa 
Figure 5.14. Effect of lO-hydroxy-camptothecin and etoposide phosphate on the 
expression of FasL and Bcl-2 proteins in the murine myeloid leukemia WEHI-3B 
JCS cells. JCS cells (lO* cells/ml) were treated with control solvent, 40 nM HCPT or 
400 nM EP for 24 or 48 hours. The cytosolic protein of each sample was extracted 
and analyzed by Western blotting as described Materials and Methods. The proteins 
were probed with specific primary antibody and horseradish peroxidase-conjugated 
secondary antibody and visualized by the ECL assay. The value at the bottom of each 
band represents the relative intensity after normalization with respect to a 
house-keeping protein, p-actin. 
�. H48: 40 nM HCPT, 48 hours 
H24: 40 nM HCPT, 24 hours 
C: control solvent, 48 hours 
E24: 400 nM EP, 24 hours 
E48: 400 nM EP, 48 hours 
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5.2.6 Induction of mitochondrial membrane depolarization in the 
murine myeloid leukemia WEHI-3B JCS cells by 
10-hydroxy-camptothecin and etoposide phosphate 
From the results of RT-PCR and Western blotting, both HCPT and EP enhanced 
the expression of FasL and reduced that of Bcl-2 at both transcriptional and 
translational levels. This implies the possible involvement of both the death receptor 
and mitochondrial pathways. To further investigate the possible involvement of the 
mitochondrial pathway in HCPT- and EP-triggered apoptosis of the leukemia JCS 
cells, the dye 5,5',6,6'-tetrachloro-l, 1 ',3,3'-tetraethylbenzimidazolylcarbocyanine 
iodide (JC-1) was used. JC-1 is a cationic, fluorescent carbocyanine dye that can be 
used as a ratiometric indicator of mitochondrial potential (AWm) in cells, tissues, and 
isolated mitochondria. JC-1 is mitochondria-selective: it forms J-aggregates in 
polarized mitochondrial membrane leading to the emission of red fluorescence at 590 
nm after excitation at 490 nm. In depolarized mitochondrial membrane, on the 
contrary, JC-1 presents in its monomeric form and emits green fluorescence at 527nm. 
Therefore, the decrease in the red:green fluorescence intensity ratio indicated 
mitochondrial membrane depolarization (Calbiochem, 2003; Dorrie et al., 2001). 
In this experiment, JCS cells were treated with control solvent, HCPT (40 nM) or 
EP (400 nM) for 48 hours. Both untreated and treated JCS cells were stained with 
JC-1 followed by flow cytometric measurement. The results are shown in Figure 5.15. 
It was observed that both HCPT and EP induced mitochondrial membrane 
depolarization after 48 hours of drug treatment. 
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Figure 5.15. Induction of mitochondrial membrane depolarization in the murine 
myeloid leukemia WEHI-3B JCS cells by lO-hydroxy-camptothecin and 
etoposide phosphate. JCS cells (lO* cells/ml) were treated with (A) control solvent, 
(B) 40 nM HCPT or (C) 400 nM EP for 48 hours. The cells were harvested and 
stained with JC-1 as described under Materials and Methods. The stained cells were 
analyzed for green (FL-1) and red (FL-2) fluorescence intensities using FACSort flow 
cytometer. 
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5.2.7 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
caspase activity in the murine myeloid leukemia WEHI-3B JCS cells 
As mentioned in section 5.1, caspases (cysteinyl-aspartate-specific proteinases) 
play an important role in the initiation and execution of apoptosis. Up till now, at least 
11 different members of caspases in mammalian cells have been characterized (Eisel 
et al., 2002). In our study, the activities of caspases 3，8 and 9 in HCPT- or EP-treated 
JCS cells were examined. 
Caspase 3 is one of the effector caspases. It is involved in both the death receptor 
and mitochondrial pathways of apoptosis. In the downstream of caspase signaling 
cascade, caspase 3 promotes the proteolysis of ICAD and other death substrates, 
eventually leading to chromosomal DNA degradation. Caspase 3 is activated by both 
caspases 8 and 9. Caspase 8 is activated by the binding of Fas-associated death 
domain (FADD) protein, which is initiated by the ligand-induced trimerization of Fas 
receptor. In the downstream, caspase 8 cleaves pro-caspase 3 and Bid, leading to 
caspase 3 and truncated Bid (tBid) formation. As tBid is involved in the release of 
cytochrome c from mitochondria, caspase 8 is also involved in both the death receptor 
and mitochondrial pathways. Caspase 9，however, is involved in the mitochondrial 
pathway only. 
In this experiment, JCS cells were treated with control solvent, 40 nM HCPT or 
400 nM EP for 24 or 48 hours. The protein of each sample was extracted and the 
activities of caspase 3，8 and 9 were measured by fluorometric assay. The results are 
shown in Figure 5.16 - 5.18. It was observed that both 40 nM HCPT and 400 nM EP 
increased caspase 3 activity by at least 4 fold after 24 and 48 hours of treatment. On 
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the other hand, HCPT and EP increased caspase 8 activity by about 1.5 - 2.5 fold. For 
caspase 9，HCPT and EP increased the activity by about 1.9 - 3 fold. The results 
suggest that caspases 3, 8 and 9 may be involved in the induction of apoptosis in JCS 
cells by these two drugs. 
V 
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Figure 5.16. Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
caspase 3 activity in the murine myeloid leukemia WEHI-3B JCS cells. JCS cells 
(104 cells/ml) were treated with control solvent, 40 nM HCPT (24 or 48 hours) or 400 
nM EP (24 or 48 hours) at 37°C. The protein of each sample was extracted and 
incubated with caspase 3-specific substrate with or without its specific inhibitor 
(DEVD-CHO). The fluorescence units released were measured by the fluorescent 
plate reader, Cytofluo. The units were quantified by comparing with the standard 
curve of free fluorescence units. AMC is the fluorescence unit released from the 
caspase 3-specific substrate. 
V 
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Figure 5.17. Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
caspase 8 activity in the murine myeloid leukemia WEHI-3B JCS cells. JCS cells 
(104 cells/ml) were treated with control solvent, 40 nM HCPT (24 or 48 hours) or 400 
nM EP (24 or 48 hours) at 37°C. The protein of each sample was extracted and 
incubated with caspase 8-specific substrate with or without its specific inhibitor 
(z-IETD-FMK). The fluorescence units released were measured by the fluorescent 
plate reader, Cytofluo. The units were quantified by comparing with the standard 
curve of free fluorescence units. AMC is the fluorescence unit released from the 
caspase 8-specific substrate. 
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Figure 5.18. Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
caspase 9 activity in the murine myeloid leukemia WEHI-3B JCS cells. JCS cells 
(104 cells/ml) were treated with control solvent, 40 nM HCPT (24 or 48 hours) or 400 
nM EP (24 or 48 hours) at 37°C. The protein of each sample was extracted and 
incubated with caspase 9-specific substrate with or without its specific inhibitor 
(LEHD-CHO). The fluorescence units released were measured by the fluorescent 
plate reader, Cytofluo. The units were quantified by comparing with the standard 
curve of free fluorescence units. AFC is the fluorescence unit released from the 
caspase 9-specific substrate. 
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5.2.8 Effect of 10-hydroxy-camptothecin and etoposide phosphate on 
the intracellular Ca^ ^ level in the murine myeloid leukemia WEHI-3B 
JCS cells 
The results in Section 5.2.7 showed that caspases 3, 8 and 9 might be involved in 
the HCPT- and EP-induced JCS cell apoptosis. Besides the regulation of apoptosis by 
caspases, previous studies had shown that the calcium signaling system might also 
play a pivotal role in this process (Qi et al., 2002; Zhang et al., 2000). Therefore, in 
I 
this study, the intracellular Ca level of HCPT- and EP-treated JCS cells was 
examined. Briefly, JCS cells were treated with control solvent, HCPT (40 nM) or EP 
(400 nM) for 6, 12 and 24 hours. The harvested cells were then incubated with 10 |iM 
Fluo-3/AM for 1 hour at room temperature. The fluorescence intensity of the samples 
was then measured by flow cytometry. From the results shown in Figure 5.19 and 
5.20, we can see that the intracellular Ca^^ level of both HCPT- and EP-treated JCS 
cells remained relatively constant throughout the 24-hour treatment process. 
Therefore, it is speculated that the calcium signaling system may not be involved in 
HCPT- or EP-induced apoptosis in JCS cells. 
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Figure 5.19. Effect of lO-hydroxy-camptothecin on the intracellular Ca^ ^ level in 
the murine myeloid leukemia WEHI-3B JCS cells. JCS cells (10^ cells/ml) were 
treated with control solvent or 40 nM HCPT for (A) 6 hours, (B) 12 hours or (C) 24 
hours at 37。C. The harvested JCS cells were then incubated with 10 |iM Fluo-3/AM 
for 1 hour at room temperature. The fluorescence intensity (FLl-H) of the samples 
was then measured by flow cytometry. 
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Figure 5.20. Effect of etoposide phosphate on the intracellular Ca^ ^ level in the 
murine myeloid leukemia WEHI-3B JCS cells. JCS cells (lO* cells/ml) were treated 
with control solvent or 400 nM EP for (A) 6 hours, (B) 12 hours or (C) 24 hours at 
37�C. The harvested JCS cells were then incubated with 10 |iM Fluo-3/AM for 1 hour 
at room temperature. The fluorescence intensity (FLl-H) of the samples was then 
measured by flow cytometry. 
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5.3 Discussion 
Like differentiation therapy, induction of apoptosis is a novel approach in the 
treatment of cancer. It is well documented that topoisomerase-targeting agents could 
induce apoptosis in a variety of cancer cells, for instance, SN-38 (a Top I inhibitor) 
and etoposide could induce apoptosis in various lung cancer cell lines (Oizumi et al., 
2002). Moreover, a recent report showed that etoposide could induce apoptosis in 
human promyelocytic leukemia HL-60 cells (Bjorling-Poulsen & Issinger，2003). 
Therefore, in the present study, the possible involvement of apoptosis in the 
anti-leukemic activity of 10-hydroxycamptothecin and etoposide phosphate was 
investigated. In light of this, both the morphological and biochemical features of 
HCPT- and EP-treated JCS cells were examined. To examine the nuclear morphology 
of the JCS cells, the DNA-binding fluorescent dye Hoechst 33342 was used. Hoechst 
33342 is commonly used in the study of apoptosis (Mak et al.’ 2002). When observed 
under the fluorescence microscope, the nuclei of the control JCS cells were round and 
intact; this was in contrast to both treatment groups, in which there was formation of 
micronuclei in the JCS cells, a feature characteristic of apoptosis. The 
apoptosis-inducing effect of HCPT and EP on the leukemia JCS cells was also studied 
� by DNA fragmentation assay. It was found that both HCPT and EP induced 
intemucleosomal DNA fragmentation in JCS cells in a dose- and time-dependent 
manner. In addition to DNA fragmentation, apoptotic cells are also characterized by 
the translocation of phosphatidylserine (PS) in the plasma membrane (Uthaisang et al., 
2003). To detect PS translocation, JCS cells were stained with Annexin V and PI and 
analyzed by flow cytometry. The results showed that both HCPT (40 nM) and EP (400 
nM) induced PS translocation in JCS cells after 24 hours of treatment. These results, 
when taken together, suggested that both HCPT and EP could induce JCS cells to 
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undergo apoptosis. 
Cell survival is determihed by the balance between the pro-apoptotic and 
anti-apoptotic signals (Cory & Adams, 2002). To further investigate the mechanism of 
HCPT- and EP-induced apoptosis in JCS cells, RT-PCR and Western blotting were 
used to study the expression of several pro-apoptotic and anti-apoptotic genes in both 
drug-treated or untreated JCS cells. It was found that both HCPT and EP enhanced the 
gene and protein expression of pro-apoptotic FasL gene; on the contrary, the 
expression of anti-apoptotic Bcl-2 gene was down-regulated by both drugs. 
Interestingly, the gene expression of BCI-XL was only down-regulated by HCPT but 
not EP. In addition, the expression of the pro-apoptotic genes such as Bak and Bad 
remained virtually unchanged after treatment with HCPT and EP, although a slight 
transient decrease in Bak expression was seen at 3 - 6 hours after treatment with 
HCPT. The reason for the transient downregulation of Bak gene expression is 
unknown. Recently, it was reported that Bak resembles more the anti-apoptotic than 
the pro-apoptotic proteins of the Bcl-2 family than Bax (another pro-apoptotic protein 
of the Bcl-2 family) does (Degli & Dive, 2003). However, whether this accounts for 
the transient downregulation of Bak gene expression still awaits further investigation. 
V 
In addition to the pro-apoptotic and anti-apoptotic proteins mentioned above, 
caspases (cysteinyl-aspartate-specific proteinases) also play an important role in the 
initiation and execution of apoptosis (Kim & Andreas, 2003). Caspases 3 and 8 are 
involved in both the death receptor and mitochondrial pathways of apoptosis. Caspase 
9，however, is involved in the mitochondrial pathway only. In the present study, the 
activities of caspases 3, 8 and 9 were measured by fluorometric assay. It was found 
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that both HCPT and EP significantly increased the activity of these three caspases, 
indicating that the induction of apoptosis in JCS cells by HCPT and EP might be 
mediated via both the death receptor and mitochondrial pathways. Previous studies 
had also demonstrated that the calcium signaling system might also play a pivotal role 
in this process (Qi et al., 2002; Zhang et al” 2000). Therefore, in this study, the 
intracellular Ca^ "^  level of HCPT- and EP-treated JCS cells was examined by flow 
cytometry using the calcium-sensitive fluorescent dye Fluo-3. From the results, no 
appreciable change was observed in both HCPT- and EP-treated JCS cells throughout 
the 24-hour time period. Since mitochondrial membrane depolarization is also a 
characteristic of the mitochondrial apoptosis pathway, therefore, it was studied in both 
HCPT- and EP-treated JCS cells. It was observed that both HCPT and EP induced 
mitochondrial membrane depolarization after 48 hours of drug treatment, thus further 
supporting that the mitochondrial pathway was clearly involved in the HCPT- and EP-
induced apoptosis of the leukemia JCS cells. 
V 
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Conclusions & future perspectives 
In the present study, the anti-leukemic effect of 10-hydroxy-camptothecin 
(HCPT) and etoposide phosphate (EP) was studied using a well-characterized murine 
myelomonocytic leukemia cell line WEHI-3B JCS. HCPT and EP are two novel 
topoisomerase-targeting agents. The topoisomerase I (Top I) inhibitor HCPT has been 
shown to be more potent and less toxic than its parent compound camptothecin (CPT) 
and has recently undergone clinical trials (Zhang et al” 1998). The substitution of 
hydroxyl group at carbon 10 also enhances its solubility in aqueous solutions 
(Takimoto & Arbuck, 2001). EP is a pro-drug of etoposide but with higher solubility 
in aqueous solution. It is easier to administer than its parent compound etoposide, a 
topoisomerase II (Top II) inhibitor (Greco & Hainsworth, 1996) and is well tolerated 
by the patients (Sidevov et al., 2002). These are the reasons why they were chosen in 
our study. 
First of all, the effect of the Top I inhibitor HCPT and its parent compound CPT, 
and the Top II inhibitors etoposide and its pro-drug EP, on the proliferation of six 
murine and human leukemia cell lines was studied by the [^H]-TdR proliferation assay. 
� The results showed that the six leukemia cell lines displayed differential sensitivity to 
the four topoisomerase-targeting agents, with the human myelogenous leukemia 
K-562 cells being more sensitive to the Top I inhibitors CPT and HCPT, whereas the 
murine myelomonocytic leukemia WEHI-3B JCS cells were more sensitive to the Top 
II inhibitors VP-16 and EP. Recent studies suggested that the differential sensitivity 
of cancer cells to topoisomerase-targeting agents might be correlated to cell-to-cell 
differences in the level of topoisomerase, the rate of DNA repair, mutations in the 
ATM gene and the level of multidrug resistance protein etc. (Ulukan et al., 2001; 
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Fedier et al., 2003; Hansen et al.’ 2003; Vassal et al., 2003). Whether the factors 
mentioned above are involved in the differential anti-proliferative effect of 
topoisomerase-targeting agents" on myeloid leukemia cells remain unclear and await 
further investigation. Apart from myeloid leukemia, whether HCPT and EP could 
exert potent anti-leukemic activity on the lymphocytic leukemia has yet to be 
determined. 
In addition to the dose-activity relationship, the kinetics and reversibility of the 
anti-proliferative effect of HCPT and EP on JCS cells were also examined. It was 
observed that both HCPT and EP inhibited the proliferation of JCS cells in a dose-
and time-dependent manner, with the maximum inhibitory activity attained after 48 
hours of drug treatment. The potent anti-proliferative activity of HCPT and EP was 
also revealed by their significant inhibitory effect on the growth and clonogenicity of 
the JCS cells. The reversibility test showed that the anti-proliferative effect of HCPT 
on JCS cells seemed to be irreversible after 12 hours of drug treatment, however, the 
effect of EP was partially reversible after 12 or 24 hours of incubation. This might be 
due to the reversible interaction of Top II-DNA cleavage complexes and DNA 
non-intercalators without alkylating potential such as etoposide (Kong et al., 1992). 
V 
Besides the in vitro anti-proliferative effect, both HCPT and EP inhibited the 
tumorigenicity and growth of JCS cells in vivo. In this study, the in vivo anti-leukemic 
activity of HCPT and EP was assessed by examining the growth of JCS cells in the 
peritoneal cavity of the BALB/c mice. Whether HCPT and EP exhibit similar in vivo 
anti-leukemic activity on human myeloid leukemia has not been determined, and this 
could easily be tested by examining the growth of xenogeneic human leukemia cells 
in nude mice. In addition, the in vitro cytotoxicity assay showed that the 
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growth-inhibitory effect of HCPT and EP on the leukemia JCS cells could be 
attributed to the cytostatic rather than cytotoxic effect of the drugs on the leukemia 
cells, especially at low drug concentrations. In future, the toxicity tests of these two 
drugs on organs such as liver and heart should be also carried out in vivo. 
Previous studies in our laboratory showed that natural products like coumarins 
and taxol could induce cell cycle arrest, differentiation and apoptosis in JCS cells 
(Leung, 1999; Leung, 2002). From our preliminary data, it was speculated that HCPT 
and EP also exerted their anti-leukemic effect on JCS cells via these 3 ways. This 
hypothesis was supported by the mechanistic studies. Retardation of cell proliferation 
is closely related to cell cycle arrest (Fukumi et al, 2000; Higginbottom et al., 2002). 
In the present study, using flow cytometry, it was found that HCPT and EP arrested 
the JCS cell cycle at the G Q / G I phase with a marked decrease of cells at the S phase. 
This phenomenon might be contributed by the alterations in the expression of the cell 
cycle-regulatory genes, for instance, the genes of cyclins and cyclin-dependent 
kinases (cdks). The results of reverse transcription-polymerase chain reaction 
(RT-PCR) showed that these genes were differentially expressed in HCPT- and 
EP-treated JCS cells. It was observed that the mRNA expression of cyclin A, cyclin B 
V 
and cyclin E genes was down-regulated in HCPT-treated JCS cells, however, EP had 
no appreciable effect on the expression of these three genes. On the other hand, both 
HCPT and EP enhanced cyclin D3 and down-regulated Cdk-2 and Cdk-6 mRNA 
expression. The significance of these alterations in gene expression had been 
discussed in section 3.3. Besides the expression of these cyclin and cdk genes, it is 
worth investigating the mRNA and protein expression of other growth-regulatory 
genes such as those involved in the protein kinase C (PKC) and mitogen-activated 
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protein kinase (MAPK) pathways. In fact, our preliminary study found that the mRNA 
expression of PKC-S gene was slightly enhanced in EP- but not HCPT-treated JCS 
cells (data not shown), though the significance of this finding has yet to be determined. 
As reported previously, PKC-5 might also be involved in the promotion of apoptosis 
(Emoto et al., 1996; Matassa et al., 2001). In addition, attempts had also been made to 
investigate the combination effect of HCPT or EP with cytokines including TNF-a, 
IFN-y and IL-lp on the proliferation of JCS cells. It was found that TNF-a acted in 
synergy with HCPT and EP in inhibiting the proliferation of the JCS cells. This 
implied a possible cross-talk between the signaling pathways of HCPT/ EP and 
TNF-a. Moreover, the potential efficacy of these cocktails in clinical situations is an 
intriguing aspect that is worthy of investigation. 
The differentiation-inducing activity of HCPT and EP was examined by the 
morphological, functional and phenotypic characteristics of the drug-treated and 
untreated JCS cells. Using light microscopy, it was found that both HCPT and EP 
induced morphological changes in JCS cells, including an increase in cell size and the 
cytoplasm to nucleus ratio. The results of flow cytometric analysis showed that both 
drugs increased the size and granularity of JCS cells. These features are typical 
V 
characteristics of JCS cells undergoing terminal differentiation (Leung, 1999; Leung, 
2002). Besides morphological changes, HCPT and EP also enhanced the functional 
maturity of JCS cells. This included the increase in plastic adhering ability, the 
production of superoxide anions and the induction of non-specific esterase activity. In 
addition to the functional changes, HCPT and EP also enhanced the phenotypic 
expression of macrophage differentiation antigens Mac-1 and F4/80 (Fung et al, 1997) 
on JCS cells without altering the level of the granulocytic Gr-1 antigen. Taken 
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together, it was speculated that both HCPT and EP induced the majority of the 
leukemia JCS cells to undergo differentiation via the macrophage/ monocyte pathway. 
To have a better understanding of the mechanism in HCPT- and EP-induced 
differentiation in JCS cells, it is worth studying the expression of some 
differentiation-associated genes such as jun B, c-fos and the binding activity of the 
transcription factor AP-1 (Mollinedo et al” 1993). Previous study in our laboratory 
also showed that JCS cells undergoing monocytic differentiation were accompanied 
by an increase in endocytic activity (Leung, 1999). This is also an interesting area for 
further investigation. 
In addition to the differentiation-inducing activity, HCPT and EP also induced 
apoptosis-related morphological and biochemical changes in JCS cells. These 
included nuclear disintegration, intemucleosomal DNA fragmentation and the 
translocation of phosphatidylserine to the outer plasma membrane. To further 
investigate the mechanism behind their apoptosis-inducing effect, the mRNA and 
protein expressions of several pro-apoptotic and anti-apoptotic genes in treated and 
untreated JCS cells were studied by RT-PCR and Western blotting. It was found that 
the mRNA and protein expressions of FasL gene were enhanced and that of Bcl-2 
V 
gene were reduced in both HCPT- and EP-treated JCS cells. Interestingly, the mRNA 
expression of BCI-XL gene was down-regulated in HCPT- but not EP-treated JCS cells. 
The pro-apoptotic proteins Bak and Bad seemed not to be involved in this apoptotic 
process, although a transient reduction in the mRNA expression of Bak was observed. 
To gain better insights for the signaling pathways of HCPT- and EP-induced 
apoptosis of the leukemia JCS cells, the activity of downstream caspase 3, 8 and 9 
was measured by fluorometric assay. Caspase 3 and 8 are involved in both the death 
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receptor and mitochondrial pathways of apoptosis, however, caspase 9 is involved in 
the mitochondrial pathway only (Raff, 1998). It was found that both HCPT and EP 
significantly increased the activity of these 3 caspases. Mitochondrial membrane 
depolarization, which is characteristic of the mitochondrial apoptotic pathway, was 
also detected in HCPT- and EP-treated cells. Previous studies have also demonstrated 
that the calcium signaling system might play a pivotal role in apoptosis (Qi et al., 
2002; Zhang et al., 2000). Our results, however, revealed that neither HCPT nor EP 
increased the intracellular Ca^^ level in JCS cells under the prescribed experimental 
conditions. To conclude, our results implied that both HCPT and EP might trigger the 
leukemia JCS cells to undergo apoptosis via both the death receptor and the 
mitochondrial pathway, and, in addition, the calcium signaling system seemed not to 
be involved in this process, yet this has to be confirmed as the early changes (< 6 
hours) in intracellular Ca^^ level was not measured in the JCS cells. Recently, there 
have been controversies about the role of mitochondrial membrane depolarization in 
apoptosis. For instance, it was suggested that the loss of mitochondrial membrane 
potential (AWm) may not be an early requirement for apoptosis, but on the contrary 
this may be a consequence of the apoptotic signaling pathway. Moreover, the loss of 
AWm has been demonstrated not to be required for cytochrome c release, whereas 
V 
release of apoptosis-inducing factor (AIF) is dependent upon disruption of AWm 
early in the apoptotic pathway (Ly et al, 2003). Clearly, the role of 
mitochondria-dependent pathway in apoptosis needs further investigation. In addition, 
it has been reported that nitric oxide and hydrogen peroxide were involved in the 
regulation of apoptosis (Brune, 2003; Kim et al., 2003). This is also an interesting 
area for future in-depth studies. 
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As a conclusion, our data showed that HCPT and EP inhibited the proliferation 
of the murine myeloid leukemia WEHI-3B JCS cells via at least 3 ways: these 
included cell cycle arrest, induction of differentiation and apoptosis. In fact, 
accumulating evidence has shown that these 3 types of cellular events are intertwined. 
For instance, Jin and colleagues suggested that the activity of the cell cycle regulatory 
protein cdk2 was related to mitochondrial membrane depolarization in apoptosis (Jin 
et al., 2003). Moreover, the growth-regulatory protein PKC-5 might also be involved 
in the promotion of apoptosis (Emoto et aL, 1996; Matassa et al., 2001). In addition, 
the mechanism by which DNA breaks induced by topoisomerase-targeting agents 
could induce cell cycle arrest, differentiation and apoptosis in JCS cells remains 
poorly understood. These are all interesting questions arose in the present study. Last 
but not the least, it is hoped that our findings can provide some insights for further 
studies on the anti-leukemic activity of novel topoisomerase-targeting agents with a 
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